
<html lang="en"     class="pb-page"  data-request-id="8881bcbd-9b12-41a9-b3a3-4bc0db2f7e97"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01765;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor" /></meta><meta name="dc.Creator" content="Sandip B.  Bharate" /></meta><meta name="dc.Creator" content="Vikas  Kumar" /></meta><meta name="dc.Creator" content="Shreyans K.  Jain" /></meta><meta name="dc.Creator" content="Mubashir J.  Mintoo" /></meta><meta name="dc.Creator" content="Santosh K.  Guru" /></meta><meta name="dc.Creator" content="Vijay K.  Nuthakki" /></meta><meta name="dc.Creator" content="Mohit  Sharma" /></meta><meta name="dc.Creator" content="Sonali S.  Bharate" /></meta><meta name="dc.Creator" content="Sumit G.  Gandhi" /></meta><meta name="dc.Creator" content="Dilip M.  Mondhe" /></meta><meta name="dc.Creator" content="Shashi  Bhushan" /></meta><meta name="dc.Creator" content="Ram A.  Vishwakarma" /></meta><meta name="dc.Description" content="Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via..." /></meta><meta name="Description" content="Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 6, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01765" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01765" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01765" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01765" /></link>
        
    
    

<title>Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01765" /></meta><meta property="og:title" content="Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0012.jpeg" /></meta><meta property="og:description" content="Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition and cellular antiproliferative activity. The 2,6-dichloro-styryl derivative IIIM-290 (11d) showed strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50 &lt; 1.0 μM) and was found to be highly selective for cancer cells over normal fibroblast cells. It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis. It achieved 71% oral bioavailability with in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po. It did not have CYP/efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic, and was metabolically stable. The preclinical data presented herein indicates the potential of 11d for advancement in clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01765"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01765">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01765&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01765&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01765&amp;href=/doi/10.1021/acs.jmedchem.7b01765" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1664-1687</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01760" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01863" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandip+B.++Bharate">Sandip B. Bharate</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>○</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6081-5787" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vikas++Kumar">Vikas Kumar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shreyans+K.++Jain">Shreyans K. Jain</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mubashir+J.++Mintoo">Mubashir J. Mintoo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol "><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Santosh+K.++Guru">Santosh K. Guru</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vijay+K.++Nuthakki">Vijay K. Nuthakki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohit++Sharma">Mohit Sharma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sonali+S.++Bharate">Sonali S. Bharate</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sumit+G.++Gandhi">Sumit G. Gandhi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dilip+M.++Mondhe">Dilip M. Mondhe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shashi++Bhushan">Shashi Bhushan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ram+A.++Vishwakarma">Ram A. Vishwakarma</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-0752-6238" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Academy of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Preformulation Laboratory, PK−PD Toxicology & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Natural Products Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Plant Biotechnology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">∇</span> <span class="aff-text">Indian Pharmacopeia Commission, Sec-23, Raj Nagar, Ghaziabad-201002, India</span></div><div class="corresp-info"><strong>*</strong>Tel: +91 191 2569006. Fax: +91 191 2569333. E-mail: <a href="/cdn-cgi/l/email-protection#8cffeee4edfeedf8e9cce5e5e5e1a2edefa2e5e2"><span class="__cf_email__" data-cfemail="a3d0c1cbc2d1c2d7c6e3cacacace8dc2c08dcacd">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Tel: +91 191 2569111. Fax: +91 191 2569333. E-mail: <a href="/cdn-cgi/l/email-protection#7002111d301919191d5e11135e191e"><span class="__cf_email__" data-cfemail="44362529042d2d2d296a25276a2d2a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01765&amp;href=/doi/10.1021%2Facs.jmedchem.7b01765" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1664–1687</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 25, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 November 2017</li><li><span class="item_label"><b>Published</b> online</span>6 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01765" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01765</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1664%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSandip%2BB.%2BBharate%252C%2BVikas%2BKumar%252C%2BShreyans%2BK.%2BJain%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D4%26contentID%3Dacs.jmedchem.7b01765%26title%3DDiscovery%2Band%2BPreclinical%2BDevelopment%2Bof%2BIIIM-290%252C%2Ban%2BOrally%2BActive%2BPotent%2BCyclin-Dependent%2BKinase%2BInhibitor%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1687%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01765"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2288</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01765" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sandip&quot;,&quot;last_name&quot;:&quot;B. Bharate&quot;},{&quot;first_name&quot;:&quot;Vikas&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Shreyans&quot;,&quot;last_name&quot;:&quot;K. Jain&quot;},{&quot;first_name&quot;:&quot;Mubashir&quot;,&quot;last_name&quot;:&quot;J. Mintoo&quot;},{&quot;first_name&quot;:&quot;Santosh&quot;,&quot;last_name&quot;:&quot;K. Guru&quot;},{&quot;first_name&quot;:&quot;Vijay&quot;,&quot;last_name&quot;:&quot;K. Nuthakki&quot;},{&quot;first_name&quot;:&quot;Mohit&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Sonali&quot;,&quot;last_name&quot;:&quot;S. Bharate&quot;},{&quot;first_name&quot;:&quot;Sumit&quot;,&quot;last_name&quot;:&quot;G. Gandhi&quot;},{&quot;first_name&quot;:&quot;Dilip&quot;,&quot;last_name&quot;:&quot;M. Mondhe&quot;},{&quot;first_name&quot;:&quot;Shashi&quot;,&quot;last_name&quot;:&quot;Bhushan&quot;},{&quot;first_name&quot;:&quot;Ram&quot;,&quot;last_name&quot;:&quot;A. Vishwakarma&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1664-1687&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01765&quot;},&quot;abstract&quot;:&quot;Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition and cellular antiproliferative activity. The 2,6-dichloro-styryl derivative IIIM-290 (11d) showed strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50 &lt; 1.0 μM) and was found to be highly selective for cancer cells over normal fibroblast cells. It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis. It achieved 71% oral bioavailability with in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po. It did not have CYP/efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic, and was metabolically stable. The preclinical data presented herein indi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01765&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01765" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01765&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01765" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01765&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01765" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01765&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01765&amp;href=/doi/10.1021/acs.jmedchem.7b01765" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01765" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01765" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01765%26sid%3Dliteratum%253Aachs%26pmid%3D29370702%26genre%3Darticle%26aulast%3DBharate%26date%3D2018%26atitle%3DDiscovery%2Band%2BPreclinical%2BDevelopment%2Bof%2BIIIM-290%252C%2Ban%2BOrally%2BActive%2BPotent%2BCyclin-Dependent%2BKinase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D4%26spage%3D1664%26epage%3D1687%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/jmcmar.2018.61.issue-4/20180222/jmcmar.2018.61.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Rohitukine (<b>1</b>), a chromone alkaloid isolated from Indian medicinal plant <i>Dysoxylum binectariferum</i>, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition and cellular antiproliferative activity. The 2,6-dichloro-styryl derivative IIIM-290 (<b>11d</b>) showed strong inhibition of Cdk-9/T1 (IC<sub>50</sub> 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI<sub>50</sub> < 1.0 μM) and was found to be highly selective for cancer cells over normal fibroblast cells. It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis. It achieved 71% oral bioavailability with in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po. It did not have CYP/efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic, and was metabolically stable. The preclinical data presented herein indicates the potential of <b>11d</b> for advancement in clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cell division is one of the basic requirements for survival of all living cells. Classically, the cell growth occurs via four distinct phases, namely G1, S, G2, and M phases. Progression through each of these phases is tightly controlled by the interaction of cyclin-dependent kinases (Cdks) and cyclins. Cdks are a family of serine-threonine protein kinases that interact with associated cyclins to activate their function. Cdk-1, 2, 3, 4, and 6 directly interfere with cell cycle, and Cdk-8, 9, and 7 play a crucial role as regulator of transcription.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> A number of cancers are associated with hyperactivation of Cdks as a result of mutation of Cdk genes or Cdk inhibitory genes.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Therefore, in recent years, Cdk inhibitors have elicited great interest in oncology to discover novel anticancer therapeutics.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Two Cdk inhibitors have reached the market; palbociclib (Pfizer) was the first one to enter the market (2015) for treatment of breast cancer.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> In 2017, second Cdk inhibitor ribociclib (Novartis) received FDA approval for HER2-negative advanced breast cancer in combination with an aromatase inhibitor.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Eli Lilly’s abemaciclib (LY2835219) is another Cdk-4/6 inhibitor that has recently completed Phase III trial.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> There are several follow-on Cdk inhibitor candidates in the clinical pipeline (with >100 clinical studies ongoing) including rigosertib sodium, FLX925, dinaciclib, P276-00 (riviciclib), etc.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">In addition to the Cdks (Cdk-2,4,6) involved in cell cycle regulation, the inhibition of transcriptional Cdks (particularly, Cdk-9) are also gaining great interest for effective anticancer therapy because of their role in controlling short-lived mitotic regulatory kinases and apoptosis regulators such as Mcl-1 for their survival.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> Among the transcriptional Cdks, the Cdk-9 has been investigated as a therapeutic target by many groups.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17-20)</a> Flavopiridol (alvocidib), the first Cdk inhibitor to enter clinical trials, is the most active Cdk-9 inhibitor reported so far, with IC<sub>50</sub> value of 20 nM.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a></div><div class="NLM_p">Rohitukine (<b>1</b>) is a chromone alkaloid, initially isolated from <i>Amoora rohituka</i> (Roxb.),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and later from <i>Dysoxylum binectariferum</i> Hook. (Meliaceae).<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> This alkaloid is present in abundance in all parts of <i>Dysoxylum binectariferum</i>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and therefore, it is being used as a primary source for isolation of this precious natural product. Inspired from rohitukine, two clinical candidates have been discovered, <i>viz</i>. flavopiridol (<b>2</b>) and riviciclib (P276-00, <b>3</b>; structures are shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Flavopiridol inhibits a number of Cdks and other kinases; however, its primary mechanism of action is believed to be through Cdk-9 inhibition, leading to down-regulation of the transcription of antiapoptotic proteins in cancer cells.<a onclick="showRef(event, 'ref21 ref22 ref28'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref28">(21, 22, 28)</a> It was evaluated in a number of clinical trials as a single agent<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> as well as in combination<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> with other anticancer agents, and recently, it received orphan drug status from FDA for treatment of AML and CLL.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> Riviciclib (P276-00)<a onclick="showRef(event, 'ref36 ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39 ref40 ref41">(36-41)</a> is another potent inhibitor of Cdks (IC<sub>50</sub> for Cdk-4/D1 = 63 nM, Cdk-9/T1 = 20 nM) discovered from this scaffold, which has recently completed phase II clinical trials in patients with relapsed or refractory mantle cell lymphoma.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> However, both these clinical candidates are administered in preclinical and clinical studies as a daily intravenous (IV) infusion and have no oral bioavailability. In the present work, we set out to address the issue of oral bioavailability of rohitukine scaffold, and we now report a discovery of the first preclinical candidate IIIM-290<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> with 71% oral bioavailability from this scaffold.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of rohitukine (<b>1</b>) and its inspired anticancer candidates <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The synthesis strategy employed to prepare new derivatives was semisynthetic modifications on rohitukine, as this approach was never explored in prior medicinal chemistry efforts on this scaffold. Four series of rohitukine derivatives were designed based on the known structural information<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> and reported structure–activity relationship (SAR) on flavopiridol.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> All synthesized compounds were screened for Cdk inhibition and cellular antiproliferative activity in a panel of cancer cell lines. The best-identified lead IIIM-290 (<b>11d</b>) was subjected to complete preclinical characterization.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design and Synthesis of Rohitukine Derivatives</h3><div class="NLM_p">To design new derivatives of rohitukine, we utilized prior structural information on the cocrystal structure of Cdk-2 with deschloroflavopiridol<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and flavopiridol<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and previous work of Murthi,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Kim,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Schoepfer,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and Ahn<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> on this scaffold. On comparing the lipophilicity of rohitukine and flavopiridol, it was observed that the additional 2-chlorophenyl ring present in the later compound provided extra-lipophilicity, which was translated into its cytotoxic properties (cLogP of rohitukine, 1.01; flavopiridol, 3.42; MCF-7 of rohitukine, GI<sub>50</sub> = 15 μM; flavopiridol, GI<sub>50</sub> = 26 nM<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a>). This observation prompted us to incorporate lipophilic substituents on rohitukine to fine-tune its Cdk inhibition and cellular activity. Taking the advantage of easy isolation of natural alkaloid rohitukine from any part of the <i>D. binectariferum</i> tree in good quantity,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> it was decided to follow a semisynthetic approach for creating structurally diverse compounds within this scaffold. Four series of modifications were planned, as shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. This includes (a) preparation of C7-O-ether derivatives (series A), (b) Mannich reaction at C6 active hydrogen (series B), (c) Baylis–Hillman reaction with aldehydes (series C), and (d) Claisen–Schmidt condensation (styrylation at C2-methyl) with aryl aldehydes (series D).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of four different series A–D of rohitukine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The powdered leaves or barks of <i>Dysoxylum binectariferum</i> were subjected to cold maceration with methanol. The obtained methanolic extract was loaded on a silica gel column chromatography, eluting with DCM/MeOH to get rohitukine (<b>1</b>) in bulk quantity. Rohitukine was obtained in 0.8–3% w/w from both parts of the plant.</div><div class="NLM_p">The isolated rohitukine was subjected to four series of semisynthetic modifications (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). To synthesize series A compounds, various base catalyzed <i>O</i>-benzylation methods were attempted. Initially, a mixture of mono-, di-, and tri-<i>O</i>-benzylation products were observed, under different basic conditions (K<sub>2</sub>CO<sub>3</sub>, NaH, NaOH, CH<sub>3</sub>ONa, etc.) and solvents (acetone, THF, dioxane, DCM, etc.). Subsequent attempts discovered that the treatment of rohitukine with alkyl or benzyl halide in the presence of KF-alumina using grind-stone chemistry results in the regioselective formation of 7-O-ethers.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Our motivation to synthesize this series (series A) was to check the tolerance of 7-hydroxyl group with respect to the biological activity. In series A compounds (e.g., <b>8a</b>), the presence of a peak at δ 12.78 ppm in the <sup>1</sup>H NMR spectrum represents the presence of free phenolic OH at position C-5, which is H-bonded with C-4 carbonyl oxygen. This also indicated that benzylation occurred regioselectively at 7-OH position. This series of derivatives also showed characteristic additional peaks for -<i>O</i>-C<u class="uu">H</u><sub>2</sub>-Ph at δ 5.15 and 4.44 ppm in the <sup>1</sup>H NMR spectrum. Next, one esterification reaction was also attempted, using furoyl chloride in similar reaction conditions. Interestingly, in contrast to the etherification, furoylation occurred at piperidinyl OH group. This was revealed from the <sup>1</sup>H NMR spectrum of compound <b>8h</b> wherein there is a significant downfield shift in the chemical shift value of <i>O</i>-linked CH proton of piperidine ring. The δ value was shifted from 4.14 to 5.58 ppm.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Rohitukine Derivatives <b>8a</b>–<b>h</b>, <b>9a</b>–<b>o</b>, <b>10a</b>–<b>n</b>, and <b>11a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a). KF/alumina (5 mol %); grinding, substituted benzyl halide, 5–15 min, rt, 42–62%; (b) formalin solution (1.7 equiv), secondary amine, DMSO, 60 °C, 5 h, 34–52%; (c) DABCO (1.2 equiv), substituted aldehydes (1.2 equiv), MeOH, rt, 15 days, 36–65%; (d) KOH (10 equiv), substituted aldehydes (1.2 equiv), MeOH, 110 °C, 10 h, 45–61%.</p></p></figure><div class="NLM_p">Mannich products (series B) at position C-6 in rohitukine (<b>1</b>) were synthesized by conventional Mannich reaction protocol. The reaction was performed with different secondary amines in the presence of formalin solution and DMSO as a solvent under the heating (60–70 °C, 5 h) condition. In this series, the <sup>1</sup>H NMR spectrum showed that the C6 aromatic proton of rohitukine disappears with the appearance of additional expected peaks (for R<sub>2</sub>R<sub>2</sub>-N-C<u class="uu">H</u><sub>2</sub>-Ar) of Mannich product.</div><div class="NLM_p">Based on the known SAR,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> it was understood that the substitution at the 2-position of chromone nucleus helps in gaining selectivity within Cdks and improves its Cdk inhibition activity. The flavopiridol possesses 2-chlorophenyl substituent, whereas rohitukine has 2-methyl substituent. The flavopiridol is at least a 10-fold more potent Cdk-9 inhibitor than rohitukine. Therefore, it was decided to investigate substitution at the C-2 methyl of rohitukine. For this, the Claisen–Schmidt condensation with aryl aldehydes was planned. A model reaction of rohitukine (<b>1</b>) with 4-chlorobenzaldehyde (<b>7b</b>) was investigated. Various weaker to stronger bases were investigated for this reaction. Reaction optimization results are summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reaction Conditions for Condensation of Rohitukine (<b>1</b>) with 4-Chlorobenzaldehyde (<b>7b</b>)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0011.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">base (equiv)</th><th class="colsep0 rowsep0" align="center">solvent</th><th class="colsep0 rowsep0" align="center">temp (°C)</th><th class="colsep0 rowsep0" align="center">time</th><th class="colsep0 rowsep0" align="center"><b>11b</b>, % yield</th><th class="colsep0 rowsep0" align="center"><b>10b</b>, % yield</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">DABCO (1)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">24 h</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">DABCO (1)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">15 days</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">DABCO (1)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">20 days</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">DABCO (10)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">15 days</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">KOH (10)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">15 days</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">KOH (10)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">15 days</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">KOH (10)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">20 days</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">KOH (10)</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">10 h</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Rohitukine (0.328 mmol) and aldehyde (0.394 mmol).</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">KOH solution was made in water, and then it was added to the reaction mixture (containing a substrate in methanol).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Optimized reaction condition for synthesis of Baylis–Hillman products.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Optimized reaction condition for synthesis of styryl products.</p></div></div></div><div class="NLM_p">In an effort toward the synthesis of styryl derivative <b>11b</b>, the reaction of rohitukine (<b>1</b>) with 4-chlorobenzaldehyde (<b>7b</b>) was performed in the presence of DABCO as a base at room temperature for 24 h. It was observed that a Baylis–Hillman reaction was followed and that the corresponding 3-substituted Baylis–Hillman product <b>10b</b> was formed in 20% yield (entry 1 of <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Further optimization efforts with respect to time indicated that longer duration of reaction (up to 15–20 days) results in the formation of Baylis–Hillman product <b>10b</b> in >70% yield (entries 3–4). To get styryl derivative <b>11b</b>, further variation in the base and reaction temperature was studied. It was observed that in the presence of KOH as a base at reflux temperature, styryl derivative <b>11b</b> was formed as the primary product, along with <b>10b</b> as a minor product. Thus, the reaction conditions 2 and 8 (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) were optimal for the synthesis of products <b>10b</b> and <b>11b</b>, respectively. Interestingly, when product <b>10b</b> was further refluxed under reaction conditions mentioned in entry 8, styryl product <b>11b</b> was formed. Results presented in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> indicate that when rohitukine was treated with aryl aldehyde in the presence of a weak base in methanol, it undergoes Baylis–Hillman reaction (Series C) at room temperature while under reflux condition in the presence of a strong base; it follows Claisen–Schmidt condensation (Series D). The Baylis–Hillman reaction proceeded with slow kinetics, and full conversion was not observed even after 20 days. Typical reaction time for this was 15 days at room temperature. Using optimized reaction conditions, a series of derivatives were prepared. In total, 14 Baylis–Hillman adducts <b>10a</b>–<b>n</b> and nine styryl products <b>11a</b>–<b>i</b> were synthesized (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). In case of all styryl products, <i>trans</i>-isomer was formed as a major product, with traces of <i>cis</i>-product in few cases.</div><div class="NLM_p last">The <sup>1</sup>H NMR of Baylis–Hillman product <b>10a</b> showed a multiplet of 2H at δ 5.9 ppm, for one aromatic proton (H-6) and another proton (7′-H), confirming the formation of Baylis–Hillman adduct at the C-3 position of rohitukine. The position of the newly formed bond was confirmed by HMBC correlations wherein the 7′-H is correlated with 2-CH<sub>3</sub> and C═O. The <sup>1</sup>H NMR spectra (series D) of styryl derivative <b>11a</b> showed the presence of a typical doublet at δ 6.92 and 7.44 ppm with <i>trans</i>-coupling (<i>J</i> = 16 Hz) corresponding to the newly constructed styryl bond. As depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, a total of 46 derivatives of rohitukine were synthesized and characterized based on their spectral properties.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Inhibition of Cdk-2/A and Cdk-9/T1</h3><div class="NLM_p">Rohitukine (<b>1</b>) along with all four series of rohitukine derivatives <b>8a–h</b>, <b>9a–o</b>, <b>10a–n</b>, and <b>11a</b>–<b>i</b> were screened for in vitro inhibition of Cdk-2/A and Cdk-9/T1. The initial screening was performed at a single concentration of 0.5 μM, followed by the determination of IC<sub>50</sub> values of active compounds. At 0.5 μM, rohitukine showed strong inhibition (75%) of Cdk-9/T1; however, only 10% inhibition of Cdk-2/A was observed. On determination of IC<sub>50</sub> values, it was observed that rohitukine inhibits Cdk-2/A and Cdk-9/T1 with IC<sub>50</sub> values of 7.3 and 0.3 μM, respectively. The single concentration results of all derivatives are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Among 7-<i>O</i>-ether derivatives <b>8a</b>–<b>h</b> (series A), none of the compounds was active, indicating that substitution at the 7-hydroxy position is not favorable for Cdk inhibition. Series B compounds <b>9a</b>–<b>o</b> also showed weak activity against Cdk-2/A and Cdk-9/T1 at 0.5 μM, indicating that introduction of any hydrophilic (nitrogen containing) functional group at this position is not tolerable probably because of the change in the orientation of the molecule in enzyme cavity (interaction of <b>9a</b> with Cdk-9 is shown in section S4 of the <a class="ref internalNav" href="#notes-7" aria-label="Supporting Information">Supporting Information</a>). Among Baylis–Hillman adducts (series C), again most of the compounds showed weak or no activity, the best among this series was compound <b>10d</b> (29% inhibition of Cdk-9/T1 at 0.5 μM). Like C7-OH and C-6 positions, the substitution at C-3 position was also not tolerated with respect to Cdk-2/A and Cdk-9/T1 inhibition activity. In series D, the modification at the 2-methyl position of rohitukine was found to be most favorable and tolerable.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Inhibition of Cdk-2/A and Cdk-9/T1 and Cellular Antiproliferative Activity of Rohitukine Derivatives at Single Concentration</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">enzyme inhibition % inhibition (±SD) at 0.5 μM<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">cellular activity % growth inhibition (±SD) at 10 μM<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center" char="±">Cdk-2/A</th><th class="colsep0 rowsep0" align="center" char="±">Cdk-9/T1</th><th class="colsep0 rowsep0" align="center" char="±">HL-60</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th><th class="colsep0 rowsep0" align="center" char="±">MIAPaCa-2</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">Caco-2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 3.4</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="char" char="±">6 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">45 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g</b></td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8h</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">47 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">34 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="char" char="±">2 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9e</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 4.8</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9f</b></td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9g</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9h</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9i</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9j</b></td><td class="colsep0 rowsep0" align="char" char="±">5</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9k</b></td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9l</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9m</b></td><td class="colsep0 rowsep0" align="char" char="±">17 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9n</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9o</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="char" char="±">6 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">29 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">52 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">45 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 1/4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">45 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10i</b></td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">41 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10j</b></td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10k</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10l</b></td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10m</b></td><td class="colsep0 rowsep0" align="char" char="±">5 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10n</b></td><td class="colsep0 rowsep0" align="char" char="±">13 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 3.4</td><td class="colsep0 rowsep0" align="char" char="±">0</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">66 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">87 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">71 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">58 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">88 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">70 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">53 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">53 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">52 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">82 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="char" char="±">90 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">84 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">88 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">80 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">68 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="char" char="±">42 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">80 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">82 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">89 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">64 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">59 ± 3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="char" char="±">43 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">80 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">77 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">44 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="char" char="±">53 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">88 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">67 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">67 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 5.5</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">68 ± 2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">59 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">63 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">65 ± 2.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Values are reported as average of two independent determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Values are reported as average of three independent determinations.</p></div></div></div><div class="NLM_p">The Cdk screening results shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> indicated that most of the compounds of series D (<b>11a</b>–<b>i</b>) showed >50% inhibition of Cdk-9/T1 at 0.5 μM. Therefore, the IC<sub>50</sub> values were determined for all compounds from series D, and results are presented in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. The 2,6-dichloro styryl derivative <b>11d</b> was found to be the most potent Cdk-2/A and Cdk-9/T1 inhibitor with IC<sub>50</sub> values of 16 and 1.9 nM, respectively.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values for in Vitro Inhibition of Cdk-2/A and Cdk-9/T1 and GI<sub>50</sub> Values for Cellular Antiproliferative Activity by Styryl Derivatives <b>11a</b>–<b>i</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">enzyme inhibition IC<sub>50</sub> (nM) ± SD<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">cellular activity GI<sub>50</sub> (μM) ± SD<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center" char="±">Cdk-2/A</th><th class="colsep0 rowsep0" align="center" char="±">Cdk-9/T1</th><th class="colsep0 rowsep0" align="center" char="±">HL-60</th><th class="colsep0 rowsep0" align="center" char="±">PC-3</th><th class="colsep0 rowsep0" align="center" char="±">MIAPaCa-2</th><th class="colsep0 rowsep0" align="center" char="±">MCF-7</th><th class="colsep0 rowsep0" align="center" char="±">Caco-2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">7300 ± 89</td><td class="colsep0 rowsep0" align="char" char="±">300 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">25 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="char" char="±">925 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">66 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">58 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char="±">3300 ± 31</td><td class="colsep0 rowsep0" align="char" char="±">310 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 2.4</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char="±">3000 ± 34</td><td class="colsep0 rowsep0" align="char" char="±">280 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="char" char="±">16 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="char" char="±">608 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">11.5 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="char" char="±">1800 ± 67</td><td class="colsep0 rowsep0" align="char" char="±">350 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.2</td><td class="colsep0 rowsep0" align="center" char="±">>100</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="char" char="±">466 ± 31</td><td class="colsep0 rowsep0" align="char" char="±">29 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="char" char="±">1520 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">260 ± 21</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="char" char="±">1410 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">160 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 1.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Values are reported as average of two independent determinations.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Values are reported as average of three independent determinations.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationship and Molecular Modeling for Cdk-9/T1 Inhibition</h3><div class="NLM_p">The substitution of various possible positions of rohitukine provided four series of compounds. The substitution at C3, C6, C7-OH, and C2′-OH positions resulted in the loss of Cdk inhibition activity, particularly the Cdk-9/T1 inhibition. However, substitution of C2-methyl with styryl moiety resulted in improvement of activity. Literature precedence also indicated that C2-position is the most tunable position for favorable modulation of Cdk inhibition activity. The replacement of C2-methyl with 2-chlorophenyl group provided flavopiridol (<b>2</b>), which possesses 15-fold improvement in Cdk-9/T1 inhibition activity (IC<sub>50</sub> of rohitukine, 300 nM; flavopiridol, 20 nM). Similarly, the substitution of C2-methyl with styryl group (compound <b>11a</b>, IC<sub>50</sub> 66 nM) led to ∼5-fold improvement in the Cdk-9/T1 inhibition activity. The styryl moiety was further substituted with “Cl” at the ortho position, resulting in a marginal decrease (by 2.4-fold) in activity; however, introduction of another “Cl” at other ortho position (compound <b>11d</b>, IC<sub>50</sub> 1.9 nM) resulted in tremendous improvement in the Cdk-9/T1 inhibition potency. This 2,6-dichloro derivative <b>11d</b> possesses ∼160-fold improvement in Cdk-9/T1 potency over parent natural product rohitukine.</div><div class="NLM_p">In particular, the position and type of halogen substituent on styryl ring was found to a play crucial role in selectivity for Cdk-9/T1 versus Cdk-2/A. The penta-fluorobenzyl derivative <b>11e</b> showed higher selectivity (52-fold) for Cdk-9/T1 (IC<sub>50</sub> 11.5 nM) versus Cdk-2/A (IC<sub>50</sub> 608 nM). The 2,6-dichlorostyryl derivative <b>11d</b> was found to be the most potent inhibitor of Cdk-9/T1 (IC<sub>50</sub> 1.9 nM) with 7-fold selectivity over Cdk-2/A (IC<sub>50</sub> =15.5 nM). Furthermore, the 2-chlorostyryl derivative <b>11i</b> (Cdk-9: IC<sub>50</sub> = 160 nM) is more active than 3-chlorostyryl derivative <b>9c</b> (Cdk-9/T1: IC<sub>50</sub> = 280 nM), which is more active than 4-chlorostyryl derivative <b>11b</b> (Cdk-9/T1: IC<sub>50</sub> = 310 nM). The similar trend of activity was also seen for Cdk-2/A inhibition, indicating that chloro-substitution at the ortho position of the styryl ring is more favorable. Furthermore, the presence of two chloro substituent’s at both ortho positions resulted in the highly active Cdk-9/T1 and Cdk-2/A inhibitor <b>11d</b> (IC<sub>50</sub> = 1.9 and 15.5 nM for Cdk-9/T1 and Cdk-2/A, respectively). In general, the activity of chloro-substituted analogues has ∼10× higher activity against Cdk-9/T1 over Cdk-2/A. Overall, these results indicated that series D compounds are potent Cdk-9 and Cdk-2 inhibitors with better selectivity toward Cdk-9; however, other three series of compounds were weakly active or completely inactive. <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> depicts the key features of the SAR of rohitukine scaffold for Cdk inhibition.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure–activity relationship of rohitukine scaffold for Cdk inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the molecular modeling studies were performed to understand the interaction pattern of styryl derivative <b>11d</b> with the active site of Cdk-9. The docking of styryl derivative <b>11d</b> and flavopiridol was performed using Cdk-9/flavopiridol crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). The compound <b>11d</b> was found to occupy the ATP binding cavity of the Cdk-9 enzyme exactly in a similar fashion like flavopiridol. The surface view of the ATP binding pocket showing orientation of <b>11d</b> inside the cavity is shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a, and the overlay of <b>11d</b> with flavopiridol in the binding cavity is displayed in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>c. The key interactions of <b>11d</b> with ATP binding site residues are shown in the <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b,d. The chromenone moiety of both these compounds orients toward the bottom of the cavity, forming an important bidentate H-bonding interaction with the Cys 106 residue. In addition, compound <b>11d</b> forms two other important H-bonds with Ala 153 and Asp 167. The protonated NH of the piperidine ring forms H-bond with the carbonyl oxygen of Ala 153, and the oxygen of C-7 hydroxyl forms H-bond with NH of Asp 167. Apart from these H-bond interactions, two important π–π interactions were observed, <i>viz</i>. the ring A (a ring which is connected with piperidine) of <b>11d</b> shows π–π interaction with Phe 103, and protonated NH of piperidine interacts with Phe 30 via π–π interaction. The surface view of the binding pocket also revealed that the dichlorophenyl moiety orients toward the solvent, i.e., outside the front specificity pocket of Cdk-9. This computational information indicated that three functionalities, <i>viz</i>. keto–enol of chromenone ring, piperidinyl moiety, and <i>ortho</i>-chloro substituted styryl ring, are important functionalities for binding to Cdk-9 enzyme (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a–d).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Interactions of <b>11d</b> with the ATP-binding site of Cdk-9 kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). (a) Surface view of the ATP-binding site of Cdk-9 showing orientation of <b>11d</b> inside the cavity; (b) two-dimensional view of the key interactions of <b>11d</b> with active site residues; (c) overlay of flavopiridol (green) with <b>11d</b> (red) in the active site; (d) key interactions of <b>11d</b> with binding site residues in the 3D view.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Screening of IIIM-290 (<b>11d</b>) in a Panel of Cdks and Kinase Profiling</h3><div class="NLM_p">As depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the promising Cdk inhibition profile and cellular antiproliferative activity of <b>11d</b> prompted us to further explore its potential as an anticancer agent. The <b>11d</b> was screened in a panel of 13 Cdk enzymes, <i>viz</i>. Cdk-1/cyclin A, Cdk-1/cyclin E, Cdk-2/cyclin O, Cdk-2/cyclin A, Cdk-3/cyclin E, Cdk-4/cyclin D3, Cdk-5/cyclin p25, Cdk-5/cyclin p35, Cdk-6/cyclin D1, Cdk-6/cyclin D3, Cdk-7/cyclin H, Cdk-9/cyclin K, and Cdk-9/cyclin T1. It exhibited strong inhibition of Cdk-1/cyclin A and Cdk-9/cyclin T1 with IC<sub>50</sub> values of 4.9 and 1.9 nM, respectively. It also showed promising activity against Cdk-4/D3 and Cdk-6/D1 with IC<sub>50</sub> values of 22.5 and 45 nM, respectively. IIIM-290, like flavopiridol and riviciclib, belongs to the flavone class of compounds. However, unlike flavopiridol and riviciclib, it shows better selectivity toward Cdk-1/A and Cdk-9/T1 as compared with Cdk-7/H. The Cdk screening results are shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Profiling of <b>11d</b> in a Panel of Cdks<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cdk</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) ± SD</th><th class="colsep0 rowsep0" align="center">Cdk</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) ± SD</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-1/cyclin A</td><td class="colsep0 rowsep0" align="char" char="±">4.93 ± 0.5</td><td class="colsep0 rowsep0" align="left">Cdk-5/cyclin p35</td><td class="colsep0 rowsep0" align="char" char="±">15.7 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-1/cyclin E</td><td class="colsep0 rowsep0" align="char" char="±">75.9 ± 12</td><td class="colsep0 rowsep0" align="left">Cdk-6/cyclin D1</td><td class="colsep0 rowsep0" align="char" char="±">45 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-2/cyclin O</td><td class="colsep0 rowsep0" align="char" char="±">138 ± 14</td><td class="colsep0 rowsep0" align="left">Cdk-6/cyclin D3</td><td class="colsep0 rowsep0" align="char" char="±">199 ± 5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-2/cyclin A</td><td class="colsep0 rowsep0" align="char" char="±">15.5 ± 1.4</td><td class="colsep0 rowsep0" align="left">Cdk-7/cyclin H</td><td class="colsep0 rowsep0" align="char" char="±">711 ± 13.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-3/cyclin E</td><td class="colsep0 rowsep0" align="char" char="±">>1000</td><td class="colsep0 rowsep0" align="left">Cdk-9/cyclin K</td><td class="colsep0 rowsep0" align="char" char="±">412 ± 22.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-4/cyclin D3</td><td class="colsep0 rowsep0" align="char" char="±">22.5 ± 2.3</td><td class="colsep0 rowsep0" align="left">Cdk-9/cyclin T1</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cdk-5/cyclin p25</td><td class="colsep0 rowsep0" align="char" char="±">15.5 ± 1.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Values are reported as average of two independent determinations.</p></div></div></div><div class="NLM_p">The kinase selectivity of <b>11d</b> was then studied in a panel containing 468 kinases (scanMAX KINOMEscan, DiscoverX) at a compound concentration of 0.5 μM. A set of 468 kinases covers AGC, CAMK, CMGC, CK1, STE, TK, TKL, lipid, and atypical kinase families, plus important mutant forms. The kinome profiling indicated that the compound <b>11d</b> is somewhat promiscuous by inhibiting some of the Ser/Thr and Tyr kinases. The most prominent kinases, other than Cdk-9/T1, which were also inhibited (>98% inhibition) by <b>11d</b>, includes ABL1 mutants (E255 K, H396P, Q252H), BLK, Cdk4/D1, Cdk4/D3, CIT, ERBB3, ICK, KIT A829P mutant, MEK5, PRKCE, and Tyk2. The complete profiling data on 468 kinases is provided in section S5 of the <a class="ref internalNav" href="#notes-7" aria-label="Supporting Information">Supporting Information</a>, and the TREEspot Interaction Map showing the percent inhibition profile is shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>. The percent inhibition values for kinases (with >65% inhibition) are displayed in the TREEspot interaction map, wherein the bigger circles are indicative of the stronger inhibition of particular kinase by compound <b>11d</b>.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Percent inhibition profile (TREEspot Interaction Map) in the DiscoverX ScanMax kinome scan for compound <b>11d</b>. The kinase groups and number of kinases in the panel: TK, tyrosine kinases (87); TKL, tyrosine kinase like (31); STE, STE kinases (43); CK1, cell kinase 1 (8); AGC, PKA, PKG, PKC kinases (46); CAMK, calcium and calmodulin regulated kinases (46); CMGC, Cdk, MAP, GSK, Cdk-like kinases (54); other, other kinases (54); mutant kinases (60); atypical kinases (8); lipid kinases (13); pathogen kinases (3). The red (and blue) circles indicate the kinases where compound <b>11d</b> has reduced the kinase activity to less than 35% of control. Two blue circles indicates Cdk-4 and Cdk-9 kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PRKCE (protein kinase C, epsilon) is an AGC group of wild-type human kinase, which plays a role in cardioprotection.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> As <b>11d</b> inhibits PRKCE, it was investigated for its potential cardiotoxic effect, using hERG channel binding assay. This assay involved a competitive radioligand binding assay in HEK293 cells expressing the hERG K<sup>+</sup> channel. The IC<sub>50</sub> of <b>11d</b> for inhibition of hERG K<sup>+</sup> channel was found to be >50 μM, indicating that the compound does not have liability for cardiac toxicity.</div><div class="NLM_p last">The selectivity scores (S-score) provide a quantitative method of describing compound selectivity to facilitate comparison of different compounds. The S(35), S(10), and S(1) scores for <b>11d</b> were computed from the kinase profiling results and these scores were found to be 0.114, 0.04, and 0.012, respectively. The comparison of the S(35) score of <b>11d</b> with kinase inhibitor clinical candidates and drugs indicated that <b>11d</b> has superior S-score over several of these candidates (details are provided in section S5 of the <a class="ref internalNav" href="#notes-7" aria-label="Supporting Information">Supporting Information</a>). In particular, the selectivity score [S(35) = 0.114] of <b>11d</b> was found to be better than several clinically approved kinase inhibitors erlotinib, sorafenib, dasatinib, and sunitinib.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cellular Antiproliferative Activity in a Panel of Cancer Cell Lines</h3><div class="NLM_p">The cellular antiproliferative activity of all four series of compounds was evaluated in a panel of cancer cell lines including HL-60 (leukemia), PC-3 (prostate), MIAPaCa-2 (pancreatic), MCF-7 (breast), and Caco-2 (colon) using tetrazolium-based calorimetric antiproliferation assay (MTT assay). The initial screening was performed at a single concentration of 10 μM, followed by determination of GI<sub>50</sub> values for the best compounds. Like Cdk inhibition results, series A–C were weak to moderately active in a panel of five cell lines tested (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). None of the compounds from these three series showed >50% growth inhibition of cancer cell lines at 10 μM. However, several compounds from series D showed >50% inhibition of the cell growth, the most promising among them were compounds <b>11d</b> and <b>11e</b>, which were active against all five cell lines. Therefore, the GI<sub>50</sub> values were determined for series D compounds (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Compound <b>11d</b> from series D, which was most active in Cdk screening, displayed promising cellular antiproliferative activity in HL-60 and MIAPaCa-2 cells with GI<sub>50</sub> values of 0.9 and 1 μM, respectively.</div><div class="NLM_p">Further, compound <b>11d</b> was studied for its cellular antiproliferative activity in a panel of 27 cancer and three normal cell lines. Results are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. The representative dose–response curves for antiproliferative activity of <b>11d</b> are shown in section S2 of the <a class="ref internalNav" href="#notes-7" aria-label="Supporting Information">Supporting Information</a>. It exhibited significant cellular activity across the panel; however, the most prominent activity was observed in leukemia and pancreatic cancer cell lines. Compound <b>11d</b> displayed strong antiproliferative activity in leukemia cells, which could be because of the higher expression of Cdks and cyclins in these cells.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> In contrast, the cell cycle proteins are less expressed in Caco-2 cells,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> resulting in comparatively low cellular antiproliferative activity of <b>11d</b> in this cell line. In addition to the panel of human cancer cell lines, compound <b>11d</b> was also tested for cellular antiproliferative activity in mouse adenocarcinoma cell line, wherein the GI<sub>50</sub> was found to be 1.2 μM. Compound <b>11d</b> showed significantly low toxicity to normal cell lines (GI<sub>50</sub> values of 18–22 μM), indicating a good cellular therapeutic window of the compound.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cellular Antiproliferative Activity (IC<sub>50</sub> Values) of <b>11d</b> in a Panel of Cancer Cell Lines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line (tissue)</th><th class="colsep0 rowsep0" align="center" char="±">GI<sub>50</sub>, μM (±SD)</th><th class="colsep0 rowsep0" align="center">cell line (tissue)</th><th class="colsep0 rowsep0" align="center" char="±">GI<sub>50</sub>, μM (±SD)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HL60 (leukemia)</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.3</td><td class="colsep0 rowsep0" align="left">NCIH322 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MOLT-4 (leukemia)</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">NCIH522 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MIAPaCa-2 (pancreatic)</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.4</td><td class="colsep0 rowsep0" align="left">HOP62 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Panc-1 (pancreatic)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.6</td><td class="colsep0 rowsep0" align="left">HOP92 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3 (prostate)</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.5</td><td class="colsep0 rowsep0" align="left">NCIH-226 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU145 (prostate)</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.3</td><td class="colsep0 rowsep0" align="left">786-O (renal)</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF-7 (breast)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.4</td><td class="colsep0 rowsep0" align="left">A431 (skin)</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDAMB-231 (breast)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.3</td><td class="colsep0 rowsep0" align="left">LOXIMVI (skin)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDAMB-468 (breast)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 0.4</td><td class="colsep0 rowsep0" align="left">OVCAR-3 (ovarian)</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT-549 (breast)</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 0.2</td><td class="colsep0 rowsep0" align="left">OVCAR-4 (ovarian)</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T47D (breast)</td><td class="colsep0 rowsep0" align="char" char="±">6 ± 0.3</td><td class="colsep0 rowsep0" align="left">OVCAR-5 (ovarian)</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 (colon)</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.4</td><td class="colsep0 rowsep0" align="left">mouse adenocarcinoma</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW630 (colon)</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.01</td><td class="colsep0 rowsep0" align="left">HGF (normal)</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Colo-205 (colon)</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 0.8</td><td class="colsep0 rowsep0" align="left">fR2 (normal)</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT116 (colon)</td><td class="colsep0 rowsep0" align="char" char="±">5 ± 1.0</td><td class="colsep0 rowsep0" align="left">HEK293 (normal)</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549 (lung)</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 1.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Cellular antiproliferative activity is average of three independent determinations and is performed at 48 h of incubation time.</p></div></div></div><div class="NLM_p">It has been reported that the inhibition of Cdk-9 selectively targets survival proteins and reinstates apoptosis in cancer cells. Therefore, for compound <b>11d</b>, which is a highly potent Cdk-9 inhibitor, the mechanistic studies were performed in MIAPaCa-2 (pancreatic cancer) cell line, and results are shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. The compound was studied for cell cycle analysis (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a), by apoptosis study via scanning electron microscopy (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>b), by DAPI staining (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>c), and for mitochondrial membrane potential loss (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>d). The cell cycle analysis indicated that there is a marginal cell cycle arrest by <b>11d</b>, in G1 phase. This may be because of the higher selectivity of the compound for Cdk-9/T1 inhibition, the Cdk, which is not a cell cycle regulator. However, in apoptosis study, there is an increased formation of apoptotic bodies and chromatin condensation in nuclei of cells treated with <b>11d</b>, which suggests that this compound inhibits the growth of MIAPaCa-2 cells by inducing apoptosis. The scanning electron microscopy of treated cells showed vesicle formation inside the cells, while the control cells were healthy. The untreated cells showed healthy and round nuclei with no DNA fragmentation. The compound <b>11d</b> was also found to trigger mitochondrial membrane potential (MMP) loss in MIAPaCa-2 cells (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>d). Further, we studied the effect of compound <b>11d</b> on important apoptosis markers, <i>viz</i>. PARP, caspase-3, and caspase-7. Western-blot studies (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) indicated the concentration-dependent cleavage of PARP, caspase-3, and caspase-7 by compound <b>11d</b>, confirming the apoptosis mediated cell death of MIAPaCa-2 cells.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>11d</b> on cell cycle (a), apoptosis via scanning electron microscopy (b), and DAPI staining (c), and mitochondrial membrane potential loss (using Rh123 dye) (d) in MIAPaCa-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>11d</b> on PARP, caspase-3, and caspase-7 using western-blot analysis in MIAPaCa-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Physicochemical Properties and ADME Profile of <b>11d</b></h3><div class="NLM_p">The experimental physicochemical parameters such as thermodynamic equilibrium solubility in water and biological medias (PBS, SGF, and SIF), log P, and p<i>K</i><sub>a</sub> values were determined using our established protocols.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Compound <b>11d</b> was found to possess moderate solubility in water (20 μg/mL). The experimental log P, log D, and p<i>K</i><sub>a</sub> of compound <b>11d</b> were found to be 3.09, 1.65, and 5.4, respectively. The compound was also studied for pH-dependent solution stability and stability in various biorelevant medias and in mouse plasma. It was found to be stable at all the conditions tested. Furthermore, the compound <b>11d</b> also follows the Lipinski Rule of Five (passes 4/4 rules). The physicochemical parameters of <b>11d</b> are summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Characterization of <b>11d</b> and Metabolic Stability in Liver Microsomes, Hepatocytes, and in the S9 Liver Fraction</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">solubility (μg/mL ± SD)</th><th class="colsep0 rowsep0" align="center">log P/p<i>K</i><sub>a</sub></th><th class="colsep0 rowsep0" align="center">chemical stability</th><th class="colsep0 rowsep0" align="center">PPB, % bound</th><th class="colsep0 rowsep0" align="center">CYP inhibition, IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water: 20.31 ± 4.04</td><td class="colsep0 rowsep0" align="left">log P: 3.09</td><td class="colsep0 rowsep0" align="left">% drug remaining (after h):</td><td class="colsep0 rowsep0" align="left">mouse: 97.2</td><td class="colsep0 rowsep0" align="left">1A2: >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBS (pH 7.4): 2.29 ± 0.07</td><td class="colsep0 rowsep0" align="left">log D: 1.65</td><td class="colsep0 rowsep0" align="left">pH 1.2: 100 (24)</td><td class="colsep0 rowsep0" align="left">rat: 95.4</td><td class="colsep0 rowsep0" align="left">2D6: >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SGF (pH 1.2): 8.81 ± 0.39</td><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub>: 5.4</td><td class="colsep0 rowsep0" align="left">pH 4.0: 100 (24)</td><td class="colsep0 rowsep0" align="left">dog: 95</td><td class="colsep0 rowsep0" align="left">2C9: >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SIF (pH 6.8): 2.18 ± 0.16</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 6.8: 81 (24)</td><td class="colsep0 rowsep0" align="left">human: 96.7</td><td class="colsep0 rowsep0" align="left">2C19: >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 7.4: 100 (24)</td><td class="colsep0 rowsep0" align="left">HSA: 96.7</td><td class="colsep0 rowsep0" align="left">3A4: >20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SGF: 100 (8)</td><td class="colsep0 rowsep0" align="left">AAG: 98.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SIF: 100 (8)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mouse plasma: 94 (8)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="7" align="center">metabolic stability</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">liver microsomes</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">hepatocytes</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">S9 liver fraction</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (μL/min/mg protein)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (μL/min/mg protein)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char="."><8.8</td><td class="colsep0 rowsep0" align="char" char=".">186</td><td class="colsep0 rowsep0" align="char" char=".">14.9</td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char="."><13</td><td class="colsep0 rowsep0" align="char" char=".">376</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char="."><8.6</td><td class="colsep0 rowsep0" align="char" char=".">726</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">72</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dogs</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">>29</td><td class="colsep0 rowsep0" align="char" char=".">281</td><td class="colsep0 rowsep0" align="char" char=".">12.3</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">54.8</td><td class="colsep0 rowsep0" align="char" char=".">326</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr></tbody></table></div></div><div class="NLM_p">Human serum protein binding affinity affects the drug distribution in the body, and it also has an impact on the drug–drug interaction. In plasma, drug exists in bound ↔ unbound form. The percent protein binding of <b>11d</b> in human plasma was found to be 96.7%. The plasma protein binding in other species. <i>viz</i>. rat, mouse, and dog plasma, was also determined, which was found to be in a similar range (95–97.2% binding). The human serum albumin (HSA) and α1-acid glycoprotein (AAG) are the most relevant drug carriers in blood plasma, and it is generally accepted that basic drugs mainly bind to these two proteins. Therefore, the binding of <b>11d</b> with AAG and HSA was also assessed, which showed that the compound also possess higher binding to these two proteins (98.3 and 96.7%).</div><div class="NLM_p last">The in vitro metabolism of compound <b>11d</b> was investigated using pooled liver microsomes, hepatocytes, and S9 liver fraction of mouse, rat, human, dog, and monkeys. First, the microsomal stability was studied to investigate phase I metabolism using NADPH as the enzyme cofactor. The half-life (<i>t</i><sub>1/2</sub>) value was measured by monitoring substrate disappearance over time. Intrinsic clearance (CL<sub>int</sub>) was also determined, which helps to confirm whether metabolism is the main clearance pathway when it is compared with the total body clearance in vivo. The compound showed <i>t</i><sub>1/2</sub> > 30 min in mouse, rat, and human liver microsomes, whereas this value was <30 min in dog and monkey liver microsomes. It has low intrinsic clearance in mouse, rat, and human liver microsomes, whereas medium CL<sub>int</sub> in monkey and high CL<sub>int</sub> in dog liver microsomes. Next, the metabolic stability was assessed in hepatocytes of all five species in order to investigate the phase II metabolism. Compound <b>11d</b> showed higher <i>t</i><sub>1/2</sub> value in hepatocytes compared with microsomes. The <i>t</i><sub>1/2</sub> in human hepatocytes was found to be 12 h, as the corresponding intrinsic clearance was very low. Overall, <b>11d</b> falls in medium clearance category in all the species of hepatocytes. The S9 liver fractions contain both microsomal (CYPs) and cytosolic enzymes (SULT, GST, XO, ADHs, NATs), and therefore, it offers a more complete representation of the metabolic profile compared with microsomes and cytosolic fractions. Compound <b>11d</b> was also studied for metabolic stability in S9 liver fraction of all five species, wherein it displayed moderate half-life and intrinsic clearance. In a nutshell, compound <b>11d</b> undergoes metabolic degradation in all three matrixes with varied half-lives and intrinsic clearance, and it has acceptable metabolic stability profile (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacokinetics of <b>11d</b></h3><div class="NLM_p">The pharmacokinetics of compound <b>11d</b> was evaluated in BALB/c mice following a single 10 mg/kg dose administration by oral route and 1.0 mg/kg dose administration by IV route. Following oral administration, elimination half-life (<i>t</i><sub>1/2,ß</sub>) was found to be 4.65 h and AUC<sub>0-t</sub> was found to be 4503 nM·h. Following IV administration, elimination half-life (<i>t</i><sub>1/2,ß</sub>) was found to be 5.46 h, and clearance was ∼55 mL/min/kg. The absolute oral bioavailability was 71% (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The data presented in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> and <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a> indicated that compound <b>11d</b> has optimal ADME parameters for anticancer therapeutics.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacokinetic analysis of <b>11d</b> in BALB/c mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the dose-dependent pharmacokinetics of <b>11d</b> was studied in BALB/c mice and also in SD rats. Results are shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Compound <b>11d</b> displayed a dose-dependent increase in the plasma exposure upon oral administration, both in mice and rats. In a tissue-distribution study performed in SD rats (at 30 mg/kg, po) to find the exposure of the compound to organs of interest (pancreas, the targeted cancer), it was observed that the compound has good tissue distribution in the pancreas. The pancreas/plasma ratio (kp) of compound <b>11d</b> was found to be 5.3, 4.1, and 10.5 at 0.5, 1, and 8 h. Similarly, in the tissue distribution study in BALB/c mice (at 30 mg/kg, po), the pancreas/plasma ratio (kp) of compound <b>11d</b> was found to be 14.2, 24.4, and 6.79 at 0.5, 1, and 8 h, indicating a good exposure of drug to the pancreas. Other tissues where compound showed good exposure include lung, liver, and kidneys.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Dose-Dependent Pharmacokinetics of <b>11d</b> in BALB/c Mice and SD Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">BALB/c mice</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">SD rats</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center" char=".">3 mpk, p.o.</th><th class="colsep0 rowsep0" align="center" char=".">10 mpk, p.o.</th><th class="colsep0 rowsep0" align="center" char=".">30 mpk, p.o.</th><th class="colsep0 rowsep0" align="center" char=".">3 mpk, p.o.</th><th class="colsep0 rowsep0" align="center" char=".">10 mpk, p.o.</th><th class="colsep0 rowsep0" align="center" char=".">30 mpk, p.o.</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">216</td><td class="colsep0 rowsep0" align="char" char=".">670</td><td class="colsep0 rowsep0" align="char" char=".">4108</td><td class="colsep0 rowsep0" align="char" char=".">316</td><td class="colsep0 rowsep0" align="char" char=".">900</td><td class="colsep0 rowsep0" align="char" char=".">3623</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">1.71</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">3.09</td><td class="colsep0 rowsep0" align="char" char=".">3.61</td><td class="colsep0 rowsep0" align="char" char=".">3.62</td><td class="colsep0 rowsep0" align="char" char=".">4.67</td><td class="colsep0 rowsep0" align="char" char=".">5.16</td><td class="colsep0 rowsep0" align="char" char=".">3.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (nM·h)</td><td class="colsep0 rowsep0" align="char" char=".">642.88</td><td class="colsep0 rowsep0" align="char" char=".">2414</td><td class="colsep0 rowsep0" align="char" char=".">11266</td><td class="colsep0 rowsep0" align="char" char=".">1441</td><td class="colsep0 rowsep0" align="char" char=".">5676</td><td class="colsep0 rowsep0" align="char" char=".">15876</td></tr></tbody></table></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Anticancer Activity of <b>11d</b> in Murine and Xenograft Models</h3><div class="NLM_p">The preliminary anticancer activity investigation of styryl derivative <b>11d</b> was performed in Ehrlich solid tumors, a murine mice model to understand the effective dose-range in a 15-day study. The purpose of this study was 2-fold, first to determine the maximum tolerated dose in mice, and second to determine the effective dose-range. Initial dose-optimization studies involved various doses ranging from 10 to 100 mg/kg. Compound <b>11d</b> at 70 and 100 mg/kg p.o. showed 31 and 39% tumor growth inhibition without causing any mortality (mortality: 0/7). The doses above 100 mg/kg resulted in mortality. The detailed results of anticancer activity in murine models are shown in section S3 of the <a class="ref internalNav" href="#notes-7" aria-label="Supporting Information">Supporting Information</a>. This study indicated that the maximum tolerated dose of <b>11d</b> by oral route in mice is 100 mg/kg.</div><div class="NLM_p">After getting indication of the anticancer activity of <b>11d</b> in the murine mice model via oral route, further we tested the compound <b>11d</b> in three human xenograft models, <i>viz</i>. pancreatic, colon, and leukemia cancer at 25 and 50 mg/kg doses via a peroral route. The selection of these tumor types for xenograft study was based on cellular antiproliferative activity results. Compound <b>11d</b> possesses the most prominent in vitro cellular antiproliferative activity in Molt-4 and MIAPaCa-2 cells with GI<sub>50</sub> values of <1 μM; therefore, these cell lines were selected for xenograft studies. In all these models, compound <b>11d</b> was found to display promising tumor growth inhibition, showing up to 40–52% TGI at 50 mg/kg, p.o. dose, without causing any mortality. Results are shown in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>. There was no significant change in the body weight of animals during these studies. Results obtained from the <i>in vivo</i> study confirmed the anticancer potential of the compound <b>11d</b>, indicating its potential for detailed preclinical characterization.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor effect of styryl derivative <b>11d</b> in human pancreatic (MIAPaCa-2), colon (HCT-116), and leukemia (Molt-4) xenograft nude mice models. (a,b) Graph showing the effect of <b>11d</b> on the MIAPaCa-2 tumor growth along with representative tumor images. (c,d) Graph showing the effect of <b>11d</b> on the HCT-116 tumor growth along with representative tumor images. (e,f) Graph showing the effect of <b>11d</b> on the Molt-4 tumor growth along with representative images of Molt-4 xenograft studies. Data represent the mean (<i>n</i> = 6) ± SEM. Statistical significance (*<i>p</i> < 0.05) was determined by one-way analysis of variance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In order to have a look at the in vitro/in vivo efficacy correlation, the tissue distribution pharmacokinetics data was analyzed. The single dose tissue distribution PK study (30 mg/kg, po) in BALB/c mice as well as in SD rats indicated that drug reaches to the target tissue, pancreas, significantly, with the highest concentration within 0.5 h; however, after 8 h, the concentration drops by 5–10-fold because of the rapid elimination of compound. This is also evidenced from the metabolic stability data of the compound in liver microsomes and hepatocytes (<i>t</i><sub>1/2</sub> less than 4 h). As shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, the <i>C</i><sub>max</sub> of the compound at 30 mg/kg, p.o. is 4.1 μM, which is ∼4-fold higher than the average GI<sub>50</sub> of <b>11d</b> in leukemia/pancreatic cancer cell lines. However, the equivalent dose (25 mg/kg) in the in vivo xenograft study does not show significant antitumor activity, which could be due to the permeability and metabolic inactivation barriers. However, the statistically significant in vivo antitumor activity was obtained at 50 mg/kg in all three xenograft models, without causing any mortality.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Safety Pharmacology Studies of <b>11d</b></h3><div class="NLM_p">After obtaining interesting in vitro and in vivo anticancer activity for compound <b>11d</b>, a thorough investigation of the safety profile of this lead was carried out. Various studies that are performed include CYP inhibition liability, efflux pump substrate liability, cardiac toxicity (hERG channel binding), mutagenicity (Ames test), in vitro micronucleus test (genotoxicity), and acute oral toxicity in rats. Cytochrome P450 is a group of drug metabolizing enzymes, and their induction or inhibition affects the blood level of a drug and hence can affect toxicity and efficacy. Compound <b>11d</b> was studied for inhibition of five major CYP enzymes, using 10 min incubation time. It showed inhibition of CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2C19 with IC<sub>50</sub> values of >20 μM. In order to understand the propensity of <b>11d</b> for inhibition of CYP enzymes over the time, the time-dependent inhibition study was then performed against three CYP enzymes, <i>viz</i>. CYP3A4, CYP2D6, and CYP2C9. Compound was tested at 2 and 20 μM, at two incubation times (5 and 30 min). Compound was found to show some propensity of time-dependent inhibition of 3A4 isoform (at 2 μM, 30% and 40% inhibition after 5 and 30 min incubation time, respectively), whereas no propensity was observed for 2D6 and 2C9 isoforms.</div><div class="NLM_p">The Caco-2 permeability is also an important parameter to predict oral absorption and cellular permeability or mechanism of transport of a drug molecule. This information indicates whether the compound is a substrate for efflux pumps. This assay is considered to be the gold standard for in vitro prediction of in vivo human intestinal permeability and bioavailability of orally administered drugs. An efflux ratio of 1 is indicative of passive diffusion, and a value less than 0.5 and greater than 2 is regarded as active influx and active efflux, respectively. The Papp values of <b>11d</b> were found to be: (10<sup>–6</sup> cm/s) A to B, 2.1; B to A, 3.9; efflux ratio = 1.8. The efflux ratio of 1.8 indicates that <b>11d</b> is not a substrate of an efflux pump.</div><div class="NLM_p">The hERG channel binding potential of compound <b>11d</b> was studied using competitive radioligand binding assay in HEK293 cells expressing the hERG K<sup>+</sup> channel. Astemizole was used as a positive control in the study. The IC<sub>50</sub> of <b>11d</b> for inhibition of the hERG K<sup>+</sup> channel was found to be >50 μM (Amestizole, IC<sub>50</sub> = 14 nM). This indicated that compound does not have liability for cardiac toxicity.</div><div class="NLM_p">Ames study was performed to evaluate <b>11d</b> for its possible mutagenic activity, by the bacterial reverse mutation test, using five histidine deficient (his-) mutant tester strains of <i>Salmonella typhimurium</i>, <i>viz</i>. TA1537, TA1535, TA98, TA100, and TA102. This has been evaluated along with known mutagens (positive controls), sodium azide, 9-aminoacridine, 2-nitrofluorene, and mitomycin C, in the absence and presence of a metabolic activation system. Based on these cytotoxicity observations, a maximum concentration of 50 μg/plate was selected for the mutagenicity test, both in the absence and presence of the metabolic activation system, for all the tester strains. There was no statistically significant increase in the number of revertant colonies in any strain, both with (5% and 10%, v/v S9 mix) and without a metabolic activation system when compared with the concurrent negative control. This indicates that <b>11d</b> is nonmutagenic in the bacterial reverse mutation test in the absence and presence of a metabolic activation system.</div><div class="NLM_p last">The in vitro mammalian cell micronucleus study was performed to evaluate the clastogenic and aneugenic activity of <b>11d</b> in cells that have undergone cell division after exposure with cytokinesis blocking substance cytochalasin B in the absence and presence of a metabolic activation using human peripheral blood lymphocytes. Cyclophosphamide (30 μg/mL) and mitomycin-C (1 μg/mL) were used as the positive controls in the presence and absence of metabolic activation, respectively. Human peripheral blood lymphocyte cultures were exposed to <b>11d</b> at five dose-levels (two cultures/dose level) between 0.125 and 2 μg/mL of culture medium both in the absence and presence of a metabolic activation system (5% v/v S9 mix). Compound <b>11d</b> did not induce statistically significant or biologically relevant increases in the number of binucleated cell micronuclei in the absence and presence of a metabolic activation in either of the two independently conducted experiments, indicating a nongenotoxic property of compound <b>11d</b>. Next, the acute oral toxicity in Wistar rats indicated that the LD<sub>50</sub> of the compound is 1000 mg/kg. Overall, compound <b>11d</b> displayed a desirable profile in safety pharmacology studies.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Medicinal chemistry efforts on rohitukine have resulted in the identification of the first orally bioavailable Cdk inhibitor IIIM-290 (<b>11d</b>) from the rohitukine scaffold, exhibiting anticancer activity in cellular and animal models. Compound <b>11d</b> is a potent Cdk-9/T1 inhibitor with an IC<sub>50</sub> value of 1.9 nM and exhibited promising in vivo efficacy in human xenograft models by the oral route. Compound <b>11d</b>, which targets cell cycle-related Cdk-2/4 and transcription-related Cdk-9, might contribute to the antitumor activity. It possesses drug-like properties (good aqueous solubility, Log P = 3.09, p<i>K</i><sub>a</sub> 5.4, no violation of any Lipinski rule), is stable throughout the pH range and in all biological medias, does not possess CYP inhibition liability, does not have efflux pump substrate liability, is metabolically stable in microsomes, heaptocytes, and S9 liver fraction, is nonmutagenic and nongenotoxic, does not have hERG channel binding (no cardiac toxicity), and has a good profile in acute oral toxicity in rats. The preclinical data presented herein warrants the clinical investigation of this lead compound in cancer patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General</h3><div class="NLM_p"><sup>1</sup>H, <sup>13</sup>C, and DEPT and 2D-NMR spectra were recorded on Bruker-Avance DPX FT-NMR 500 and 400 MHz instruments. NMR experiments were carried out in the indicated solvent. Chemical data for protons are reported in parts per million (ppm) downfield from tetramethylsilane and are referenced to the residual proton in the NMR solvent [CDCl<sub>3</sub> 7.24 ppm, CD<sub>3</sub>OD 3.31 ppm, DMSO-<i>d</i><sub>6</sub> 2.4 ppm, acetone-<i>d</i><sub>6</sub> 2.04 ppm]. <sup>13</sup>C NMR were recorded at 125 or 100 MHz: chemical data for carbons are reported in parts per million (ppm, δ scale) downfield from tetramethylsilane and are referenced to the carbon resonance of the solvent [CDCl<sub>3</sub> 77 ppm, CD<sub>3</sub>OD 49.3 ppm, DMSO-<i>d</i><sub>6</sub> 39.7 ppm, acetone-<i>d</i><sub>6</sub> 29.8 ppm]. ESI-MS and HRMS spectra were recorded on Agilent 1100 LC-Q-TOF and HRMS-6540-UHD machines. All chromatographic purifications were performed on Sephadex and Dianion HP-20 resin. Thin layer chromatography (TLC) was performed on precoated silica gel 60 GF<sub>254</sub> aluminum sheets (Merck). All solvents used were of analytical grade and purchased from Merck. HPLC and HRMS were used to ascertain the purity of synthesized compounds. The HPLC purity analysis of all samples was carried out on a UPLC Shimadzu system (LC20ADXR), connected with a Lichrosphere RP18e (5 μ, 4.6 mm × 250 mm) column and was eluted with water (0.1% formic acid)/ACN gradient at the flow rate of 0.8 mL/min. The gradient elution was set with the increasing concentration of ACN in the following format: 5% ACN (0–3 min), 5–80% ACN (3–8 min), 80% ACN (8–12 min), 80–20% ACN (12–14 min), 5% ACN (14–16 min). The detection wavelength used was 254/280 nm.</div><div class="NLM_p last">The authentic plant material <i>Dysoxylum binectariferum</i> (leaves/bark) was collected by the Plant Biotechnology Division of Indian Institute of Integrative Medicine (CSIR), Jammu, during 2014–2016 from Forest Research Institute, Dehradun (Uttarakhand). The plant was identified and authenticated at IIIM, and herbarium sheet was prepared and submitted to Janaki Ammal herbarium, IIIM (Acronym RRLH, accession no. 22163). Dried samples of leaves were submitted to the institutional crude drug repository (accession no. 3892). The Ames test, micronucleus test, CYP inhibition, metabolic stability, pharmacokinetics, and Caco-2 permeability studies were performed at Jubilant Biosys Bangalore. MIAPaCa-2 and HCT-116 xenograft studies were performed at Sphaera Pharma Manesar and acute oral toxicity at Advinus Therapeutics Bangalore on a commercial basis. The animals used in the in vivo study were bred in-house and used. The animal facility is registered with CPCSEA vide registration no. 67/99/CPCSEA. All of the biologically tested compounds have met the >92% purity requirement.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Isolation of Rohitukine (<b>1</b>) from <i>Dysoxylum binectariferum</i></h3><div class="NLM_p last">The dried and powdered leaves (2 kg) of <i>D. binectariferum</i> were defatted with hexane (3 L × 3). The obtained residue was then extracted using 3 L of MeOH/CHCl<sub>3</sub> (15:85) using a mechanical stirrer for 2 h. MeOH/CHCl<sub>3</sub> extraction was repeated five times, and combined extract was concentrated under reduced pressure to get an extract (120 g). The obtained extract was partitioned between equal volume (500 mL each) of EtOAc and water. The aqueous layer was separated and concentrated under reduced pressure to a minimum volume (25 mL) without any precipitation. The concentrated solution was chilled in ice-bath, and acetone was added slowly until complete precipitation. Upon decantation of the acetone, brown residue (stage 3) was obtained, which was further recrystallized using methanol-acetone (2 times) to obtain a cream colored powder (rohitukine: 18.4 g, 0.92% yield). The compound was characterized by NMR, mass, and melting point.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> 5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>1</b>): cream colored powder (18.4 g, 0.92% yield); mp 215–218 °C; HPLC <i>t</i><sub>R</sub> = 1.96 min (98.60% purity); [α]<sup>20</sup><sub>D</sub> −17.07 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3584, 3312, 2956, 2920, 2870, 1741, 1653, 1460, 1378, 1247, 1082, 1020 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 6.15 (s, 1H), 5.97 (s, 1H), 4.14 (s, 1H), 3.62–3.59 (m, 1H), 3.49 (d, <i>J</i> = 8.4 Hz, 1H), 3.38 (t, <i>J</i> = 4.4 Hz, 1H), 3.35 (d, <i>J</i> = 4 Hz, 1H), 3.22–3.20 (m, 1H), 3.15 (d, <i>J</i> = 12 Hz, 1H), 2.82 (s, 3H), 2.32 (s, 3H), 1.75 (d, <i>J</i> = 8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183, 167.7, 163.1, 160.7, 156.5, 107.4, 106.4, 104, 99.4, 66.7, 60.4, 55.4, 42.9, 35.7, 21.9, 18.9. ESI-MS: <i>m</i>/<i>z</i> 306.01 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 306.1367 (calcd for C<sub>16</sub>H<sub>20</sub>NO<sub>5</sub><sup>+</sup> 306.1341).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of 5-<i>O</i>-Ether/Ester Derivatives <b>8a</b>–<b>h</b></h3><div class="NLM_p">Rohitukine (<b>1</b>, 100 mg, 0.328 mmol), KF-Al<sub>2</sub>O<sub>3</sub> (5 mol %), and benzyl halides/benzoyl halides (0.394 mmol) were mixed in a mortar and grinded intermittently using a pestle. The mixture was changed to a mushy state within a proper reaction time, and then it solidified itself. Formation of the product was monitored by TLC. On completion of the reaction, dichloromethane was added to the reaction mixture. After filtration of the catalyst, the filtrate was washed with aqueous NaOH (10%), and the organic phase was evaporated under reduced pressure. The crude products were purified over silica gel column chromatography (# 100–200) using hexane-ethyl acetate mobile phase, to furnish desired products <b>8a</b>–<b>h</b>.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (1′<i>R</i>,2′<i>S</i>)-7-(Benzyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8a</b>)</h4><div class="NLM_p last">Light yellowish powder (80 mg, 62% yield); mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 6.5 min (92.2% purity); [α]<sup>20</sup><sub>D</sub> −50 (<i>c</i> 0.1, MeOH). IR (KBr): ν<sub>max</sub> 3325, 2923, 1658, 1588, 1420, 1270, 1120, 1028 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD + CDCl<sub>3</sub>): δ 7.54–7.47 (m, 3H, ArH), 7.37–7.28 (m, 2H, ArH), 6.67 (s, 1H, ArH), 6.17 (s, 1H, ArH), 5.21 (2H, 2H), 4.31 (brs, 1H), 3.82–3.36 (m, 6H of piperidine), 2.93 (s, 3H), 2.48 (s, 3H) 1.93 (m, 1H of piperidine). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 184.6, 169.6, 165.0, 162.7, 157.5, 137.5, 134.6, 132.9, 129.8, 129.5, 129.0, 108.9, 97.8, 72.5, 65.9, 65.3, 63.1, 53.5, 38.4, 21.5, 20.5. HR-ESIMS: <i>m</i>/<i>z</i> 396.1802 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>26</sub>NO<sub>5</sub><sup>+</sup>, 396.1805).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1′<i>R</i>,2′<i>S</i>)-7-(4-Methoxybenzyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8b</b>)</h4><div class="NLM_p last">White powder (81 mg, 58% yield); mp 208–210 °C; HPLC <i>t</i><sub>R</sub> = 6.39 min (93.2% purity); [α]<sup>20</sup><sub>D</sub> −29 (<i>c</i> 0.1, MeOH). IR (KBr): ν<sub>max</sub> 3415, 2854, 1617, 1352, 1258, 1180 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.39 (s, 1H, H-bonded), 7.71 (d, <i>J</i> = 8.2 Hz, 2H), 7.09 (d, <i>J</i> = 8.2 Hz, 2H), 5.82 (s, 1H), 5.57 (s, 1H), 5.29 (d, <i>J</i> = 12.7 Hz, 1H), 4.71 (d, <i>J</i> = 12.7 Hz, 1H), 4.15 (brs, 1H), 3.80 (s, 3H), 3.57–3.35 (m, 6H of piperidine), 2.83 (s, 3H), 2.27 (s, 3H), 1.54 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 179.6, 176.4, 163.7, 159.9, 159.6, 155.3, 134.3, 120.2, 113.7, 106.8, 106.1, 102.1, 98.0, 68.3, 62.5, 62.2, 61.8, 54.8, 51.5, 35.5, 19.8, 19.3; ESIMS: <i>m</i>/<i>z</i> 448.2 [M + Na]<sup>+</sup>; HR-ESIMS: <i>m</i>/<i>z</i> 426.1913 [M + H]<sup>+</sup> (calcd for C<sub>24</sub>H<sub>28</sub>NO<sub>6</sub><sup>+</sup>, 426.1911).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (1′<i>R</i>,2′<i>S</i>)-7-(4-Bromobenzyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8c</b>)</h4><div class="NLM_p last">Off-white powder (82 mg, 53% yield); mp 208–210 °C; HPLC <i>t</i><sub>R</sub> = 6.6 min (99.2% purity); [α]<sup>20</sup><sub>D</sub> −48 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.71–7.68 (m, 4H), 6.31 (s, 1H), 6.11 (s, 1H), 5.27 (d, <i>J</i> = 12 Hz, 1H), 4.84 (d, <i>J</i> = 12 Hz, 1H, merge with moisture), 4.33 (brs, 1H), 3.73–3.30 (m, 6H of piperidine), 2.89 (s, 3H), 2.43 (s, 3H), 2.01 (m, 1H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 183.8, 172.1, 167.8, 161.8, 157.6, 144.2, 129.3, 128.6, 128.2, 128.0, 108.2 (2C), 103.1, 78.4, 69.3, 65.4, 61.9, 56.8, 44.4, 37.1, 23.3, 20.7. ESIMS: <i>m</i>/<i>z</i> 476.0895 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 476.0906 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub><sup>81</sup>BrNO<sub>5</sub><sup>+</sup>, 476.0896).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (1′<i>R</i>,2′<i>S</i>)-7-(4-Nitrobenzyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8d</b>)</h4><div class="NLM_p last">White powder (76 mg, 53% yield), mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 12.56 min (93% purity); [α]<sup>20</sup><sub>D</sub> −9.8 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.36 (d, <i>J</i> = 8.4 Hz, 2H), 8.07 (d, <i>J</i> = 8.4 Hz, 2H), 6.17 (m, 2H), 5.57 (d, <i>J</i> = 12.8 Hz, 1H), 4.89 (d, <i>J</i> = 12.8 Hz, 1H), 4.13 (brs, 1H), 3.77–3.35 (m, 6H of piperidine), 2.95 (s, 3H), 2.35 (s, 3H), 1.74 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.4, 176.2, 167.3, 157.6, 151.3, 149.1, 136.5 (2C), 124.9 (2C), 107.9, 107.9, 104.3, 104.0, 101.8, 70.9, 65.1, 64.5, 62.7, 57.2, 37.7, 21.7, 20.2. HR-ESIMS: <i>m</i>/<i>z</i> 441.1646 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>7</sub><sup>+</sup>, 441.1656).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (1′<i>R</i>,2′<i>S</i>)-7-(2-Bromobenzyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8e</b>)</h4><div class="NLM_p last">White powder (65 mg, 42% yield); mp 214–218 °C; HPLC <i>t</i><sub>R</sub> = 6.75 min (97% purity); [α]<sup>20</sup><sub>D</sub> −11.2 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.01 (d, <i>J</i> = 8.0, 1H), 7.83 (m, <i>J</i> = 8.0, 6.8 Hz, 1H), 7.55–7.43 (m, 2H), 5.97 (brs, 2H), 5.42 (d, <i>J</i> = 13.2 Hz, 1H), 5.17 (d, <i>J</i> = 13.3 Hz, 1H), 4.38 (brs, 1H), 3.95–3.59 (m, 6H of piperidine), 2.41 (s, 3H), 2.01 (s, 3H), 1.84 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 184.4, 169.3, 164.1, 161.9, 158.3, 137.2, 136.4, 135.6, 133.7, 129.6, 128.9, 108.8, 106.2, 105.5, 100.3, 72.1, 68.8, 66.7, 64.6, 53.3, 38.0, 21.3, 20.7. HR-ESIMS: <i>m</i>/<i>z</i> 474.0886 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>BrNO<sub>5</sub><sup>+</sup>, 474.0910).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (1′<i>R</i>,2′<i>S</i>)-7-(Cinnamyloxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8f</b>)</h4><div class="NLM_p last">Yellow powder (65 mg, 47% yield); mp 206–210 °C; HPLC <i>t</i><sub>R</sub> = 6.64 min (98% purity); [α]<sup>20</sup><sub>D</sub> −2.0 (<i>c</i> 0.1, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.57 (m, 2H), 7.37 (m, 3H), 7.08 (d, <i>J</i> = 15.6 Hz, 1H), 6.51 (m, <i>J</i> = 15.6 Hz, 1H), 6.07 (s, 1H) 5.97 (s, 1H), 4.85 (m, 1H), 4.51 (m, 1H), 4.28 (brs, 1H), 3.78–3.33 (m, 6H of piperidine ring) 3.10 (s, 3H), 2.36 (s, 3H), 1.74 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 180.7, 165.2, 164.6, 159.9, 155.8, 140.8, 135.2, 128.6 (2C), 127.0 (2C), 117.2, 106.7, 106.6, 101.6, 101.2, 68.2, 64.8, 63.7, 62.4, 52.2, 36.1, 19.9, 19.7. HR-ESIMS: <i>m</i>/<i>z</i> 422.1946 [M + H]<sup>+</sup> (C<sub>25</sub>H<sub>28</sub>NO<sub>5</sub><sup>+</sup>, 422.1962).</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (1′<i>R</i>,2′<i>S</i>)-7-((Furan-2-yl)methoxy)-5-hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>8g</b>)</h4><div class="NLM_p last">White crystalline powder (64 mg, 51% yield); mp 199–200 °C; HPLC <i>t</i><sub>R</sub> = 6.37 min (99.5% purity); [α]<sup>20</sup><sub>D</sub> −6.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2923, 2359, 1661, 1558, 1418, 1362, 1272, 1186, 1082 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD + CDCl<sub>3</sub>): δ 7.72 (d, <i>J</i> = 1.2 Hz, 1H), 6.92 (d, <i>J</i> =  3.2 Hz, 1H), 6.58 (dd, <i>J</i> = 3.2,1.6 Hz, 1H), 6.07 (s, 1H), 5.94 (s, 1H), 5.26 (d, <i>J</i> = 14.4 Hz, 1H), 5.14 (d, <i>J</i> = 14.4 Hz, 1H), 4.29 (brs, 1H), 3.71–3.50 (m, 6H of piperidine), 3.10 (s, 3H), 2.36 (s, 3H), 1.84 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.6, 172.2, 167.8, 162.0, 158.0, 157.9, 147.3, 144.9, 118.2, 112.5, 111.9, 108.2, 107.7, 103.1, 66.9, 65.1, 62.7, 58.3, 54.2, 37.4, 23.7, 21.5. HR-ESIMS: <i>m</i>/<i>z</i> 386.1571 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>6</sub><sup>+</sup>, 386.1598).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (1′<i>R</i>,2′<i>S</i>)-5-Hydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-7-yl furan-2-carboxylate (<b>8h</b>)</h4><div class="NLM_p last">White powder (60 mg, 46% yield); mp 184–186 °C; HPLC <i>t</i><sub>R</sub> = 4.88 min (92% purity); [α]<sup>20</sup><sub>D</sub> −8.0 (<i>c</i> 0.1, MeOH). IR (KBr): ν<sub>max</sub> 3416, 2924, 1617, 1560, 1424, 1290, 1177, 1113 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, ppm): 7.73 (dd, <i>J</i> = 0.4, 1.6 Hz, 1H), 7.49 (dd, <i>J</i> = 0.8, 3.6 Hz, 1H), 6.60 (dd, <i>J</i> = 1.6, 3.6 Hz, 1H), 6.22 (s, 1H), 5.96 (s, 1H), 5.58 (brs, 1H, 2′H of piperidine ring), 3.89–3.33 (m, 6H of piperidine), 2.97 (s, 3H), 2.14 (s, 3H), 2.10 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD, ppm): 184.2, 169.0, 164.1, 162.3, 158.7, 158.2, 148.8, 145.0, 120.9, 113.3, 108.7, 105.2, 104.6, 99.8, 70.4, 58.3, 56.9, 44.7, 36.5, 24.4, 20.5. ESI-MS: <i>m</i>/<i>z</i> 400.16 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 400.1394 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>22</sub>NO<sub>7</sub><sup>+</sup>, 400.1391).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Synthesis of Mannich Derivatives <b>9a</b>–<b>o</b></h3><div class="NLM_p">To the solution of rohitukine (<b>1</b>, 100 mg, 0.328 mmol) in methanol–water (10 mL, ratio 7:3) was slowly added a solution of formaldehyde (1 mL solution) and secondary amine (0.394 mmol). The resultant reaction mixture was then stirred at 70 °C for 5 h. Products were purified over Sephadex LH20 using methanol as eluent to get a gummy sticky mass, which was solidified in acetone.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (1′<i>R,</i>2′<i>S</i>)-6-((Diethylamino)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>9a</b>)</h4><div class="NLM_p last">White solid (57 mg, 45% yield); mp 200–202 °C; HPLC <i>t</i><sub>R</sub> = 4.76 min (99.1% purity); [α]<sup>20</sup><sub>D</sub> −3.8 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2958, 2927, 2958, 1738, 1660, 1610, 1274, 1153, 1019 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MH<sub>Z</sub>, CD<sub>3</sub>OD): δ 5.88 (s, 1H), 4.15 (m, 3H), 3.32–3.05 (m, 6H of piperidine + 4H of N-C<u class="uu">H</u><sub>2</sub>CH<sub>3</sub>), 2.79 (s, 3H), 2.29 (s, 3H), 1.51 (m, 1H), 1.26 (m, 6H of N-CH<sub>2</sub>C<u class="uu">H</u><sub>3</sub>). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): 183.1, 174.8, 168.1, 160.8, 158.0, 108.6, 108.0, 103.3, 101.1, 69.2, 61.9, 56.6, 51.5, 44.2, 36.8, 34.8, 23.3, 20.3, 9.4. ESIMS: <i>m</i>/<i>z</i> 391.10 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 391.2229 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup>, 391.2227).</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-((4-(piperidin-1-yl)piperidin-1-yl)methyl)-4<i>H</i>-chromen-4-one (<b>9b</b>)</h4><div class="NLM_p last">White solid (66 mg, 42% yield); mp 194–196 °C; HPLC <i>t</i><sub>R</sub> = 5.31 min (97% purity); [α]<sup>20</sup><sub>D</sub> +5.6 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3399, 3335, 2857, 1659, 1556, 1397, 1322.1152 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 5.91 (s, 1H), 3.93 (brs, 2H), 3.85 (m, 1H), 3.25–2.47 (m, 15H), 2.47 (s, 3H), 2.23 (s, 3H), 1.78–134 (m, 11H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 182.0, 172.6, 166.7, 159.7, 156.5, 107.1, 106.6, 102.1, 99.9, 67.7, 60.5, 60.2, 55.3, 49.8, 49.7, 43.0, 42.8, 39.0, 35.6, 24.2, 22.0, 21.9, 18.9. ESIMS: <i>m</i>/<i>z</i> 486.20 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 486.2961 [M + H]<sup>+</sup> (calcd for C<sub>27</sub>H<sub>39</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup>, 486.2968).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-((pyrrolidin-1-yl)methyl)-4<i>H</i>-chromen-4-one (<b>9c</b>)</h4><div class="NLM_p last">White solid (56 mg, 44% yield); mp 189–191 °C; HPLC <i>t</i><sub>R</sub> = 1.56 min (96.0% purity); [α]<sup>20</sup><sub>D</sub> +11.4 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2958, 2924, 1738, 1658, 1394, 1151, 1021 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MH<sub>Z</sub>, CD<sub>3</sub>OD + DMSO-<i>d</i><sub>6</sub>): δ 5.86 (s, 1H), 4.72 (brs, 2H), 4.16 (d, <i>J</i> = 8 Hz, 1H), 3.51–3.05 (m, 10H), 2.76 (s, 3H), 2.26 (s, 3H), 1.99–1.85 (m, 4H), 1.51 (d, 1H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): δ 183.2, 175.3, 167.8, 158.0, 108.9, 107.8, 104.4, 100.5, 69.4, 62.1, 56.8, 54.6, 50.1, 44.6, 44.3, 37.0, 24.0, 20.1. ESIMS: <i>m</i>/<i>z</i> 389.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 389.2071 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>29</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup>, 389.2071).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (1′<i>R</i>,2′<i>S</i>)-<i>tert</i>-Butyl-4-((5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-6-yl)methyl)piperazine-1-carboxylate (<b>9d</b>)</h4><div class="NLM_p last">Cream colored solid (68 mg, 41% yield); mp 197–205 °C; HPLC <i>t</i><sub>R</sub> = 5.82 min (95.8% purity); [α]<sup>20</sup><sub>D</sub> +2.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3394, 2931, 2719, 1692, 1660, 1611, 1459, 1418, 1365, 1280, 1248, 1152, 1167 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 5.92 (s, 1H), 4.09 (m, 3H), 3.56–3.00 (m, 14H), 2.79 (s, 3H), 2.28 (s, 3H), 1.61 (m, 1H), 1.21 (brs, 9H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100 MHz): δ 183.7, 168.4, 160.7, 157.7, 155.7, 108.3, 108.0, 103.3, 102.3, 82.1, 68.8, 61.9, 56.8, 52.5, 52.4, 50.3, 49.2, 44.4, 44.2, 40.5, 37.1, 28.7, 28.5, 28.5, 23.3, 20.3; ESIMS: <i>m</i>/<i>z</i> 504 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 504.2705 [M + H]<sup>+</sup> (calcd for C<sub>26</sub>H<sub>38</sub>N<sub>3</sub>O<sub>7</sub><sup>+</sup> 504.2704).</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-6-((2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-2-methyl-4<i>H</i>-chromen-4-one (<b>9e</b>)</h4><div class="NLM_p last">White crystalline solid (50 mg, 36% yield); mp 200–202 °C; HPLC <i>t</i><sub>R</sub> = 5.24 min (99% purity); [α]<sup>20</sup><sub>D</sub> −2.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3335, 2958, 1657, 1463, 1164, 1044 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD + DMSO-<i>d</i><sub>6</sub>): δ 6.04 (s, 1H), 4.56–4.03 (m, 3H), 3.99–3.25 (m, 11H, 6H of piperidine + 5H of prolinol), 2.75 (s, 3H), 2.56 (s, 3H), 2.14 (m, 2H), 2.02–1.77 (m, 2H), 1.56–1.50 (m, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub> + CD<sub>3</sub>OD): δ 182.8, 169.1, 161.16, 157.8, 108.7, 103.9, 69.9, 68.8, 62.9, 61.5, 60.6, 56.3, 55.4, 48.8, 48.4, 40.5, 39.6, 36.1, 27.3, 24.8, 23.4, 20.4. ESIMS: <i>m</i>/<i>z</i> 419 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 419.2170 [M + H]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>31</sub>N<sub>2</sub>O<sub>6</sub><sup>+</sup>, 419.2176).</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (1′<i>R</i>,2′<i>S</i>)-6-((4-Benzylpiperidin-1-yl)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>9f</b>)</h4><div class="NLM_p last">Cream colored solid (60 mg, 37% yield); mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 6.18 min (92% purity); [α]<sup>20</sup><sub>D</sub> −7.3 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3401, 2930, 2704, 1731, 1660, 1609, 1556, 1454, 1396, 1361, 1151, 1041 (cm<sup>–1</sup>). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.18–7.10 (m, 5H), 5.86 (s, 1H), 4.11 (m, 3H), 3.35–2.80 (m, 10H); 2.79 (s, 3H), 2.26 (s, 3H), 1.75 (brs, 4H), 1.53–1.40 (m, 2H), 0.89 (m, 1H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 184.8, 173.7, 166.5, 159.8, 156.5, 139.2, 128.8, 128.0, 125.5, 107.3, 106.6, 101.6, 99.5, 67.9, 66.2, 60.4, 55.2, 47.1, 42.8, 38.8, 38.2, 35.4, 30.21, 28.7, 22.4, 18.9. ESIMS: <i>m</i>/<i>z</i> 479.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 493.2694 [M + H]<sup>+</sup> (calcd for C<sub>29</sub>H<sub>37</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup>, 493.2697).</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1′<i>R</i>,2′<i>S</i>)-2-(<i>N</i>-((5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-6-yl)methyl)-<i>N</i>-methylamino)acetic Acid (<b>9g</b>)</h4><div class="NLM_p last">White powder (45 mg, 34% yield); mp 210–212 °C; HPLC <i>t</i><sub>R</sub> = 3.82 min (99% purity); [α]<sup>20</sup><sub>D</sub> +6.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2229, 2852, 1618, 1384, 1021 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 6.01 (s, 1H), 4.31–4.28 (m, 3H), 3.68–3.25 (m, 8H), 2.83 (s, 3H), 2.80 (s, 3H), 2.32 (s, 3H), 1.61 (d, <i>J</i> = 13.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 182.3, 167.5, 166.2, 159.8, 156.3, 107.2, 106.3, 102.08 101.3, 67.0, 59.8, 54.7, 49.3, 42.6, 40.4, 34.6, 28.0, 21.4, 18.7. ESIMS: <i>m</i>/<i>z</i> 407.0 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 407.1809 [M + H]<sup>+</sup> (calcd for C<sub>20</sub>H<sub>27</sub>N<sub>2</sub>O<sub>7</sub><sup>+</sup>, 407.1812).</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-(morpholinomethyl)-4<i>H</i>-chromen-4-one (<b>9h</b>)</h4><div class="NLM_p last">Cream colored solid (46 mg, 35% yield); mp 202–205 °C; HPLC <i>t</i><sub>R</sub> = 1.89 min (99% purity); [α]<sup>20</sup><sub>D</sub> +3.2 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3435, 2921, 2851, 1740, 1631, 1384, 1019 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD + DMSO-<i>d</i><sub>6</sub>): δ 5.90 (S, 1H), 4.11 (m, 3H), 3.77 (brs, 4H), 3.42–3.00 (m, 14H), 2.78 (s, 3H), 2.25 (s, 3H), 1.55 (d, <i>J</i> = 12 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.6, 175.25, 168.43, 161.0, 157.9, 108.2, 102.8, 102.0, 65.7, 64.9, 61.8, 56.7, 52.8, 52.7, 44.7, 44.2, 24.8, 20.4. ESIMS: <i>m</i>/<i>z</i> 403.2 [M – H]<sup>−</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 405.2028 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>29</sub>N<sub>2</sub>O<sub>6</sub><sup>+</sup>, 405.2020).</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-((4-phenylpiperidin-1-yl)methyl)-4<i>H</i>-chromen-4-one (<b>9i</b>)</h4><div class="NLM_p last">Cream colored solid (55 mg, 35% yield); mp 197–200 °C; HPLC <i>t</i><sub>R</sub> = 5.89 min (98% purity); [α]<sup>20</sup><sub>D</sub> +9.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2932, 2700, 1732, 1661, 1604, 1558, 1454, 1396, 1362, 1152, 1042 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, Pyr-<i>d</i><sub>5</sub>): δ 7.48–7.22 (m, 5H), 6.13 (s, 1H), 4.54 (s, 1H), 4.25 (s, 2H), 3.92–3.75 (m, 5H), 3.52–2.89 (m, 5H), 2.55 (s, 3H), 2.32 (s, 3H), 2.22–1.81 (m, 6H). <sup>13</sup>C NMR (100 MHz, Pyr-<i>d</i><sub>5</sub>): δ 186.3, 175.3, 167.9, 161.3, 158.0, 145.4, 129.7, 127.9, 127.7, 108.8, 108.0, 103.1, 100.8, 69.3, 61.9, 56.7, 47.2, 46.1, 42.0, 41.0, 37.0, 31.1, 23.1, 20.2. ESIMS: <i>m</i>/<i>z</i> 479.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 479.2536 [M + H]<sup>+</sup> (calcd for C<sub>28</sub>H<sub>35</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup>, 479.2540).</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (1′<i>R</i>,2′<i>S</i>)-Ethyl-4-((5,7-dihydroxy-8-(3-hydroxy-1-methyl piperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-6-yl)methyl)piperazine-1-carboxylate (<b>9j</b>)</h4><div class="NLM_p last">White colored solid (55 mg, 35% yield); mp 218–224 °C; HPLC <i>t</i><sub>R</sub> = 6.03 min (99% purity); [α]<sup>20</sup><sub>D</sub> −4.8 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2930, 1696, 1660, 1611, 1468, 1429, 1395, 1323, 1245, 1151, 1100, 1034 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 5.92 (s, 1H), 4.08–4.01 (m, 5H), 3.57–2.80 (m, 14H), 2.79 (s, 3H), 2.39 (s, 3H), 1.63 (m, 1H), 1.19 (m, 3H). <sup>13</sup>C NMR (101 MHz, Pyr-<i>d</i><sub>5</sub>): δ 184.7, 169.0, 166.1, 160.7, 158.3, 156.9, 109.7, 107.9, 105.5, 105.0, 82.4, 69.8, 63.1, 62.9, 54.2, 53.5, 52.9, 45.2, 45.0, 38.9, 21.9, 16.4. ESIMS: <i>m</i>/<i>z</i> 476.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 476.2400 [M + H]<sup>+</sup> (calcd for C<sub>24</sub>H<sub>34</sub>N<sub>3</sub>O<sub>7</sub><sup>+</sup>, 476.2391).</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1′<i>R</i>,2′<i>S</i>)-6-((Diisopropylamino)-methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>9k</b>)</h4><div class="NLM_p last">Cream colored solid (65 mg, 47% yield); mp 190–196 °C; HPLC <i>t</i><sub>R</sub> = 4.73 min (99% purity); [α]<sup>20</sup><sub>D</sub> −19.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 2852, 1618, 1384, 1022 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.05 (s, 1H), 4.41 (m, 1H), 4.00 (s, 2H), 4.00–3.17 (m, 8H), 2.80 (s, 3H), 2.33 (s, 3H), 1.52 (m, 1H), 1.33–1.22 (m, 12H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 184.0, 169.2, 167.9, 163.2, 155.8, 113.0, 108.1, 106.8, 102.9, 68.3, 61.4, 56.5, 55.5, 43.9, 36.5, 35.1, 31.5, 22.9, 20.3. ESIMS: <i>m</i>/<i>z</i> 419.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 419.2543 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>35</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup>, 419.2540).</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (1′<i>R</i>,2′<i>S</i>)-4-Hydroxy-1-((5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-6-yl)methyl)pyrrolidine-2-carboxylic Acid (<b>9l</b>)</h4><div class="NLM_p last">Crystalline solid (55 mg, 37% yield); mp 201–205 °C; HPLC <i>t</i><sub>R</sub> = 3.80 min (92% purity); [α]<sup>20</sup><sub>D</sub> +7.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3435, 2922, 2852, 1739, 1589, 1418, 1219, 1019 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 6.01 (s, 1H), 4.31 (brs, 2H), 4.26 (s, 1H), 3.95 (d, <i>J</i> = 8 Hz, 1H), 3.67 (d, <i>J</i> = 12 Hz, 1H), 3.50–3.25 (m, 6H), 2.81 (s, 3H), 2.80 (m, 1H), 2.52 (m, 1H), 2.27 (s, 3H), 2.13 (d, <i>J</i> = 12 Hz, 1H), 1.60 (d, <i>J</i> = 12 Hz, 1H), 1,25 (m, 1H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): δ 184.0 (2C), 172.4, 169.2, 161.1, 157.7, 108.9, 107.8, 103.9, 103.7, 70.2, 68.6, 62.3, 61.4, 57.5, 56.3, 44.3, 39.0, 36.0, 23.3, 20.3, 17.4. ESIMS: <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 449.1922 [M + H]<sup>+</sup> (calcd as C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>8</sub><sup>+</sup>, 449.1918).</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (1′<i>R</i>,2′<i>S</i>)-1-((5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4-oxo-4<i>H</i>-chromen-6-yl)methyl)pyrrolidine-2-carboxylic Acid (<b>9m</b>)</h4><div class="NLM_p last">White crystalline solid (65 mg, 46% yield); mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 5.18 min (99% purity); [α]<sup>20</sup><sub>D</sub> −2.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3436, 2923, 2852, 1742, 1616, 1418, 1019 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 6.04 (s, 1H), 4.69 (brs, 2H), 4.33–4.26 (m, 3H), 3.85–3.21 (m, 7H of piperidine ring and 1H of proline), 2.83 (s, 3H), 2.32 (s, 3H), 2.06 (m, 2H), 1.84 (m, 1H), 1.59 (m, 1H), 1.24 (m, 1H). <sup>13</sup>C NMR (101 MHz, Pyr-<i>d</i><sub>5</sub>): δ 184.39 (2C), 168.34, 160.89, 158.53, 151.96, 109.49, 108.49, 106.16, 104.04, 69.92, 69.12, 62.47, 57.40, 54.97, 51.12, 45.42, 38.58, 31.27, 25.36, 24.28, 21.81. ESIMS: <i>m</i>/<i>z</i> 433.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 433.1970 [M + H]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>7</sub><sup>+</sup>, 433.1969).</div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-((4-methylpiperazin-1-yl)methyl)-4<i>H</i>-chromen-4-one (<b>9n</b>)</h4><div class="NLM_p last">Cream colored powder (56 mg, 41% yield); mp 210–212 °C; HPLC <i>t</i><sub>R</sub> = 4.97 min (99% purity); [α]<sup>20</sup><sub>D</sub> −3.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2923, 2852, 1659, 1559, 1466, 1391, 1274, 1150 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD + DMSO-<i>d</i><sub>6</sub>): δ 5.88 (s, 1H), 4.04 (m, 3H), 3.51–2.56 (m, 14H), 2.81 (s, 3H), 2.56 (s, 3H), 2.25 (m, 3H), 1.54 (d, <i>J</i> = 12 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 181.2, 172.8, 165.9, 158.7, 155.6, 106.8, 106.5, 101.9, 99.8, 66.8, 59.8, 54.6, 52.2, 51.1, 50.2, 44.5, 43.2, 42.6, 35.5, 19.9. ESIMS: <i>m</i>/<i>z</i> 418.3 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 418.2341 [M + H]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup>, 418.2336).</div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-6-((piperidin-1-yl)methyl)-4<i>H</i>-chromen-4-one (<b>9o</b>)</h4><div class="NLM_p last">Cream colored solid (68 mg, 52% yield); mp 198–205 °C; HPLC <i>t</i><sub>R</sub> = 5.15 min (99% purity); [α]<sup>20</sup><sub>D</sub> +10.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2928, 2858, 1734, 1659, 1459, 1395, 1157, 1032 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 5.98 (s, 1H), 4.08–3.92 (m, 3H), 3.04–2.80 (m, 4H), 2.61 (s, 3H), 2.31 (s, 3H), 1.68 (m, 4H), 1.53 (m, 4H), 1.25 (m, 3H), 0.85 (m, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 180.8, 172.6, 165.4, 158.9, 155.5, 107.2, 106.5, 101.2, 98.6, 67.5, 65.7, 60.5, 55.06, 51.55, 50.6, 43.8, 43.5, 38.1, 33.1, 28.2, 20.3, 17.1. ESIMS: <i>m</i>/<i>z</i> 403.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 403.2232 [M + H]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup> 403.2227).</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Synthesis of Baylis–Hillman Derivatives <b>10a</b>–<b>n</b></h3><div class="NLM_p">The solution of rohitukine (<b>1</b>, 100 mg, 0.328 mmol) in methanol (5 mL) was stirred with substituted aromatic and aliphatic aldehydes (0.328 mmol) in the presence of DABCO (0.328 mmol). The reaction mixture was then continuously stirred for 10–15 days; however, in none of the reactions was starting material completely consumed. The crude products were purified by preparative TLC.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-3-(hydroxy(4-nitrophenyl)methyl)-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10a</b>)</h4><div class="NLM_p last">Cream colored solid (76 mg, 51% yield); mp 202–205 °C; HPLC <i>t</i><sub>R</sub> = 5.58 min (99% purity); [α]<sup>20</sup><sub>D</sub> +4.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2923, 1658, 1556, 1468, 1389, 1273, 1150, 1025 (cm<sup>–1</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.57 (s, 1H), 8.32 (dd, <i>J</i> = 4.8, 10 Hz, 2H), 7.72 (dd, <i>J</i> = 4.4, 10.1 Hz, 2H), 5.94 (m, 2H), 3.94 (brs, 1H), 3.25–3.05 (m, 6H of piperidine), 2.60 (s, 3H), 1.88 (s, 3H), 1.27 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 180.6, 175.2, 172.4, 164.7, 155.5, 154.6, 145.7, 126.6, 122.8, 112.4, 108.4, 106.4, 98.2, 68.5, 61.3, 55.5, 44.5, 36.4, 23.0, 21.9, 19.7. ESIMS: <i>m</i>/<i>z</i> 457.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 457.1604 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>8</sub><sup>+</sup>, 457.1605).</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (1′<i>R</i>,2′<i>S</i>)-3-((4-Chlorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one) (<b>10b</b>)</h4><div class="NLM_p last">White solid (95 mg, 65% yield); mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 5.83 min (99% purity); [α]<sup>20</sup><sub>D</sub> −7.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2926, 1659, 1556, 1468, 1361, 1127, 1014 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MH<sub>Z,</sub> CD<sub>3</sub>OD): δ 7.38–7.30 (m, 2H), 7.14–7.10 (m, 2H), 5.92 (m, 1H), 5.84 (m, 1H), 4.03 (brs, 1H), 3.50–3.00 (m, 6H), 2.73 (s, 3H), 2.24 (s, 3H), 1.81 (m, 1H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD): δ 181.9, 174.2, 165.9, 156.2, 155.3, 144.5, 131.5, 127.7, 113.1, 107.6, 106.4, 68.2, 60.7, 55.4, 42.7, 35.6, 29.3, 21.9, 18.7. ESIMS: <i>m</i>/<i>z</i> 446.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 446.1342 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>ClNO<sub>6</sub><sup>+</sup> 446.1364).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (1′<i>R</i>,2′<i>S</i>)-3-((3-Chlorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10c</b>)</h4><div class="NLM_p last">White powder (66 mg, 45% yield); mp 215–217 °C; HPLC <i>t</i><sub>R</sub> = 6.74 min (99% purity); [α]<sup>20</sup><sub>D</sub> +3.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2925,1659, 1470, 1388, 1273, 1150, 1027 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.46 (s, 1H), 7.47–7.17 (m, 4H), 5.91 (m, 1H), 5.97 (m, 1H) 3.88 (brs, 1H), 3.30–2.78 (m, 6H of piperidine), 2.51 (s, 3H), 2.24 (s, 3H), 1.13 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.6, 175.0, 167.2, 161.6, 157.7, 156.3, 149.6, 142.6, 134.2, 130.7, 127.2, 127.0, 125.8, 114.5, 108.0, 102.1, 70.6, 69.6, 62.6, 56.4, 44.2, 37.0, 23.5, 20.2. ESIMS: <i>m</i>/<i>z</i> 446.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 446.1365 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>ClNO<sub>6</sub><sup>+</sup>, 446.1364).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (1′<i>R</i>,2′<i>S</i>)-3-((2-Bromophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10d</b>)</h4><div class="NLM_p last">Colorless needles (58 mg, 36% yield); mp 212–215 °C; HPLC <i>t</i><sub>R</sub> = 6.51 min (99% purity); [α]<sup>20</sup><sub>D</sub> +6.3 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3391, 2923, 1658, 1558, 1465, 1387, 1273, 1149, 1026 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.51–7.06 (m, 4H), 6.37 (m, 1H), 5.88 (m, 1H), 4.17 (brs, 1H), 3.09–3.08 (m, 6H of piperidine), 2.96 (s, 3H), 2.32 (s, 3H), 1.60 (m, 1H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 183.3, 176.6, 167.1, 158.0, 156.7, 144.8, 133.7, 130.7, 129.7, 128.3, 125.5, 112.4, 109.7, 107.7, 101.4, 72.0, 70.5, 62.8, 57.4, 45.1, 37.8, 24.3, 20.2. ESIMS: <i>m</i>/<i>z</i> 491.1 [M + H]<sup>+</sup>. HR-ESIMS: 492.0848 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub><sup>81</sup>BrNO<sub>6</sub><sup>+</sup>, 492.0845).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (1′<i>R</i>,2′<i>S</i>)-3-((3-Bromo-4-fluorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpip-eridin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10e</b>)</h4><div class="NLM_p last">Light yellowish solid (60 mg, 36% yield); mp 217–221 °C; HPLC <i>t</i><sub>R</sub> = 5.49 min (96% purity); [α]<sup>20</sup><sub>D</sub> −12.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2925, 1659, 1551, 1490, 1468, 1411, 1100, 1026 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.70 (m, 1H), 7.42 (m, 1H), 7.23 (m, 1H), 5.92 (m, 1H), 5.75 (m, 1H), 4.00 (m, 1H), 3.34–2.51 (m, 6H of piperidine), 2.51 (s, 3H), 2.24 (s, 3H), 1.32 (m, 1H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 183.3, 175.2, 167.2, 160.0 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 254 Hz), 156.8, 145.2, 132.1, 128.1, 116.4, 116.3, 109.3, 108.2, 107.9 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 7 Hz), 101.8, 76.6, 70.2, 62.5, 57.1, 44.7, 37.4, 23.6, 20.1. ESIMS: <i>m</i>/<i>z</i> 508.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 508.0765 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>BrFNO<sub>6</sub><sup>+</sup>, 508.0765).</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (1′<i>R</i>,2′<i>S</i>)-3-((2,6-Dichlorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10f</b>)</h4><div class="NLM_p last">Cream colored solid (55 mg, 35% yield); mp 216–217 °C; HPLC <i>t</i><sub>R</sub> = 6.67 min (99% purity); [α]<sup>20</sup><sub>D</sub> +12.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 1651, 1561, 1464, 1386, 1260, 1032 cm<sup>–1</sup>. <sup>1</sup>H NMR (500, CD<sub>3</sub>OD): δ 7.89 (s, 1H), 7.30 (m, 1H), 7.17 (m, 1H), 6.91 (m, 1H), 5.93 (s, 1H), 4.20 (brs, 1H), 4.00–3.21 (m, 6H of piperidine), 3.18 (s, 3H), 2.35 (s, 3H), 1.82 (m, 1H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 182.0, 172.1, 166.1, 157, 155, 144.1, 132.3, 128.7, 127.4, 110.9, 107.3, 100.7, 68.4, 68.4, 60.7, 55.4, 43.0, 35.5, 21.8, 18.2. ESIMS: <i>m</i>/<i>z</i> 480.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 480.0947 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>Cl<sub>2</sub>NO<sub>6</sub><sup>+</sup>, 480.0951).</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (1′<i>R</i>,2′<i>S</i>)-3-((2-Chloro-6-fluorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10g</b>)</h4><div class="NLM_p last">White powder (60 mg, 40% yield); mp 214–217 °C; HPLC <i>t</i><sub>R</sub> = 5.82 min (93.7% purity); [α]<sup>20</sup><sub>D</sub> −10.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 1660, 1556, 1468, 1390, 1273, 1152, 1025 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.15 (s, 1H), 7.28 (m, 2H), 7.61 (m, 1H), 6.32 (m, 1H), 5.87 (s, 1H), 4.04 (brs, 2H), 3.33–3.10 (m, 5H of piperidine), 2.75 (s, 3H), 2.27 (s, 3H), 1.44 (m, 1H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ 181.4, 175.5, 165.4, 156.5 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 115 Hz), 144.3, 130.7, 126.9, 115.1, 113, 10.7.7 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 31 Hz), 106.5, 98.8, 68.2, 68.8, 60.6, 43.3, 35.4, 22.0, 19.5. HR-ESIMS: <i>m</i>/<i>z</i> 464.1271 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>ClFNO<sub>6</sub><sup>+</sup>, 464.1270).</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-3-(hydroxy(5-nitrothiophen-3-yl)methyl)-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10h</b>)</h4><div class="NLM_p last">Brown colored solid (75 mg, 50% yield); mp 211–216 °C; HPLC <i>t</i><sub>R</sub> = 5.41 min (97% purity); [α]<sup>20</sup><sub>D</sub> −11.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2923, 1657, 1601, 1386, 1333, 1273, 1149, 1033 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.88 (d, <i>J</i> = 4 Hz, 1H), 7.49 (d, <i>J</i> = 4 Hz, 1H), 5.92 (m, 1H), 5.83 (m, 1H), 4.07 (brs, 1H), 3.94–2.98 (m, 6H of piperidine), 2.71 (s, 3H), 2.23 (s, 3H), 1.46 (m, 1H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100 MHz): δ 181.9, 174.1, 166.1, 156.2, 151.2, 147.7, 128.4, 127.7, 127.0, 112.1, 107.8, 106.4, 99.4, 68.1, 66.4, 60.7, 55.4, 42.2, 35.6, 22.0, 18.7. ESIMS: <i>m</i>/<i>z</i> 463.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 463.1172 [M + H]<sup>+</sup> (calcd for C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>8</sub>S<sup>+</sup>, 463.1169).</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (1′<i>R</i>,2′<i>S</i>)-3-((3-Bromo-4-methoxyphenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10i</b>)</h4><div class="NLM_p last">Cream colored solid (68 mg, 40% yield); mp 203–207 °C; HPLC <i>t</i><sub>R</sub> = 5.04 min (98% purity); [α]<sup>20</sup><sub>D</sub> +10.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2928, 1659, 1602, 1552, 1494, 1464, 1397, 1271, 1121, 1042 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.65 (m, 1H), 7.39 (m, 1H), 6.89 (m, 1H), 6.97 (m, 1H), 5.88 (m, 1H), 4.0 (brs, 1H), 3.42–2.78 (m, 7H), 3.30 (s, 3H), 3.28 (s, 3H), 2.61 (s, 3H), 1.46 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.3, 167.1, 160.2, 157.4, 156.9, 155.8, 141.1, 137.7, 135.0, 132.7, 128.0, 113.2, 111.7, 109.3 107.7, 101.1, 77.8, 77.4, 62.7, 57.0, 46.1, 37.7, 30.8, 24.1, 20.2. ESIMS: <i>m</i>/<i>z</i> 520.0 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 520.0919 [M + H]<sup>+</sup> (calcd for C<sub>24</sub>H<sub>27</sub>BrNO<sub>7</sub><sup>+</sup>, 520.0935).</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (1′<i>R</i>,2′<i>S</i>)-3-((3,5-Difluorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10j</b>)</h4><div class="NLM_p last">White solid (64 mg, 44% yield); mp 202–206 °C; HPLC <i>t</i><sub>R</sub> = 5.13 min (98% purity); [α]<sup>20</sup><sub>D</sub> −14.8 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3391, 2924, 1659, 1557, 1463, 1388, 1272, 1113 cm<sup>–1</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 6.94 (m, 2H), 6.58 (m, 1H), 5.91 (m, 1H), 5.83 (m, 1H), 4.03 (m, 1H), 3.48–2.91 (m, 6H), 2.74 (s, 3H), 2.23 (s, 3H), 1.48 (m, 1H). <sup>13</sup>C NMR (CD<sub>3</sub>OD): δ 181.9, 173.7, 166.0, 163.8 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 198 <i>Hz</i>), 161.7, 156.3, 155.4, 150.9, 112.7, 108.3 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 20 <i>Hz</i>), 107.6, 100.7 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 41 <i>Hz</i>), 99.6, 68.8, 68.1, 60.6, 55.4, 44.2, 35.5, 21.9, 18.8. ESIMS: <i>m</i>/<i>z</i> 448.6 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 448.1534 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>NO<sub>6</sub><sup>+</sup>, 448.1564).</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (1′<i>R</i>,2′<i>S</i>)-3-((2-Bromo-5-ethoxyphenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10k</b>)</h4><div class="NLM_p last">Cream colored solid (75 mg, 43% yield); mp 203–206 °C; HPLC <i>t</i><sub>R</sub> = 5.36 min (99% purity); [α]<sup>20</sup><sub>D</sub> +3.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3391, 2924, 1657, 1590, 1470, 1414, 1387, 1274, 1122, 1040 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.34–7.14 (m, 2H), 6.75 (m, 1H), 6.33 (m, 1H), 5.81 (m, 1H), 3.95 (m, 3H), 3.50–3.21 (m, 9H), 2.25 (s, 3H), 1.35–1.30 (m, 4H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 182.2, 166.3, 156.9, 155.8, 155.5, 134.3, 131.3, 130.7, 128.7, 125.9, 114.3, 113.3, 111.7, 107.2, 106.6, 67.9, 64.9, 63.7, 60.8, 55.7, 42.6, 35.7, 22.0, 18.5, 13.7. ESIMS: <i>m</i>/<i>z</i> 534.6 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 534.1109 [M + H]<sup>+</sup> (calcd for C<sub>25</sub>H<sub>29</sub>BrNO<sub>7</sub><sup>+</sup>, 534.1121).</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (1′<i>R</i>,2′<i>S</i>)-3-((2,3-Dichlorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10l</b>)</h4><div class="NLM_p last">White crystalline powder (66 mg, 42% yield); mp 218–220 °C; HPLC <i>t</i><sub>R</sub> = 5.35 min (97% purity); [α]<sup>20</sup><sub>D</sub> −9.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>) ν<sub>max</sub> 3400, 2923, 1658, 1556, 1466, 1387, 1242, 1101 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.45–7.35 (m, 2H), 7.15 (m, 1H), 6.50 (m, 1H), 5.95 (brs, 1H), 4.25 (brs, 1H), 3.68–3.32 (m, 6H of piperidine), 2.88 (s, 3H), 2.39 (s, 3H), 1.78 (m, 1H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz): δ 182.0, 166.0, 157.0, 155.4, 144.3, 132.3, 132.0, 128.7, 128.2, 127.4, 126.8, 110.9, 107.3, 106.8, 100.1, 68.4, 68.02, 60.7, 55.4, 43.0, 35.6, 22.0, 18.8. HR-ESIMS: <i>m</i>/<i>z</i> 480.0947 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>Cl<sub>2</sub>NO<sub>6</sub><sup>+</sup>, 480.0975).</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (1′<i>R</i>,2′<i>S</i>)-3-((<i>E</i>)-Dodec-1-enyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10m</b>)</h4><div class="NLM_p last">White crystalline solid (70 mg, 45% yield); mp 185–192 °C; HPLC <i>t</i><sub>R</sub> = 4.80 min (99% purity); [α]<sup>20</sup><sub>D</sub> +14.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 2921, 1657, 1576, 1425, 1272, 1040 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 6.56 (m, 1H), 5.83 (s, 1H), 4.05 (brs 1H), 3.49–2.80 (m, 6H of piperidine), 2.63 (s, 3H), 2.24 (s, 3H), 2.14 (m, 2H), 1.39 (m, 1H), 1.20 (brs, 16H), 0.81 (m, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): δ 183.4, 167.0, 159.3, 155.7, 134.1, 122.2, 112.7, 108.5, 107.9, 69.8, 62.5, 57.1, 44.7, 37.2, 36.0, 33.0, 31.1, 30.7, 30.7, 30.7, 30.4, 23.8, 23.7, 20.1, 14.4. HR-ESIMS: <i>m</i>/<i>z</i> 472.3013 [M + H]<sup>+</sup> (calcd for C<sub>28</sub>H<sub>42</sub>NO<sub>5</sub><sup>+</sup>, 472.3038).</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (1′<i>R</i>,2′<i>S</i>)-3-((4-Fluorophenyl)(hydroxy)methyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4<i>H</i>-chromen-4-one (<b>10n</b>)</h4><div class="NLM_p last">White needles (65 mg, 46% yield); mp 196–200 °C; HPLC <i>t</i><sub>R</sub> = 7.38 min (99% purity); [α]<sup>20</sup><sub>D</sub> −4.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2927, 1658, 1602, 1549, 1462, 1388, 1272, 1155, 1027 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.41 (m, 2H), 6.97 (m, 2H), 5.80 (m, 1H), 5.7 (m, 1H), 3.94 (m, 1H), 3.22–2.71 (m, 6H of piperidine), 2.68 (s, 3H), 2.22 (s, 3H), 1.29 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 181.2, 166.3, 161.3 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 195 <i>Hz</i>), 157.6, 157.5, 136.8, 126.9 (d, <sup>3</sup><i>J</i><sub>CF</sub> = 7 <i>Hz</i>), 112.8 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 24 <i>Hz</i>), 110.2, 105.9, 105.7, 106.9, 99.9, 75.8, 75.4, 66.9, 54.7, 54.5, 42.0, 38.3, 35.2, 28.2, 21.4, 17.8. ESIMS: <i>m</i>/<i>z</i> 430.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 430.1664 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>25</sub>FNO<sub>6</sub><sup>+</sup>, 430.1660).</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Synthesis of Styryl Derivatives <b>11a</b>–<b>i</b></h3><div class="NLM_p">The solution of rohitukine (<b>1</b>, 100 mg, 0.328 mmol) in methanol or ethanol (10 mL) was stirred with substituted aryl aldehyde (0.394 mmol) in the presence of 15% aqueous KOH (few drops) as a catalyst (10 equiv). The reaction mixture was continuously stirred for 10–15 h. An intense yellow colored band was separated using preparative TLC to get styryl derivatives <b>11a</b>–<b>i</b>.</div><div class="NLM_p">The styryl derivative <b>11d</b> was synthesized in large quantity for testing in animal models. For large scale synthesis, a slightly modified protocol was used. Briefly, 30 g of rohitukine (0.09834 mol) was dissolved in a solution of 500 mL of methanol containing 38.5 g (0.69 mol, 7 equiv) of KOH. To this mixture was added 17.19 g (0.098 mol) of 2,6-dichlorobenzaldehyde, and the resultant mixture was stirred at 100 °C for 3–4 h. After completion of the reaction, the mixture was cooled and neutralized with 6 N HCl. The precipitate was filtered and washed with 50 mL of methanol/water (30:70) to remove the unreacted aldehyde and further washed with acetone. Finally, it was recrystallized using methanol/chloroform (20:80) to get styryl derivative <b>11d</b> in 62% yield (28 g). Using this protocol, total 270 g (HPLC purity >99%) of <b>11d</b> was synthesized.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-styryl-4<i>H</i>-chromen-4-one (<b>11a</b>)</h4><div class="NLM_p last">Yellow solid (60 mg, 47% yield); mp 198–200 °C; HPLC <i>t</i><sub>R</sub> = 7.07 min (99% purity); [α]<sup>20</sup><sub>D</sub> −2.4 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2921, 1652, 1584, 1381, 1276, 1187, 1085 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.61 (m, 2H), 7.44 (d, <i>J</i> = 16 Hz, 1H), 7.30 (m, 3H), 6.92 (d, <i>J</i> = 16 Hz, 1H), 6.09 (s, 1H), 5.91 (s, 1H), 4.17 (brs, 1H), 3.61 (m, 1H), 3.41 (m, 1H), 3.29 (m, 1H), 3.26 (m, 1H), 3.03 (m, 2H), 2.75 (s, 3H), 1.58 (m, 1H). <sup>13</sup>C NMR (125 MHz, Pyr-<i>d</i><sub>5</sub>): δ 184.8, 169.4, 164.0, 163.3, 157.6, 138.9, 132.7, 131.4, 130.3, 122.9, 110.6, 110.6, 106.6, 103.8, 100.6, 71.2, 64.7, 59.0, 47.7, 40.4, 27.1. ESIMS: <i>m</i>/<i>z</i> 394.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 394.1646 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>24</sub>NO<sub>5</sub><sup>+</sup>, 394.1649).</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (1′<i>R</i>,2′<i>S</i>)-2-(4-Chlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11b</b>)</h4><div class="NLM_p last">Yellow solid (85 mg, 61% yield); mp 190–192 °C; HPLC <i>t</i><sub>R</sub> = 9.31 min (99% purity); [α]<sup>20</sup><sub>D</sub> −4.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3990, 2925, 2854, 1651, 1584, 1463, 1408, 1384, 1149, 1090 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.48–7–42 (m, <i>J</i> = 8 Hz, 2H), 7.39–7.32 (m, 3H), 7.16 (d, <i>J</i> = 16 <i>Hz</i>, 1H), 6.16 (s, 1H), 5.71 (s, 1H), 4.04 (brs, 1H), 3.84–2.84 (m, 6H), 2.62 (s, 3H), 1.44 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 180.7, 171.5, 159.5, 155.3, 154.6, 133.6, 133.2, 129.4, 129.1, 127.2, 126.4, 121.7, 107.3, 106.2, 100.5, 67.9, 60.7, 55.1, 43.8, 35.9, 22.9. ESIMS: <i>m</i>/<i>z</i> 428.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 428.1259 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>23</sub>ClNO<sub>5</sub><sup>+</sup>, 428.1259).</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (1′<i>R</i>,2′<i>S</i>)-2-(3-Chlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11c</b>)</h4><div class="NLM_p last">Yellow solid (64 mg, 46% yield); mp 185–189 °C; HPLC <i>t</i><sub>R</sub> = 7.3 min (99% purity); [α]<sup>20</sup><sub>D</sub> −3.5 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3391, 2923, 2357, 1733, 1699, 1652, 1575, 1386, 1046 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.84 (s, 1H), 7.75 (s, 1H), 7.56–7.56 (m, 3H), 7.29 (d, <i>J</i> = 16 Hz, 1H), 7.22 (d, <i>J</i> = 16 Hz, 1H), 6.06 (s, 1H), 5.52 (s, 1H), 3.84 (brs, 1H), 3.19 (m, 1H), 2.97 (m, 1H), 2.89 (m, 1H), 2.77 (m, 1H), 2.26 (s, 3H), 2.20 (m, 2H), 1.19 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 179.1, 177.0, 159.6, 158.6, 154.5, 137.3, 133.7, 132.2, 130.7, 128.8, 126.4, 126.4, 123.0, 109.2, 108.2, 102.4, 99.4, 68.5, 62.7, 56.7, 45.8, 38.0, 22.2. ESIMS: <i>m</i>/<i>z</i> 428.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 428.1232 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>23</sub>ClNO<sub>5</sub><sup>+</sup>, 428.1259).</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (1′<i>R</i>,2′<i>S</i>)-2-(2,6-Dichlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11d</b>)</h4><div class="NLM_p last">Yellow solid (90 mg, 60% yield); mp 190–196 °C; HPLC <i>t</i><sub>R</sub> = 12.9 min (99% purity); [α]<sup>20</sup><sub>D</sub> +5.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3435, 2922, 1652, 1577, 1463, 1380, 1318, 1171, 1084 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 12 Hz, 1H), 7.43 (d, <i>J</i> = 8 Hz, 2H), 7.23 (m, 1H), 7.10 (d, <i>J</i> = 16 Hz, 1H), 6.33 (s, 1H), 6.21 (s, 1H), 4.22 (brs, 1H), 3.63 (m, 1H), 3.49 (m, 1H), 3.08 (m, 2H), 2.44 (m, 1H), 2.43 (s, 3H), 2.35 (m, 1H), 1.64 (d, <i>J</i> = 12 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 182.6, 163.9, 160.8, 160.0, 154.5, 134.9, 131.7, 129.83, 129.80, 129.7, 129.2, 129.19, 128.3, 110.5, 106.9, 105.3, 101.7, 68.9, 62.1, 56.2, 45.8, 37.7, 24.8. ESIMS: <i>m</i>/<i>z</i> 462.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 462.0873 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>22</sub>Cl<sub>2</sub>NO<sub>5</sub><sup>+</sup> 462.0869).</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (1′<i>R</i>,2′<i>S</i>)-5,7-Dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-(2,3,4,5,6-pentafluorostyryl)-4<i>H</i>-chromen-4-one (<b>11e</b>)</h4><div class="NLM_p last">Yellow solid (74 mg, 47% yield); mp 185–190 °C; HPLC <i>t</i><sub>R</sub> = 7.19 min (99% purity); [α]<sup>20</sup><sub>D</sub> −4.8 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 2356, 1652, 1475, 1366, 1279, 1116, 1035 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.56 (d, <i>J</i> = 16 Hz, 1H), 7.31 (d, <i>J</i> = 16 Hz, 1H), 6.41 (s, 1H), 5.91 (s, 1H), 4.05 (m, 1H), 4.03–3.17 (m, 6H of piperidine), 2.51 (s, 3H), 1.55 (m, 1H). <sup>13</sup>C NMR (125 MH<i>z</i>, DMSO-<i>d</i><sub>6</sub>): δ 184.1, 163.6 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 167 Hz), 156.3, 147.9, 145.9, 144.9, 144.8, 140.5, 127.6, 125.6, 117.7, 110.1, 107.8, 106.0, 69.0, 63.4, 63.3, 57.6, 45.9, 38.0, 24.2. ESIMS: <i>m</i>/<i>z</i> 484.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (1′<i>R</i>,2′<i>S</i>)-2-((<i>E</i>)-2-(Anthracen-10-yl)vinyl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11f</b>)</h4><div class="NLM_p last">Red solid (75 mg, 46% yield); mp 192–196 °C; HPLC <i>t</i><sub>R</sub> = 5.45 min (99% purity); [α]<sup>20</sup><sub>D</sub> +2.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3391, 2922, 2851, 2357, 1732,1651, 1557, 1456, 1385, 1273, 1020 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68 (s, 1H), 8.34 (m, 3H), 8.16 (m, 2H), 7.61 (m, 4H), 7.00 (d, <i>J</i> = 16 H<i>z</i>, 1H), 6.21 (s, 1H), 5.56 (s, 1H), 3.9 (brs, 1H), 2.94- 2.50 (m, 6H of piperidine), 2.05 (s, 3H), 1.28 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 183.8, 174.7, 162.2, 158.3, 155.9, 136.5, 133.9, 131.7, 131.4, 131.2, 110.1, 109.6, 103.8, 103.3, 70.3, 63.4, 57.9, 51.1, 38.9, 22.5. ESIMS: <i>m</i>/<i>z</i> 494.1 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 494.1922 [M + H]<sup>+</sup> (calcd for C<sub>31</sub>H<sub>28</sub>NO<sub>5</sub><sup>+</sup>, 494.1942).</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (1′<i>R</i>,2′<i>S</i>)-2-(3-Fluorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11g</b>)</h4><div class="NLM_p last">Yellow solid (60 mg, 45% yield); mp 187–192 °C; HPLC <i>t</i><sub>R</sub> = 5.58 min (99% purity); [α]<sup>20</sup><sub>D</sub> −9.8 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 2356, 1652, 1475, 1366, 1279, 1116, 1035 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.0 (s, 1H), 7.68–7.54 (m, 3H), 7.48 (d, <i>J</i> = 16 <i>Hz</i>, 1H), 7.32 (m, 1H), 7.27 (d, <i>J</i> =  16 Hz, 1H), 6.55 (s, 1H), 5.79 (s, 1H), 4.20 (brs, 1H), 4.03–3.10 (m, 6H of piperidine), 2.71 (s, 3H), 1.52 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 180.9, 172.1, 159.8 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 254 Hz), 157.3, 154.7, 131.2, 129.2; 128.2, 127.1, 125.0, 123.3, 120.7, 116.1, 111.8, 108.5 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 74 Hz), 101.0, 67.5, 61.3, 55.7, 44.9, 37.3, 23.3. ESIMS: <i>m</i>/<i>z</i> 412.4 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 412.1523 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>23</sub>FNO<sub>5</sub><sup>+</sup>; 412.1552).</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (1′<i>R</i>,2′<i>S</i>)-2-(2-Fluorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11h</b>)</h4><div class="NLM_p last">Yellow solid (78 mg, 58% yield); mp 191–193 °C; HPLC <i>t</i><sub>R</sub> = 8.7 min (98% purity); [α]<sup>20</sup><sub>D</sub> −6.0 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3400, 2922, 1651, 1587, 1463, 1382, 1276, 1151, 1046 cm<sup>–1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.88 (m, 1H), 7.52 (d, <i>J</i> = 16, 1H), 7.05–7.54 (m, 3H), 7.20 (d, <i>J</i> = 16, 1H), 6.05 (s, 1H), 5.32 (s, 1H), 3.92 (brs, 1H), 3.10–2.50 (m, 6H of piperidine), 2.05 (s, 3H), 1.14 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 180.5, 172.0, 159.8 (d, <sup>1</sup><i>J</i><sub>CF</sub> = 262 Hz), 154.7, 131.2, 129.1; 128.2, 127.1, 124.9, 123.3, 120.7, 116.1, 111.8, 107.8 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 74 Hz), 101.1, 67.6, 61.3, 55.7, 44.9, 37.3, 23.3. ESIMS: <i>m</i>/<i>z</i> 412.2 [M + H]<sup>+</sup>. HR-ESIMS: <i>m</i>/<i>z</i> 412.1523 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>23</sub>FNO<sub>5</sub><sup>+</sup>, 412.1552).</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (1′<i>R</i>,2′<i>S</i>)-2-(2-Chlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-4<i>H</i>-chromen-4-one (<b>11i</b>)</h4><div class="NLM_p last">Yellow solid (70 mg, 50% yield); mp 193–197 °C; HPLC <i>t</i><sub>R</sub> = 9.44 min (99% purity); [α]<sup>20</sup><sub>D</sub> −8.2 (<i>c</i> 0.1, MeOH). IR (CHCl<sub>3</sub>): ν<sub>max</sub> 3390, 2925, 2854, 1651, 1584, 1490, 1384, 1273, 1090, 1042 cm<sup>–1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.22 (s, 1H), 7.85 (m, 1H), 7.81 (d, <i>J</i> = 16 Hz, 1H), 7.52–7.32 (m, 2H), 7.20 (d, <i>J</i> = 16 Hz, 1H), 6.25 (s, 2H), 4.49 (brs, 1H), 3.88- 3.10 (m, 6H), 2.35 (s, 3H), 1.41 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 181.3, 171.9, 160.2, 158.1, 153.6, 133.4, 132.8, 131.8, 129.9, 127.7, 127.5, 127.0, 123.4, 110.8, 108.4, 106.4, 101.6, 67.0, 59.8, 55.4, 44.1, 36.5, 21.0. HR-ESIMS: <i>m</i>/<i>z</i> 428.1259 [M + H]<sup>+</sup> (calcd for C<sub>23</sub>H<sub>23</sub>ClNO<sub>5</sub><sup>+</sup>, 428.1259).</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> General Protocol for Kinase Assay</h3><div class="NLM_p">All assays were carried out using a radioactive (<sup>33</sup>P-ATP) filter-binding assay at International Centre for Kinase Profiling (ICKP), U.K. The general protocol for Cdk-2 is as follows: Cdk-2/cyclin A (5–20 mU diluted in 50 mM Hepes pH 7.5, 1 mM DTT, 0.02% Brij35, 100 mM NaCl) was assayed against Histone H1 in a final volume of 25.5 μL containing 50 mM Hepes pH 7.5, 1 mM DTT, 0.02% Brij35, 100 mM NaCl, Histone H1 (1 mg/mL), 10 mM magnesium acetate, and 0.02 mM [<sup>33</sup>P-γ-ATP] (500–1000 cpm/pmole) and incubated for 30 min at room temperature. Assays were stopped by addition of 5 μL of 0.5 M (3%) <i>ortho</i>-phosphoric acid and then harvested onto P81 Unifilter plates with a wash buffer of 50 mM <i>ortho</i>-phosphoric acid. Cdk-9/cyclin T1 (5–20 mU diluted in 50 mM Tris pH 7.5, 0.1 mM EGTA, 1 mg/mL BSA, 0.1% mercaptoethanol) was assayed against a substrate peptide (YSPTSPSYSPTSPSYSPTSPKKK) in a final volume of 25.5 μL containing 50 mM Tris pH 7.5, 0.1 mM EDTA, 10 mM DTT, 1 mg/mL BSA, 0.3 mM YSPTSPSYSPTSPSYSPTSPKKK, 10 mM magnesium acetate, and 0.05 mM [<sup>33</sup>P-γ-ATP] (50–1000 cpm/pmole) and incubated for 30 min at room temperature. Assays were stopped by the addition of 5 μL of 0.5 M (3%) <i>ortho</i>-phosphoric acid and then harvested onto P81 Unifilter plates with a wash buffer of 50 mM <i>ortho</i>-phosphoric acid.</div><div class="NLM_p last">The kinase profiling of <b>11d</b> was performed at DiscoverX corporation USA using their KINOMEscan Profiling Service.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Compound <b>11d</b> was screened at 0.5 μM, and results for primary screen binding interactions are reported as % Ctrl, where lower numbers indicate stronger hits in the matrix diagram. The selectivity score (S-score) was calculated by dividing the number of kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant variants. This value was calculated using % Ctrl as a potency threshold. The tree S-scores, S(35), S(10), and S(1), were computed using the following formulas:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/jm-2017-01765x_m001.gif" alt="" /></img></span><span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/jm-2017-01765x_m002.gif" alt="" /></img></span><span class="NLM_disp-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/jm-2017-01765x_m003.gif" alt="" /></img></span></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Cellular Antiproliferative Activity</h3><div class="NLM_p last">Cancer cell lines were procured from National Cancer Institute, USA and normal epithelial cell line fR2 was purchased from Sigma-Aldrich (ECACC type). Cells were grown in appropriate growth medium in a CO<sub>2</sub> incubator (Thermocon Electron Corporation, Houston, TX) at 37 °C with 95% humidity and 5% CO<sub>2</sub> gas environment. The stock solution of test compounds was prepared in DMSO of appropriate strength so that the final DMSO concentration during treatment in cells is <0.2%. Cells were seeded in 96 well plates and exposed to tested compounds at various concentrations for 48 h time interval. MTT dye (2.5 mg/mL in PBS) was added 4 h priors to experiment termination. The plates were then centrifuged at 1500 rpm for 15 min, and the supernatant was discarded, and MTT formazan crystals were dissolved in 150 μL of DMSO. The OD measured at 570 nm with a reference wavelength of 620 nm. The percentages of cell viability and growth inhibition were calculated using formulas:<span class="NLM_disp-formula" id="ueq4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/jm-2017-01765x_m004.gif" alt="" /></img></span></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Cell Cycle Analysis by Flow Cytometry</h3><div class="NLM_p last">Cells were incubated with <b>11d</b> at indicated concentrations for 24 h. In total, 400 μg of cells was collected, washed with ice-cold PBS, and fixed with ice-cold 70% ethanol for overnight at 4 °C. Next day, cells were incubated with RNase at a concentration of 0.2 mg/mL at 37 °C for 1 h and stained with propidium iodide (10 μg/mL) for 30 min in the dark. Cells were analyzed on flow-cytometer (FACS Calibur, Becton Dickinson), and data were collected in list mode on 10,000 events for FL2-A vs FL2-W. Resulting DNA distributions were analyzed by Modfit (Verity Software House Inc., Topsham, ME) for the proportions of cells in apoptosis, G<sub>1</sub>-phase, S-phase, and G<sub>2</sub>-M phase of the cell cycle.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Scanning Electron Microscopic (SEM) Analysis</h3><div class="NLM_p last">To assess the mechanism of cell death, the cells were processed for SEM studies. MIAPaCa-2 cells were seeded in a six-well tissue culture plate and treated with different concentrations of <b>11d</b> for 24 h. The cells on a coverslip were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) at 4 °C for 24 h, postfixed with 1% osmium tetraoxide in the same buffer for 4 h, dehydrated with graded ethanol solution, dried in a critical point drier using HMDS, and coated with gold using a sputter coater (Joel JEC-3000 FC). The specimens were examined with an electron microscope (JEOL-JSM-IT300) with ASID at 20 kV.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Western-Blot Analysis</h3><div class="NLM_p last">Protein was measured employing Bio-Rad protein assay kit using bovine serum albumin as standard. Proteins aliquots (70 μg) were resolved on SDS-PAGE and then electro-transferred to PVDF membrane overnight at 4 °C at 30 V. Nonspecific binding was blocked by incubation with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h at room temperature. The blots were probed with respective primary antibodies (Sigma and CST) for 2–4 h and washed three times with TBST. The blots were then incubated with horseradish peroxidase conjugated antimouse secondary antibodies for 1 h, followed by washing with TBST. The signals were detected then by using ECL plus chemiluminescence’s kit on X-ray film.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Molecular Docking</h3><div class="NLM_p last">Cdk-9/cylin T-flavopiridol complex was retrieved from the protein data bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and prepared by the protein preparation wizard in Maestro at pH 6.2. The site of molecular docking was defined by constructing the grid considering flavopiridol as the centroid of grid box. All docking calculations were done using GLIDE XP docking, and Δ<i>G</i> of inhibitors binding to Cdk-9/cyclin T1 complex was carried out by Prime using end-point MMGB/SA method. The validation of the docking protocol was done by performing docking of the flavopiridol and comparing it with the binding pattern with the cocrystallized structure.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Human Cytochrome P450 (CYP450) Isoenzymes Assay</h3><div class="NLM_p last">The cytochrome P450 isoenzymes were aliquoted as per the total concentration required to conduct the study and stored at −70 °C until use. Total assay volume was adjusted to 200 μL containing three components: cofactors, inhibitor/vehicle, and enzyme substrate (ES) mix. The 50 μL of working cofactor stock solution was dispensed to all the specified wells in a black nunc microtiter polypropylene plate. The 50 μL of diluted working concentrations of <b>11d</b>/positive control inhibitors/vehicle was dispensed in triplicate to the specified wells as per the plate map design. Reaction plate with a cofactor and test item was preincubated at 37 °C ± 1 °C shaking incubator for 10 min. Simultaneously, ES mix was prepared by mixing the CYP P450 isoenzymes. Remaining volume was made up with the buffer and preincubated for 10 min at 37 ± 1 °C. One hundred microliters of ES mix was dispensed per well as per the plate map design and incubated at 37 ± 1 °C with shaking for a predetermined time. A set of controls was incubated with CYP P450 isoenzymes and substrate without test or reference item. A set of blanks were incubated with substrate and test or reference item, in the absence of CYP P450 isoenzymes. The reaction was terminated by adding specific quenching solutions (for CYP2C19 and CYP3A4, 75 μL of 100% acetonitrile; for CYP2C9, 20 μL of 0.25 M Tris in 60% methanol; for CYP2D6, 75 μL of 0.25 M Tris in 60% methanol). The reaction was quenched by thoroughly mixing the final contents of the wells by repeated pipetting using a multichannel pipet. The product fluorescence per well was measured using a fluorimeter at excitation and emission wavelength for respective CYP P450 isoenzyme fluorogenic metabolites. Data was analyzed by using an Excel spreadsheet, and the % inhibition was calculated.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Determination of Solubility, Lipophilicity, and Partition Coefficient</h3><div class="NLM_p last">The thermodynamic equilibrium solubility in water, PBS, SGF, and SIF was determined using miniaturized shake-flask method, wherein the supernatant was analyzed by HPLC.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Log P, log D, and p<i>K</i><sub>a</sub> were determined using our published protocols.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The chemical stability of <b>11d</b> in different pH buffers and biological media was performed as reported earlier.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Caco-2 Permeability Assay</h3><div class="NLM_p last">Permeability study was conducted with the Caco-2 monolayer cultured for 21 days (>500 cm2 in each well) and by adding an appropriate volume of buffer (HBSS buffer containing 10 mM HEPES) containing test compounds to apical chamber. The test sample was taken from both apical and basolateral chambers at 0 and 90 min after incubation at 37 °C and analyzed by LC–MS/MS. The same experiment was repeated by adding an appropriate volume of buffer (HBSS buffer containing 10 mM HEPES) containing test compound to the basolateral chamber. The AUC defined the net influx and outflow of the test compound across the Caco-2 cell monolayer.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Plasma Protein Binding Studies</h3><div class="NLM_p last">This was done by equilibrium dialysis method. An aliquot of 150 μL respective matrixes (<i>n</i> = 3) containing test compound (3 μM final concentration) was added in the first half (plasma side) of the well of the 96-well microequilibrium dialysis device. An aliquot of 150 μL of 0.1 M sodium phosphate buffer pH 7.4 (blank) (<i>n</i> = 3) was added in the second half (buffer side) of the same well of the above plate. The plate containing plasma and buffer was equilibrated at 37 ± 1 °C for 5 h, with a constant rotation of 130 rpm on an orbital shaker. After equilibration time is over, 10 μL of plasma sample was taken out from the first half of the well to a vial/plate containing 200 μL of acetonitrile (containing internal standard, 200 ng/mL), and 50 μL of blank buffer was added. Similarly, 50 μL of buffer sample was taken out from the buffer half of the wells to a vial containing 200 μL of acetonitrile (containing internal standard, 200 ng/mL), and 10 μL of blank plasma was added. Samples were centrifuged at 14000 rpm for 5 min at 4 °C. The supernatant was transferred to LC–MS/MS vials and injected on to the column for analysis. Two reference controls were used, <i>viz</i>. warfarin for high bound and naltrexone for low bound.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">Microsomal stability studies were performed with mouse, rat, dog, monkey, and human liver microsomes at 0.5 mg/mL protein concentration. Briefly, the liver microsomal protein (25 μL), NADPH (100 μL), and phosphate buffer (870 μL) was coincubated (preincubation) in a deep 96-well plate in an orbital incubator (10 min, 37 °C). The reaction was initiated by the addition of 5 μL of 100 μM working stock solutions of <b>11d</b>. Aliquots (50 μL) were withdrawn from the reaction tube at 0, 3, 6, 9, 12, 15, 18, 24, 27, and 30 min, and the reaction was immediately terminated by transferring to a deep 96-well plate containing 50 μL of acetonitrile. NADPH-free control incubation was performed by mixing liver microsomes (25 μL) and phosphate buffer (970 μL) and incubating at 37 °C for 10 min. Reaction was initiated by addition of 5 μL of <b>11d</b>. Aliquots (50 μL) were withdrawn at 0 and 30 min, and reaction was terminated with 50 μL of acetonitrile. The reaction and control experiments were performed in duplicate. Diclofenac was used as positive control in human and rat liver microsomes, and verapamil was used as positive control in mouse, dog, and monkey liver microsomes. To the quenched samples, internal standard was added and vortex mixed followed by centrifugation at 4000 rpm for 10 min, and an aliquot of supernatant was taken for LC–MS/MS analysis. The experimental sample was analyzed by employing a suitable multiple reaction monitoring method developed on LC–MS/MS to estimate the area ratio (analyte peak area/internal standard peak area). The data was fitted to the one-phase exponential decay equation using GraphPad Prism software. The half-life (<i>t</i><sub>1/2</sub>) generated by the software was reported.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Metabolic Stability in Hepatocytes</h3><div class="NLM_p last">The hepatocytes were incubated with naloxone, imipramine, and <b>11d</b> (3 μM final concentrations) at 37 °C. Samples were removed at the appropriate time points (0, 60, 120, and 180 min) into acetonitrile containing internal standard to terminate the reaction. Following centrifugation, the supernatant was analyzed by LC–MS/MS. The disappearance of test compound was monitored over a 180 min time period.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Metabolic Stability in S9 Liver Fraction</h3><div class="NLM_p last">The S9 fractions of different species was suspended in potassium phosphate buffer (pH 7.4) in the propylene tube. The test compound was added to this mixture. This mixture was then divided in to four tubes labeled as T<sub>0,</sub> T<sub>5</sub>, T<sub>15</sub>, and T<sub>30</sub>. The experiment was performed in duplicate. All the tubes were preincubated at 37 ± 1 °C for 5 min in shaking water bath. Tubes of NADPH solution (10 mM) were similarly preincubated. After preincubation, 20 μL of NADPH solution (10 mM) was added to the T<sub>5</sub>, T<sub>15</sub>, and T<sub>30</sub> tubes, and 20 μL of buffer was added to the T<sub>0</sub> tube. At the end of the incubation period (0, 5, 15, and 30 min) of respective tubes, an aliquot of 200 μL of quenching solution was added to each tube to stop the reaction. Resulting samples were centrifuged for 20 min. The supernatant (200 μL) from each reaction tube was taken for LC–MS/MS analysis.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Pharmacokinetics Studies</h3><div class="NLM_p">Oral and intravenous (IV) pharmacokinetic studies of compound <b>11d</b> were carried out in BALB/c male mice of age 4–6 weeks, by administering <b>11d</b> orally and IV at a dose of 10 mg/kg for oral and 1 mg/kg for IV. Plasma samples were collected at appropriate time points between the range of 0–24 h and analyzed by LC–MS/MS. Mean plasma concentration was calculated, and data was further analyzed to determine PK parameters using WinNonlin 5.3 software package. Similarly, the dose-dependent and tissue distribution PK studies were carried out in BALB/c mice and SD rats.</div><div class="NLM_p last">The PK studies were carried out at Jubilant Biosys Bangalore on a commercial basis. These experiments were approved by the Jubilant Biosys Institutional Animal Ethics Committee, Bangalore, India (IAEC/JDC/2012/27), and were in accordance with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Social Justice and Environment, Government of India.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> In Vivo Activity in Ehrlich Solid Tumor Model</h3><div class="NLM_p last">Ehrlich Ascites Carcinoma (EAC) cells were collected from the peritoneal cavity of the Swiss mice weighing 18–23 g, harboring 8–10 days old ascitic tumor. One × 10<sup>7</sup> EAC cells were injected intramuscularly in the right thigh of Swiss male mice selected for the experiment on day 0. The next day, animals were randomized and divided into different groups. The treatment groups contained seven animals each, and the control group contained 10 animals. One of the treatment group was treated with 5-fluorouracil (22 mg/kg, i.p.) from days 1–9, and it served as positive control. The control group was similarly administered normal saline (0.2 mL, i.p. and p.o.) from days 1–9. On day 9 and 13, tumor-bearing thigh of each animal was shaved, and longest and shortest diameters of the tumor were measured with the help of vernier caliper. The percent tumor growth inhibition was calculated on day 13 by comparing the average values of treated groups with that of the control group. Tumor growth in saline-treated control animals was taken to be 100%.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> In Vivo Efficacy Studies in Xenograft Models</h3><div class="NLM_p">The xenograft was generated by subcutaneous injection of human cancer cell line MIAPaCa-2 in CD1 nude mice. The tumor size was measured by taking the longest length and shortest width of the tumor with a digital caliper. The tumor volume was calculated with the formula (width<sup>2</sup> × length)/2. Animals were randomized into five groups (vehicle control, standard drug, test compound: two doses), and treatment was started when average tumor size was 130 mm<sup>3</sup>. The body weight was checked before dosing or alternate day as required. The size of the tumor was measured every alternate day. Blood (35–40 μL) was drawn, and plasma separated on day 0 (before treatment). On the last day (25th day), maximum blood was collected and plasma separated after final dosing. Carbon dioxide overdosing was done to euthanize the animals at the end of the experiment. Tumor isolation was done and snap frozen in liquid nitrogen and was stored at −80 °C for further studies. Complete liver and lung tissue was isolated and snap frozen. Other two xenograft studies were also done using a similar protocol.</div><div class="NLM_p last">Data is expressed as the mean of one of three similar experiments unless otherwise indicated. Comparisons were made between control and treated groups or the entire intra group using one-way ANOVA with post Bonferroni test through GraphPad Prism 5.00.288 statistical analysis software. *p-values < 0.05 were considered significant.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> hERG Competitive Binding Assay</h3><div class="NLM_p last">hERG competitive binding assay was performed using membranes obtained from HEK293 cells expressing the hERG K<sup>+</sup> channel (PerkinElmer Catalog # RBHERGM400UA). The hERG competitive binding assay was performed at a radioligand [<sup>3</sup>H]-Astemizole concentration of 5 nM and membrane concentration of 3 μg per well. The test item and reference item Astemizole were dissolved in 100% DMSO to make the stock concentrations of 10 mM and 6 mM, respectively. Five times intermediate concentrations of test/reference item was prepared by dilution with assay buffer. Eight serial dilutions of the test/reference item were prepared with starting highest test concentration of 50000 nM (50 μM) for IIIM-290 and 30000 nM (30 μM) for Astemizole. The binding assay was performed in a total volume of 100 μL, which includes 60 μL of membrane, 20 μL of test item/reference item/vehicle, and 20 μL of radioligand. Nonspecific binding was determined in the presence of 100 μM Astemizole. The plate was incubated for 90 min at 27 °C. During incubation, Filtermat-A was presoaked in 0.3% polyethylenimine. After incubation, binding reaction mixture was transferred to the filter plate and washed eight times with wash buffer. The plate was dried and radioactive counts were measured using the top count. The percent inhibition of the compounds was calculated using the formula<span class="NLM_disp-formula" id="ueq5"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/jm-2017-01765x_m005.gif" alt="" /></img></span>where <i>F</i>(test compound) is CPM of test compound and <i>F</i>(vehicle control) is CPM of vehicle control.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> AMES Test</h3><div class="NLM_p last">This study was performed to evaluate compound <b>11d</b> for its possible mutagenic activity, by the bacterial reverse mutation test, using five histidine deficient (his<sup>–</sup>) mutant tester strains of <i>Salmonella typhimurium</i>, <i>viz</i>., TA1537, TA1535, TA98, TA100, and TA102 maintained at Jubilant Biosys Limited. Liver microsomal enzyme (S-9) homogenate was prepared in-house. This has been evaluated along with known mutagens (positive controls), sodium azide (SA), 9-aminoacridine (9-AA), 2-nitrofluorene (2-NF), and mitomycin C (MMC) in the absence and 2-aminoanthracene (2-AA) in the presence of metabolic activation system. The treatments were performed by plate incorporation technique both in the absence and presence of metabolic activation (S9 mix). The S9 mix of 5% v/v (Trial-I) and 10% v/v (Trial-II) included S9 fraction supplemented with essential cofactors. Before conducting the mutagenicity test, compound <b>11d</b> was evaluated for its possible cytotoxicity in strain TA100, both in the absence and presence of S9 mix (5%, v/v). The solubility test was performed in water and DMSO. Cytotoxicity to the tester strain TA100 was tested at concentrations of 0.039063, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mg/plate both in the presence (5%, v/v S9 mix) and absence of the metabolic activation system. Cytotoxicity is characterized by inhibition of the background bacterial lawn and/or reduction in the number of revertant colonies. Based on the results of the cytotoxicity study, compound <b>11d</b> was evaluated for its possible mutagenic effect in five strains of <i>Salmonella typhimurium</i> at dose levels of 1.5625, 3.125, 6.25, 12.5, 25, and 50 μg/plate in Trial I and 0.512, 1.28, 3.2, 8, 20, and 50 μg/plate in Trial II both in the absence and presence of metabolic activation. This study was performed as per OECD 1997 guidelines.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> In Vitro Micronucleus Test</h3><div class="NLM_p last">The test system used for the <i>in vitro</i> mammalian cell micronucleus test was human peripheral blood lymphocytes, as recommended by the OECD and other regulatory authorities. Liver microsomal enzyme (S-9) homogenate was prepared in-house. Cyclophosphamide (30 μg/mL) was used as a positive control agent, clastogen, in the presence of metabolic activation, which demonstrates both the activity of the metabolic activation system and the responsiveness of the test system. For long-term treatment, mitomycin-C was used as an aneugenic agent in the absence of metabolic activation system. Positive controls were maintained in duplicate and run with all experiments. The precipitation and pH of <b>11d</b> culture medium was assessed and considered for the selection of the highest concentration for treatment. Based on the precipitation and pH of compound <b>11d</b>, the test concentrations was determined. Treatment was performed in two phase (phase I, short-term treatment; phase II, long-term treatment). In phase I, the cells were exposed to the compound both with and without metabolic activation for 3–6 h (usually 4 h). Cells were washed with the culture medium after treatment to remove compound <b>11d</b>. If required, a second wash with culture medium was given to remove traces of treatment medium. After washing, cells were placed into complete medium with cytochalasin B and sampled at about 24 h from the beginning of the treatment. In Phase II, the cells were exposed to compound <b>11d</b> without metabolic activation with continuous treatment in the presence of cytochalasin B for about 24 h. Cultures were harvested after completion of the treatment period. Each culture was harvested and processed separately for the preparation of chromosomes. A minimum of two slides per treatment group were prepared; one was used for scoring and the other was kept as reserve. All slides were coded before microscopic scoring and decoded after completion of scoring. Slides were randomly observed under a microscope, and a minimum of 2000 binucleated cells per concentration (equally divided in replicates) were counted in different fields for micronucleus frequencies. The proportions of binucleated cells and multinucleated cells were determined for each culture by counting a minimum of 500 cells per culture.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Single-Dose Acute Oral Toxicity in Rats</h3><div class="NLM_p last">This study was performed as per OECD423 guidelines. To determine the acute oral toxicity, a stepwise procedure was employed with the use of three animals of a single sex (females) at each step. The test item was administered orally at one of the defined doses. Absence or presence of compound-related mortality of the animals dosed at one step was used to determine the dose at the next step. The study outcomes were used to determine the LD<sub>50</sub> value of the test compound.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-7"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01765">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01765" class="ext-link">10.1021/acs.jmedchem.7b01765</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H, <sup>13</sup>C, DEPT NMR, HRMS, and HPLC scans of all compounds; results of in vivo efficacy in murine models; additional molecular modeling details; kinase profiling data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_001.pdf">jm7b01765_si_001.pdf (30.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_002.csv">jm7b01765_si_002.csv (8.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01765" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandip B. Bharate</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6081-5787" title="Orcid link">http://orcid.org/0000-0001-6081-5787</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b7c4d5dfd6c5d6c3d2f7dedededa99d6d499ded9"><span class="__cf_email__" data-cfemail="fb8899939a899a8f9ebb92929296d59a98d59295">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ram A. Vishwakarma</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0752-6238" title="Orcid link">http://orcid.org/0000-0002-0752-6238</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#55273438153c3c3c387b34367b3c3b"><span class="__cf_email__" data-cfemail="097b6864496060606427686a276067">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vikas Kumar</span> - <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Preformulation
Laboratory, PK−PD Toxicology & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shreyans K. Jain</span> - <span class="hlFld-Affiliation affiliation">Natural
Products Chemistry Division, CSIR-Indian
Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mubashir J. Mintoo</span> - <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Cancer
Pharmacology Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Santosh K. Guru</span> - <span class="hlFld-Affiliation affiliation">Cancer
Pharmacology Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijay K. Nuthakki</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohit Sharma</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonali S. Bharate</span> - <span class="hlFld-Affiliation affiliation">Preformulation
Laboratory, PK−PD Toxicology & Formulation Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sumit G. Gandhi</span> - <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Plant Biotechnology
Division, CSIR-Indian Institute of Integrative
Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dilip M. Mondhe</span> - <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Cancer
Pharmacology Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shashi Bhushan</span> - <span class="hlFld-Affiliation affiliation">Cancer
Pharmacology Division, CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu-180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Indian
Pharmacopeia Commission, Sec-23, Raj Nagar, Ghaziabad-201002, India</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Contributed equally to this work as co-first authors. S.B.B. and R.A.V. designed, executed, and coordinated this whole study; V.K. and S.B.B. designed and executed large-scale isolation protocol for rohitukine; V.K., V.K.N., and M.S. synthesized IIIM-290 in bulk quantity; S.K.J. synthesized rohitukine derivatives; M.J.M. and D.M.M. designed and performed in vivo efficacy study in murine models and Molt-4 xenograft; S.K.G. and S.B. designed and performed cellular antiproliferative activity experiments; V.K. and S.S.B. performed experimental physicochemical characterization and solution-state stability studies of the lead; S.G.G. collected and authenticated D. binectariferum plant material required for this study; S.B.B. and R.A.V. contributed to manuscript writing.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">IIIM publication number. IIIM/2165/2017.</p></div></li></ul></div><div class="ack" id="ACK-d87e9903-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">V.K. and S.K.J. are thankful to UGC and CSIR for research fellowship. S.S.B. is a Women Scientist (DBT-BioCARe) receiving fellowship from Department of Biotechnology Funded project GAP-2158. Authors thank the analytical department of IIIM for analytical support. This work was supported by CSIR fast-track translational project (MLP-5008) and CSIR 12th five year plan project (Grant no. BSC-0205). S.B.B. thanks CSIR for YSA (Young Scientist Award) research grant.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i98" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i98"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i99" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i99"> ABBREVIATIONS USED</h2><tr><td class="NLM_term">AAG</td><td class="NLM_def"><p class="first last">alpha-acid glycoprotein</p></td></tr><tr><td class="NLM_term">ADH</td><td class="NLM_def"><p class="first last">alcohol dehydrogenase</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AUC<sub>0-t</sub></td><td class="NLM_def"><p class="first last">the area under the plasma concentration–time curve from 0 to last measurable time point</p></td></tr><tr><td class="NLM_term">AUC<sub>0-∞</sub></td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve from time zero to infinity</p></td></tr><tr><td class="NLM_term">BALB/c mice</td><td class="NLM_def"><p class="first last">albino, laboratory-bred strain of the house mouse</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum observed plasma concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>0</sub></td><td class="NLM_def"><p class="first last">extrapolated concentration at zero time point</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CPT</td><td class="NLM_def"><p class="first last">camptothecin</p></td></tr><tr><td class="NLM_term">CYP3A4</td><td class="NLM_def"><p class="first last">cytochrome P450 3A4</p></td></tr><tr><td class="NLM_term">CYP2D6</td><td class="NLM_def"><p class="first last">cytochrome P450 2D6</p></td></tr><tr><td class="NLM_term">CYP2C9</td><td class="NLM_def"><p class="first last">cytochrome P450 2C9</p></td></tr><tr><td class="NLM_term">CYP2C19</td><td class="NLM_def"><p class="first last">cytochrome P450 2C19</p></td></tr><tr><td class="NLM_term">CPM</td><td class="NLM_def"><p class="first last">counts per minute</p></td></tr><tr><td class="NLM_term">DABCO</td><td class="NLM_def"><p class="first last">1,4-diazabicyclo[2.2.2]octane</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">%<i>F</i></td><td class="NLM_def"><p class="first last">percentage bioavailability</p></td></tr><tr><td class="NLM_term">fR2</td><td class="NLM_def"><p class="first last">normal epithelial tissue</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione <i>S</i>-transferase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HCT-116</td><td class="NLM_def"><p class="first last">human colon carcinoma cell lines</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectroscopy</p></td></tr><tr><td class="NLM_term">HSA</td><td class="NLM_def"><p class="first last">human serum albumin</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">infrared spectroscopy</p></td></tr><tr><td class="NLM_term">MMC</td><td class="NLM_def"><p class="first last">mitomycin C</p></td></tr><tr><td class="NLM_term">NAT</td><td class="NLM_def"><p class="first last"><i>N</i>-acetyltransferase</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PRKCE</td><td class="NLM_def"><p class="first last">protein kinase C epsilon</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral route</p></td></tr><tr><td class="NLM_term">Ro5</td><td class="NLM_def"><p class="first last">rule of five</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SD rats</td><td class="NLM_def"><p class="first last">Sprague–Dawley rats</p></td></tr><tr><td class="NLM_term">SGF</td><td class="NLM_def"><p class="first last">simulated gastric fluid</p></td></tr><tr><td class="NLM_term">SIF</td><td class="NLM_def"><p class="first last">simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">SULT</td><td class="NLM_def"><p class="first last">sulfotransferase</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>last</sub></td><td class="NLM_def"><p class="first last">time at which last concentration was found</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2,β</sub></td><td class="NLM_def"><p class="first last">terminal half-life</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term">XO</td><td class="NLM_def"><p class="first last">xanthine oxidase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 62 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ingham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Cell-cycle therapeutics come of age</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2949</span><span class="NLM_x">–</span> <span class="NLM_lpage">2959</span><span class="refDoi"> DOI: 10.1200/JCO.2016.69.0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2016.69.0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28580868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2949-2959&author=M.+Inghamauthor=G.+K.+Schwartz&title=Cell-cycle+therapeutics+come+of+age&doi=10.1200%2FJCO.2016.69.0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cycle therapeutics come of age</span></div><div class="casAuthors">Ingham, Matthew; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2949-2959</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The ability to sustain unscheduled proliferation is a hallmark of cancer.  The normal process of cell division occurs via the cell cycle, a series of highly regulated steps that are orchestrated at the mol. level by specific cyclins that act in assocn. with cyclin-dependent kinases (CDKs).  Cyclin D and CDK4/6 play a key role in cell-cycle progression by phosphorylating and inactivating the retinoblastoma protein, a tumor suppressor that restrains G1- to S-phase progression.  The first-generation CDK inhibitors demonstrated broad activity upon several CDKs, which likely explains their considerable toxicities and limited efficacy.  Palbociclib, ribociclib, and abemaciclib represent a new class of highly specific ATP-competitive CDK4/6 inhibitors that induce reversible G1-phase cell-cycle arrest in retinoblastoma-pos. tumor models.  Both palbociclib and ribociclib have been approved in combination with hormone-based therapy for the treatment of na.ovrddot.ive hormone receptor-pos. advanced breast cancer on the basis of an improvement in progression-free survival.  In general, CDK4/6 inhibitors are cytostatic as monotherapy but demonstrate favorable tolerability, which has prompted interest in combination approaches.  Combinations with phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitors in breast cancer, and inhibitors of the RAS/RAF/mitogen-activated protein kinase pathway in RAS-mutant cancers are particularly promising approaches that are currently being evaluated.  Although the subject of intense preclin. study, predictive biomarkers for response and resistance to these drugs remain largely undefined.  CDK4/6 inhibitors have emerged as the most promising of the cell-cycle therapeutics and intense efforts are now underway to expand the reach of this paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy_vAO4ZbR8LVg90H21EOLACvtfcHk0ljtlE3qhsE_RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemtrzI&md5=167767d50f9089b730514d9a8f8f1cb5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.0032%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DCell-cycle%2520therapeutics%2520come%2520of%2520age%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2949%26epage%3D2959%26doi%3D10.1200%2FJCO.2016.69.0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Abou Zahr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span> </span><span class="NLM_article-title">Emerging cell cycle inhibitors for acute myeloid leukemia</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1080/14728214.2017.1330885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1080%2F14728214.2017.1330885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28506135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1ars7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=137-148&author=A.+Abou+Zahrauthor=G.+Borthakur&title=Emerging+cell+cycle+inhibitors+for+acute+myeloid+leukemia&doi=10.1080%2F14728214.2017.1330885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging cell cycle inhibitors for acute myeloid leukemia</span></div><div class="casAuthors">Abou Zahr, Abdallah; Borthakur, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-148</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: AML therapy remains very challenging despite our increased understanding of its mol. heterogeneity.  Outcomes with chemotherapy and targeted therapy remain poor.  Targeting cell cycle regulators might complement chemotherapy and targeted therapy and help in improving outcomes.: Here we cover the pre-clin. and clin. data for both for cyclin dependent kinase (CDK) and cell-cycle checkpoint inhibitors.  While CDK inhibition can inhibit proliferation, checkpoint inhibitors can facilitate cell cycle progression in presence of DNA damage and can induce mitotic catastrophe.: Though the preclin. data for cell cycle inhibitors in AML is compelling, the clin. translation so far has proven to be challenging.  This is a reflection of the complexity of both, AML and cell cycle regulators.  However, early introduction of cell-cycle active agents in combination with chemotherapy or targeted agents, identifying right sequence of use and identifying right biomarkers might pave the way into successful clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGO9l8La2YvrVg90H21EOLACvtfcHk0ljn_p3vrbLerA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1ars7s%253D&md5=cd3510a43222380a602f4bb343b6c955</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F14728214.2017.1330885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2017.1330885%26sid%3Dliteratum%253Aachs%26aulast%3DAbou%2BZahr%26aufirst%3DA.%26aulast%3DBorthakur%26aufirst%3DG.%26atitle%3DEmerging%2520cell%2520cycle%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2017%26volume%3D22%26spage%3D137%26epage%3D148%26doi%3D10.1080%2F14728214.2017.1330885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Michalides, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veelen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loftus, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balm, A.</span><span> </span><span class="NLM_article-title">Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=975-978&author=R.+Michalidesauthor=N.+van+Veelenauthor=A.+Hartauthor=B.+Loftusauthor=E.+Wientjensauthor=A.+Balm&title=Overexpression+of+cyclin+D1+correlates+with+recurrence+in+a+group+of+forty-seven+operable+squamous+cell+carcinomas+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichalides%26aufirst%3DR.%26aulast%3Dvan%2BVeelen%26aufirst%3DN.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DLoftus%26aufirst%3DB.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DBalm%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520cyclin%2520D1%2520correlates%2520with%2520recurrence%2520in%2520a%2520group%2520of%2520forty-seven%2520operable%2520squamous%2520cell%2520carcinomas%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1016/j.phrs.2016.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.phrs.2016.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26995305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=249-275&author=R.+Roskoski&title=Cyclin-dependent+protein+kinase+inhibitors+including+palbociclib+as+anticancer+drugs&doi=10.1016%2Fj.phrs.2016.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-275</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle progression.  The levels of the cell cycle CDKs are generally const. and their activities are controlled by cyclins, proteins whose levels oscillate during each cell cycle.  Addnl. CDK family members were subsequently discovered that play significant roles in a wide range of activities including the control of gene transcription, metab., and neuronal function.  In response to mitogenic stimuli, cells in the G1 phase of the cell cycle produce cyclins of the D type that activate CDK4/6.  These activated enzymes catalyze the monophosphorylation of the retinoblastoma protein.  Then CDK2-cyclin E catalyzes the hyperphosphorylation of Rb that promotes the release and activation of the E2F transcription factors, which in turn lead to the generation of several proteins required for cell cycle progression.  As a result, cells pass through the G1-restriction point and are committed to complete cell division.  CDK2-cyclin A, CDK1-cyclin A, and CDK1-cyclin B are required for S, G2, and M-phase progression.  Increased cyclin or CDK expression or decreased levels of endogenous CDK inhibitors such as INK4 or CIP/KIP have been obsd. in various cancers.  In contrast to the mutational activation of EGFR, Kit, or B-Raf in the pathogenesis of malignancies, mutations in the CDKs that cause cancers are rare.  Owing to their role in cell proliferation, CDKs represent natural targets for anticancer therapies.  Abemaciclib (LY2835219), ribociclib (Lee011), and palbociclib (Ibrance or PD0332991) target CDK4/6 with IC50 values in the low nanomolar range.  Palbociclib and other CDK inhibitors bind in the cleft between the small and large lobes of the CDKs and inhibit the binding of ATP.  Like ATP, palbociclib forms hydrogen bonds with residues in the hinge segment of the cleft.  Like the adenine base of ATP, palbociclib interacts with catalytic spine residues CS6 and CS7.  CDK antagonists are in clin. trials for the treatment of a variety of malignancies.  Significantly, palbociclib has been approved by the FDA for the treatment of hormone-receptor pos./human epidermal growth factor receptor-2 neg. breast cancer in conjunction with letrozole as a first-line therapy and with fulvestrant as a second-line treatment.  As inhibitors of the cell cycle, it is not surprising that one of their most common toxicities is myelosuppression with decreased neutrophil prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol0On7HAFtl7Vg90H21EOLACvtfcHk0ljn_p3vrbLerA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D&md5=0356807b16735e3903706eac10635bc7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DCyclin-dependent%2520protein%2520kinase%2520inhibitors%2520including%2520palbociclib%2520as%2520anticancer%2520drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D107%26spage%3D249%26epage%3D275%26doi%3D10.1016%2Fj.phrs.2016.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Burki, T. K.</span><span> </span><span class="NLM_article-title">Palbociclib improves survival in advanced breast cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30619-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS1470-2045%2816%2930619-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27890465" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=e1&author=T.+K.+Burki&title=Palbociclib+improves+survival+in+advanced+breast+cancer&doi=10.1016%2FS1470-2045%2816%2930619-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930619-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930619-2%26sid%3Dliteratum%253Aachs%26aulast%3DBurki%26aufirst%3DT.%2BK.%26atitle%3DPalbociclib%2520improves%2520survival%2520in%2520advanced%2520breast%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3De1%26doi%3D10.1016%2FS1470-2045%2816%2930619-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zerdes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziogas, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lykoudis, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roukos, D. H.</span><span> </span><span class="NLM_article-title">Palbociclib: an approval at last for HER2-negative breast cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1100</span><span class="refDoi"> DOI: 10.2217/fon-2015-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2217%2Ffon-2015-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26987714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1097-1100&author=I.+Zerdesauthor=D.+E.+Ziogasauthor=E.+G.+Lykoudisauthor=D.+H.+Roukos&title=Palbociclib%3A+an+approval+at+last+for+HER2-negative+breast+cancer&doi=10.2217%2Ffon-2015-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: an approval at last for HER2-negative breast cancer</span></div><div class="casAuthors">Zerdes, Ioannis; Ziogas, Demosthenes E.; Lykoudis, Efstathios G.; Roukos, Dimitrios H.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1097-1100</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXtnt5nV1mebVg90H21EOLACvtfcHk0ljpFcEnEAO1oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamuro%253D&md5=c80b4ea7ef0e38d3694d29bdf3ce0a39</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Ffon-2015-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2015-0056%26sid%3Dliteratum%253Aachs%26aulast%3DZerdes%26aufirst%3DI.%26aulast%3DZiogas%26aufirst%3DD.%2BE.%26aulast%3DLykoudis%26aufirst%3DE.%2BG.%26aulast%3DRoukos%26aufirst%3DD.%2BH.%26atitle%3DPalbociclib%253A%2520an%2520approval%2520at%2520last%2520for%2520HER2-negative%2520breast%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1097%26epage%3D1100%26doi%3D10.2217%2Ffon-2015-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Palanisamy, R. P.</span><span> </span><span class="NLM_article-title">Palbociclib: A new hope in the treatment of breast cancer</span> <span class="citation_source-journal">J. Cancer Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span><span class="refDoi"> DOI: 10.4103/0973-1482.168988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.4103%2F0973-1482.168988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28169231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1220-1223&author=R.+P.+Palanisamy&title=Palbociclib%3A+A+new+hope+in+the+treatment+of+breast+cancer&doi=10.4103%2F0973-1482.168988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: A new hope in the treatment of breast cancer</span></div><div class="casAuthors">Palanisamy R Priyadharsini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cancer research and therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1220-1223</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer being one of the common cancers has high morbidity and mortality.  Despite the conventional treatment, the burden of the disease increases year after year.  There is a need for newer drugs that target the different mechanisms in the pathogenesis.  The interaction of cyclins with cyclin dependent kinases (CDKs) plays a major role in the abnormal cell cycle in cancer and it is considered to be an important target.  Palbociclib is a CDK inhibitor currently approved for the treatment of breast cancer.  The preclinical studies with breast cancer lines were sensitive to palbociclib and the clinical trials phase I, phase II (PALOMA 1), and phase III (PALOMA 2, 3, PENTELOPE, PEARL) showed that the drug was efficacious when combined other conventional drugs for breast cancer.  Palbociclib was also been tested in various other germ cell tumors, melanoma, multiple myeloma, glioblastoma multiforme etc., The major adverse effect of the drug includes hematological toxicity mainly neutropenia, gastrointestinal adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnC9U-jJOxSoJKJbLTgsvCfW6udTcc2eabuOEXvsSzH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jvFWitQ%253D%253D&md5=5078e0a51063f7a427461baeb4be57b6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4103%2F0973-1482.168988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0973-1482.168988%26sid%3Dliteratum%253Aachs%26aulast%3DPalanisamy%26aufirst%3DR.%2BP.%26atitle%3DPalbociclib%253A%2520A%2520new%2520hope%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Cancer%2520Res.%2520Ther.%26date%3D2016%26volume%3D12%26spage%3D1220%26epage%3D1223%26doi%3D10.4103%2F0973-1482.168988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gupta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashier, D. B.</span><span> </span><span class="NLM_article-title">Palbociclib: A breakthrough in breast carcinoma in women</span> <span class="citation_source-journal">Med. J. Armed Forces India</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">S37</span><span class="NLM_x">–</span> <span class="NLM_lpage">S42</span><span class="refDoi"> DOI: 10.1016/j.mjafi.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.mjafi.2015.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28050067" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=S37-S42&author=A.+K.+Guptaauthor=S.+Sharmaauthor=N.+Dahiyaauthor=D.+B.+Brashier&title=Palbociclib%3A+A+breakthrough+in+breast+carcinoma+in+women&doi=10.1016%2Fj.mjafi.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.mjafi.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mjafi.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDahiya%26aufirst%3DN.%26aulast%3DBrashier%26aufirst%3DD.%2BB.%26atitle%3DPalbociclib%253A%2520A%2520breakthrough%2520in%2520breast%2520carcinoma%2520in%2520women%26jtitle%3DMed.%2520J.%2520Armed%2520Forces%2520India%26date%3D2016%26volume%3D72%26spage%3DS37%26epage%3DS42%26doi%3D10.1016%2Fj.mjafi.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>Ribociclib (Kisqali). <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm</a> (accessed on July 11,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ribociclib+%28Kisqali%29.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm546438.htm+%28accessed+on+July+11%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Torres-Guzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermoso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baquero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehnke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lallena, M. J.</span><span> </span><span class="NLM_article-title">Preclinical characterization of abemaciclib in hormone receptor positive breast cancer</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">69493</span><span class="NLM_x">–</span> <span class="NLM_lpage">69507</span><span class="refDoi"> DOI: 10.18632/oncotarget.17778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.17778" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=69493-69507&author=R.+Torres-Guzmanauthor=B.+Calsinaauthor=A.+Hermosoauthor=C.+Baqueroauthor=B.+Alvarezauthor=J.+Amatauthor=A.+M.+McNultyauthor=X.+Gongauthor=K.+Boehnkeauthor=J.+Duauthor=A.+de+Diosauthor=R.+P.+Beckmannauthor=S.+Buchananauthor=M.+J.+Lallena&title=Preclinical+characterization+of+abemaciclib+in+hormone+receptor+positive+breast+cancer&doi=10.18632%2Foncotarget.17778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17778%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Guzman%26aufirst%3DR.%26aulast%3DCalsina%26aufirst%3DB.%26aulast%3DHermoso%26aufirst%3DA.%26aulast%3DBaquero%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DB.%26aulast%3DAmat%26aufirst%3DJ.%26aulast%3DMcNulty%26aufirst%3DA.%2BM.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DBoehnke%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26atitle%3DPreclinical%2520characterization%2520of%2520abemaciclib%2520in%2520hormone%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D69493%26epage%3D69507%26doi%3D10.18632%2Foncotarget.17778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Sledge, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neven, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivot, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdaeva, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grischke, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barriga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourayou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span> </span><span class="NLM_article-title">MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2875</span><span class="NLM_x">–</span> <span class="NLM_lpage">2884</span><span class="refDoi"> DOI: 10.1200/JCO.2017.73.7585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2017.73.7585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28580882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC1cnkvFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2875-2884&author=G.+W.+Sledgeauthor=M.+Toiauthor=P.+Nevenauthor=J.+Sohnauthor=K.+Inoueauthor=X.+Pivotauthor=O.+Burdaevaauthor=M.+Okeraauthor=N.+Masudaauthor=P.+A.+Kaufmanauthor=H.+Kohauthor=E.+M.+Grischkeauthor=M.+Frenzelauthor=Y.+Linauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Llombart-Cussac&title=MONARCH+2%3A+Abemaciclib+in+combination+with+fulvestrant+in+women+with+HR%2B%2FHER2-+advanced+breast+cancer+who+had+progressed+while+receiving+endocrine+therapy&doi=10.1200%2FJCO.2017.73.7585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy</span></div><div class="casAuthors">Sledge George W Jr; Toi Masakazu; Neven Patrick; Sohn Joohyuk; Inoue Kenichi; Pivot Xavier; Burdaeva Olga; Okera Meena; Masuda Norikazu; Kaufman Peter A; Koh Han; Grischke Eva-Maria; Frenzel Martin; Lin Yong; Barriga Susana; Smith Ian C; Bourayou Nawel; Llombart-Cussac Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2875-2884</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).  Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic disease.  Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label).  The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clinical benefit rate, quality of life, and safety.  Results Between August 2014 and December 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223).  Abemaciclib plus fulvestrant significantly extended PFS versus fulvestrant alone (median, 16.4 v 9.3 months; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001).  In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm.  The most common adverse events in the abemaciclib versus placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%).  Conclusions Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCflt1Gxh1HszK395ZObgVfW6udTcc2eYZhmzU2DSd47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnkvFWhsA%253D%253D&md5=7a305322c71231a877aa099acfaec522</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.7585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.7585%26sid%3Dliteratum%253Aachs%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DPivot%26aufirst%3DX.%26aulast%3DBurdaeva%26aufirst%3DO.%26aulast%3DOkera%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DKaufman%26aufirst%3DP.%2BA.%26aulast%3DKoh%26aufirst%3DH.%26aulast%3DGrischke%26aufirst%3DE.%2BM.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26atitle%3DMONARCH%25202%253A%2520Abemaciclib%2520in%2520combination%2520with%2520fulvestrant%2520in%2520women%2520with%2520HR%252B%252FHER2-%2520advanced%2520breast%2520cancer%2520who%2520had%2520progressed%2520while%2520receiving%2520endocrine%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2875%26epage%3D2884%26doi%3D10.1200%2FJCO.2017.73.7585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schade, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulford, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulanthaivel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronier, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F2159-8290.CD-16-0095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=740-753&author=A.+Patnaikauthor=L.+S.+Rosenauthor=S.+M.+Tolaneyauthor=A.+W.+Tolcherauthor=J.+W.+Goldmanauthor=L.+Gandhiauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=J.+F.+Hiltonauthor=A.+Nasirauthor=R.+P.+Beckmannauthor=A.+E.+Schadeauthor=A.+D.+Fulfordauthor=T.+S.+Nguyenauthor=R.+Martinezauthor=P.+Kulanthaivelauthor=L.+Q.+Liauthor=M.+Frenzelauthor=D.+M.+Cronierauthor=E.+M.+Chanauthor=K.+T.+Flahertyauthor=P.+Y.+Wenauthor=G.+I.+Shapiro&title=Efficacy+and+safety+of+abemaciclib%2C+an+inhibitor+of+CDK4+and+CDK6%2C+for+patients+with+breast+cancer%2C+non-small+cell+lung+cancer%2C+and+other+solid+tumors&doi=10.1158%2F2159-8290.CD-16-0095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0095%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DHilton%26aufirst%3DJ.%2BF.%26aulast%3DNasir%26aufirst%3DA.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DSchade%26aufirst%3DA.%2BE.%26aulast%3DFulford%26aufirst%3DA.%2BD.%26aulast%3DNguyen%26aufirst%3DT.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DKulanthaivel%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DL.%2BQ.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DCronier%26aufirst%3DD.%2BM.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520abemaciclib%252C%2520an%2520inhibitor%2520of%2520CDK4%2520and%2520CDK6%252C%2520for%2520patients%2520with%2520breast%2520cancer%252C%2520non-small%2520cell%2520lung%2520cancer%252C%2520and%2520other%2520solid%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D740%26epage%3D753%26doi%3D10.1158%2F2159-8290.CD-16-0095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> (accessed on August 23,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov+%28accessed+on+August+23%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rahaman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekonnen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">T211</span><span class="NLM_x">–</span> <span class="NLM_lpage">T226</span><span class="refDoi"> DOI: 10.1530/ERC-16-0299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1530%2FERC-16-0299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27582311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=T211-T226&author=M.+H.+Rahamanauthor=M.+Kumarasiriauthor=L.+B.+Mekonnenauthor=M.+Yuauthor=S.+Diabauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Targeting+CDK9%3A+a+promising+therapeutic+opportunity+in+prostate+cancer&doi=10.1530%2FERC-16-0299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Kumarasiri, Malika; Mekonnen, Laychiluh B.; Yu, Mingfeng; Diab, Sarah; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">T211-T226</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment.  Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression.  In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen.  CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and antiapoptotic proteins, improving the chances of pos. outcomes, esp. in patients with the advanced disease.  This review focuses on biol. functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmSh9D9_op7Vg90H21EOLACvtfcHk0lipuOQD1AAIgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D&md5=cea302eeb765840884f60cb170ec1640</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1530%2FERC-16-0299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-16-0299%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK9%253A%2520a%2520promising%2520therapeutic%2520opportunity%2520in%2520prostate%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2016%26volume%3D23%26spage%3DT211%26epage%3DT226%26doi%3D10.1530%2FERC-16-0299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sonawane, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napoleon, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contreras, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, A.</span><span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 knhibitors for cancer therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8667</span><span class="NLM_x">–</span> <span class="NLM_lpage">8684</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+knhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520knhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Morales, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Overview of CDK9 as a target in cancer research</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span><span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+target+in+cancer+research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0lipuOQD1AAIgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520target%2520in%2520cancer%2520research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span><span class="refDoi"> DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure-activity+relationship%2C+and+anticancer+activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure-activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Nemeth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekely, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebestyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaszay, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirat, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virieux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyuris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelemenics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ay, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szathmary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3939</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span><span class="refDoi"> DOI: 10.1021/jm401742r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401742r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3939-3965&author=G.+Nemethauthor=Z.+Greffauthor=A.+Siposauthor=Z.+Vargaauthor=R.+Szekelyauthor=M.+Sebestyenauthor=Z.+Jaszayauthor=S.+Beniauthor=Z.+Nemesauthor=J.+L.+Piratauthor=J.+N.+Volleauthor=D.+Virieuxauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=E.+Ayauthor=J.+Minarovitsauthor=S.+Szathmaryauthor=G.+Keriauthor=L.+Orfi&title=Synthesis+and+evaluation+of+phosphorus+containing%2C+specific+CDK9%2FCycT1+inhibitors&doi=10.1021%2Fjm401742r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm401742r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401742r%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DSzekely%26aufirst%3DR.%26aulast%3DSebestyen%26aufirst%3DM.%26aulast%3DJaszay%26aufirst%3DZ.%26aulast%3DBeni%26aufirst%3DS.%26aulast%3DNemes%26aufirst%3DZ.%26aulast%3DPirat%26aufirst%3DJ.%2BL.%26aulast%3DVolle%26aufirst%3DJ.%2BN.%26aulast%3DVirieux%26aufirst%3DD.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DAy%26aufirst%3DE.%26aulast%3DMinarovits%26aufirst%3DJ.%26aulast%3DSzathmary%26aufirst%3DS.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520phosphorus%2520containing%252C%2520specific%2520CDK9%252FCycT1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3939%26epage%3D3965%26doi%3D10.1021%2Fjm401742r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span> </span><span class="NLM_article-title">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3231</span><span class="NLM_x">–</span> <span class="NLM_lpage">3237</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2017.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2017.06.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=3231-3237&author=Y.+Liauthor=Q.+Guoauthor=C.+Zhangauthor=Z.+Huangauthor=T.+Wangauthor=X.+Wangauthor=X.+Wangauthor=G.+Xuauthor=Y.+Liuauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+a+highly+potent%2C+selective+and+novel+CDK9+inhibitor+as+an+anticancer+drug+candidate&doi=10.1016%2Fj.bmcl.2017.06.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%2520and%2520novel%2520CDK9%2520inhibitor%2520as%2520an%2520anticancer%2520drug%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D3231%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2017.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Tong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeranki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mejia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstetter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maru, D.</span><span> </span><span class="NLM_article-title">Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">28696</span><span class="NLM_x">–</span> <span class="NLM_lpage">28710</span><span class="refDoi"> DOI: 10.18632/oncotarget.15645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.15645" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=28696-28710&author=Z.+Tongauthor=D.+Chatterjeeauthor=D.+Dengauthor=O.+Veerankiauthor=A.+Mejiaauthor=J.+A.+Ajaniauthor=W.+Hofstetterauthor=S.+Linauthor=S.+Guhaauthor=S.+Kopetzauthor=S.+Krishnanauthor=D.+Maru&title=Antitumor+effects+of+cyclin+dependent+kinase+9+inhibition+in+esophageal+adenocarcinoma&doi=10.18632%2Foncotarget.15645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15645%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DVeeranki%26aufirst%3DO.%26aulast%3DMejia%26aufirst%3DA.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DHofstetter%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DGuha%26aufirst%3DS.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DMaru%26aufirst%3DD.%26atitle%3DAntitumor%2520effects%2520of%2520cyclin%2520dependent%2520kinase%25209%2520inhibition%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D28696%26epage%3D28710%26doi%3D10.18632%2Foncotarget.15645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Yeh, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoney, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span> </span><span class="NLM_article-title">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2667</span><span class="NLM_x">–</span> <span class="NLM_lpage">2679</span><span class="refDoi"> DOI: 10.18632/oncotarget.2096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.2096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2667-2679&author=Y.+Y.+Yehauthor=R.+Chenauthor=J.+Hesslerauthor=E.+Mahoneyauthor=A.+M.+Lehmanauthor=N.+A.+Heeremaauthor=M.+R.+Greverauthor=W.+Plunkettauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Up-regulation+of+CDK9+kinase+activity+and+Mcl-1+stability+contributes+to+the+acquired+resistance+to+cyclin-dependent+kinase+inhibitors+in+leukemia&doi=10.18632%2Foncotarget.2096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2096%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DUp-regulation%2520of%2520CDK9%2520kinase%2520activity%2520and%2520Mcl-1%2520stability%2520contributes%2520to%2520the%2520acquired%2520resistance%2520to%2520cyclin-dependent%2520kinase%2520inhibitors%2520in%2520leukemia%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D2667%26epage%3D2679%26doi%3D10.18632%2Foncotarget.2096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span> </span><span class="NLM_article-title">Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2513</span><span class="NLM_x">–</span> <span class="NLM_lpage">2519</span><span class="refDoi"> DOI: 10.1182/blood-2005-04-1678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1182%2Fblood-2005-04-1678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=15972445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=2513-2519&author=R.+Chenauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Transcription+inhibition+by+flavopiridol%3A+mechanism+of+chronic+lymphocytic+leukemia+cell+death&doi=10.1182%2Fblood-2005-04-1678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death</span></div><div class="casAuthors">Chen, Rong; Keating, Michael J.; Gandhi, Varsha; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2513-2519</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Flavopiridol is active against chronic lymphocytic leukemia (CLL) cells in vitro and in the treatment of advanced stage disease, but the mechanisms of these actions remain unclear.  Originally developed as a general cyclin-dependent kinase inhibitor, flavopiridol is a potent transcriptional suppressor through the inhibition of pos. transcription elongation factor b (P-TEFb; CDK9/cyclin T).  P-TEFb phosphorylates the C-terminal domain (CTD) of RNA polymerase II to promote transcriptional elongation.  Because most CLL cells are not actively cycling, and their viability is dependent upon the continuous expression of antiapoptotic proteins, we hypothesized that flavopiridol induces apoptosis in CLL cells through the transcriptional down-regulation of such proteins.  This study demonstrated that flavopiridol inhibited the phosphorylation of the CTD of RNA polymerase II in primary CLL cells and reduced RNA synthesis.  This was assocd. with a decline of the transcripts and the levels of short-lived antiapoptotic proteins such as myeloid cell leukemia 1 (Mcl-1), and resulted in the induction of apoptosis.  The B-cell lymphoma 2 (Bcl-2) protein level remained stable, although its mRNA was consistently reduced, suggesting that the outcome of transcriptional inhibition by flavopiridol is governed by the intrinsic stability of the individual transcripts and proteins.  The dependence of CLL-cell survival on short-lived oncoproteins may provide the biochem. basis for the therapeutic index in response to flavopiridol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Pk8ThZIWabVg90H21EOLACvtfcHk0lhGiQzrBf6GLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKqt7rN&md5=428335b578ab40e36c8956905ebf0bea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-04-1678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-04-1678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DTranscription%2520inhibition%2520by%2520flavopiridol%253A%2520mechanism%2520of%2520chronic%2520lymphocytic%2520leukemia%2520cell%2520death%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D2513%26epage%3D2519%26doi%3D10.1182%2Fblood-2005-04-1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Harmon, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, U.</span><span> </span><span class="NLM_article-title">The structure of rohitukine, the main alkaloid of <i>Amoora rohituka</i> (Syn. <i>Aphanamixis polystachya</i>) (Meliaceae)</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)93556-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0040-4039%2801%2993556-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=721-724&author=A.+D.+Harmonauthor=U.+Weiss&title=The+structure+of+rohitukine%2C+the+main+alkaloid+of+Amoora+rohituka+%28Syn.+Aphanamixis+polystachya%29+%28Meliaceae%29&doi=10.1016%2FS0040-4039%2801%2993556-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2993556-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252993556-7%26sid%3Dliteratum%253Aachs%26aulast%3DHarmon%26aufirst%3DA.%2BD.%26aulast%3DWeiss%26aufirst%3DU.%26atitle%3DThe%2520structure%2520of%2520rohitukine%252C%2520the%2520main%2520alkaloid%2520of%2520Amoora%2520rohituka%2520%2528Syn.%2520Aphanamixis%2520polystachya%2529%2520%2528Meliaceae%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26spage%3D721%26epage%3D724%26doi%3D10.1016%2FS0040-4039%2801%2993556-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Naik, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kattige, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alreja, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Souza, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupp, R. H.</span><span> </span><span class="NLM_article-title">An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span><span class="refDoi"> DOI: 10.1016/S0040-4020(01)90352-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0040-4020%2801%2990352-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1988&pages=2081-2086&author=R.+G.+Naikauthor=S.+L.+Kattigeauthor=S.+V.+Bhatauthor=B.+Alrejaauthor=N.+J.+de+Souzaauthor=R.+H.+Rupp&title=An+antiinflammatory+cum+immunomodulatory+piperidinylbenzopyranone+from+dysoxylum+binectariferum%3A+isolation%2C+structure+and+total+synthesis&doi=10.1016%2FS0040-4020%2801%2990352-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2990352-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252990352-7%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DR.%2BG.%26aulast%3DKattige%26aufirst%3DS.%2BL.%26aulast%3DBhat%26aufirst%3DS.%2BV.%26aulast%3DAlreja%26aufirst%3DB.%26aulast%3Dde%2BSouza%26aufirst%3DN.%2BJ.%26aulast%3DRupp%26aufirst%3DR.%2BH.%26atitle%3DAn%2520antiinflammatory%2520cum%2520immunomodulatory%2520piperidinylbenzopyranone%2520from%2520dysoxylum%2520binectariferum%253A%2520isolation%252C%2520structure%2520and%2520total%2520synthesis%26jtitle%3DTetrahedron%26date%3D1988%26volume%3D44%26spage%3D2081%26epage%3D2086%26doi%3D10.1016%2FS0040-4020%2801%2990352-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Mohanakumara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sreejayan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramesha, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganeshaiah, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudeva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhoshkumar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uma Shaanker, R.</span><span> </span><span class="NLM_article-title"><i>Dysoxylum binectariferum</i> Hook.f (Meliaceae), a rich source of rohitukine</span> <span class="citation_source-journal">Fitoterapia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.fitote.2009.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.fitote.2009.08.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=145-148&author=P.+Mohanakumaraauthor=N.+Sreejayanauthor=V.+Pritiauthor=B.+T.+Rameshaauthor=G.+Ravikanthauthor=K.+N.+Ganeshaiahauthor=R.+Vasudevaauthor=J.+Mohanauthor=T.+R.+Santhoshkumarauthor=P.+D.+Mishraauthor=R.+A.+Vishwakarmaauthor=R.+Uma+Shaanker&title=Dysoxylum+binectariferum+Hook.f+%28Meliaceae%29%2C+a+rich+source+of+rohitukine&doi=10.1016%2Fj.fitote.2009.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.fitote.2009.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fitote.2009.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DMohanakumara%26aufirst%3DP.%26aulast%3DSreejayan%26aufirst%3DN.%26aulast%3DPriti%26aufirst%3DV.%26aulast%3DRamesha%26aufirst%3DB.%2BT.%26aulast%3DRavikanth%26aufirst%3DG.%26aulast%3DGaneshaiah%26aufirst%3DK.%2BN.%26aulast%3DVasudeva%26aufirst%3DR.%26aulast%3DMohan%26aufirst%3DJ.%26aulast%3DSanthoshkumar%26aufirst%3DT.%2BR.%26aulast%3DMishra%26aufirst%3DP.%2BD.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DUma%2BShaanker%26aufirst%3DR.%26atitle%3DDysoxylum%2520binectariferum%2520Hook.f%2520%2528Meliaceae%2529%252C%2520a%2520rich%2520source%2520of%2520rohitukine%26jtitle%3DFitoterapia%26date%3D2010%26volume%3D81%26spage%3D145%26epage%3D148%26doi%3D10.1016%2Fj.fitote.2009.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guru, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhushan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">A chromatography-free isolation of rohitukine from leaves of <i>Dysoxylum binectariferum</i>: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3457</span><span class="NLM_x">–</span> <span class="NLM_lpage">3463</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2016.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3457-3463&author=V.+Kumarauthor=S.+K.+Guruauthor=S.+K.+Jainauthor=P.+Joshiauthor=S.+G.+Gandhiauthor=S.+B.+Bharateauthor=S.+Bhushanauthor=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=A+chromatography-free+isolation+of+rohitukine+from+leaves+of+Dysoxylum+binectariferum%3A+Evaluation+for+in+vitro+cytotoxicity%2C+Cdk+inhibition+and+physicochemical+properties&doi=10.1016%2Fj.bmcl.2016.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DJoshi%26aufirst%3DP.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DA%2520chromatography-free%2520isolation%2520of%2520rohitukine%2520from%2520leaves%2520of%2520Dysoxylum%2520binectariferum%253A%2520Evaluation%2520for%2520in%2520vitro%2520cytotoxicity%252C%2520Cdk%2520inhibition%2520and%2520physicochemical%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3457%26epage%3D3463%26doi%3D10.1016%2Fj.bmcl.2016.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Mahajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khajuria, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedi, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, S. G.</span><span> </span><span class="NLM_article-title">Production of rohitukine in leaves and seeds of <i>Dysoxylum binectariferum</i>: an alternate renewable resource</span> <span class="citation_source-journal">Pharm. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.3109/13880209.2014.923006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3109%2F13880209.2014.923006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25472605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFCiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2015&pages=446-450&author=V.+Mahajanauthor=N.+Sharmaauthor=S.+Kumarauthor=V.+Bhardwajauthor=A.+Aliauthor=R.+K.+Khajuriaauthor=Y.+S.+Bediauthor=R.+A.+Vishwakarmaauthor=S.+G.+Gandhi&title=Production+of+rohitukine+in+leaves+and+seeds+of+Dysoxylum+binectariferum%3A+an+alternate+renewable+resource&doi=10.3109%2F13880209.2014.923006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Production of rohitukine in leaves and seeds of Dysoxylum binectariferum: An alternate renewable resource</span></div><div class="casAuthors">Mahajan, Vidushi; Sharma, Neha; Kumar, Sunil; Bhardwaj, Vikram; Ali, Asif; Khajuria, R. K.; Bedi, Y. S.; Vishwakarma, Ram A.; Gandhi, Sumit G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Biology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-450</span>CODEN:
                <span class="NLM_cas:coden">PHBIFC</span>;
        ISSN:<span class="NLM_cas:issn">1388-0209</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Rohitukine is an important precursor for the synthesis of potential anticancer drugs flavopiridol (Sanofi-Aventis) and P-276-00 (Piramal Healthcare Limited, Mumbai, India).  Trunk bark of Dysoxylum binectariferum (Roxb.) Hook. f. ex Bedd. (Meliaceae) is the widely used source for isolation of rohitukine.  However, removal of trunk bark threatens the survival of the tree.  The aim was to investigate the amt. of rohitukine accumulated in other tissues of D. binectariferum.  Materials and methods: Rohitukine std. was isolated from leaves of D. binectariferum.  Its purity was ascertained using HR-MS and NMR.  Crude exts. were prepd. from different tissues of D. binectariferum.  Rohitukine content in all the tissues was quantified by HPLC.  Rohitukine accumulates in a significant amt. in seeds, trunk bark, leaves, twigs, and fruits of D. binectariferum.  Seeds have the highest rohitukine content (2.42%, dry wt.) followed by trunk bark (1.34%, dry wt.), leaves (1.064%, dry wt.), twigs (0.844% dry wt.), and fruits (0.4559% dry wt.).  Discussion and conclusion: Seeds and leaves of D. binectariferum could be used as alternate renewable sources for isolation of rohitukine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobpkFXP3CHDLVg90H21EOLACvtfcHk0ljaDzXjsaAstQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFCiurc%253D&md5=bd502e873aa1802768c71ca03754c62b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3109%2F13880209.2014.923006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F13880209.2014.923006%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DKhajuria%26aufirst%3DR.%2BK.%26aulast%3DBedi%26aufirst%3DY.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26atitle%3DProduction%2520of%2520rohitukine%2520in%2520leaves%2520and%2520seeds%2520of%2520Dysoxylum%2520binectariferum%253A%2520an%2520alternate%2520renewable%2520resource%26jtitle%3DPharm.%2520Biol.%26date%3D2015%26volume%3D53%26spage%3D446%26epage%3D450%26doi%3D10.3109%2F13880209.2014.923006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyoshi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, Y.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing’s family tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1218</span><span class="refDoi"> DOI: 10.1002/ijc.22820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1002%2Fijc.22820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17520676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSmt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2007&pages=1212-1218&author=Y.+Liauthor=K.+Tanakaauthor=X.+Liauthor=T.+Okadaauthor=T.+Nakamuraauthor=M.+Takasakiauthor=S.+Yamamotoauthor=Y.+Odaauthor=M.+Tsuneyoshiauthor=Y.+Iwamoto&title=Cyclin-dependent+kinase+inhibitor%2C+flavopiridol%2C+induces+apoptosis+and+inhibits+tumor+growth+in+drug-resistant+osteosarcoma+and+Ewing%E2%80%99s+family+tumor+cells&doi=10.1002%2Fijc.22820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells</span></div><div class="casAuthors">Li, Yan; Tanaka, Kazuhiro; Li, Xu; Okada, Takamitsu; Nakamura, Tomoyuki; Takasaki, Minoru; Yamamoto, Shunsaku; Oda, Yoshinao; Tsuneyoshi, Masazumi; Iwamoto, Yukihide</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1212-1218</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors.  Although the clin. outcome of primary OS and EFTs is greatly improved, the relapsed cases often are assocd. with multidrug resistance of the tumors and the prognosis of these patients is still poor.  Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells.  However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs.  Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-assocd. protein 1 (MRP1) as effectively as in their parental cells.  Our data also showed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK).  The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs.  These results suggest that flavopiridol might be promising in clin. therapy for the relapsed OS and EFTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj6WI4ypRZh7Vg90H21EOLACvtfcHk0ljaDzXjsaAstQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSmt7fL&md5=19abe5cc41bf20c5466e574982ef54dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fijc.22820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22820%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DTsuneyoshi%26aufirst%3DM.%26aulast%3DIwamoto%26aufirst%3DY.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520flavopiridol%252C%2520induces%2520apoptosis%2520and%2520inhibits%2520tumor%2520growth%2520in%2520drug-resistant%2520osteosarcoma%2520and%2520Ewing%25E2%2580%2599s%2520family%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D121%26spage%3D1212%26epage%3D1218%26doi%3D10.1002%2Fijc.22820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Lanasa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligaris-Cappio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblond, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stilgenbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span> </span><span class="NLM_article-title">Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.leukres.2015.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.leukres.2015.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25804339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=495-500&author=M.+C.+Lanasaauthor=L.+Andritsosauthor=J.+R.+Brownauthor=J.+Gabriloveauthor=F.+Caligaris-Cappioauthor=P.+Ghiaauthor=R.+A.+Larsonauthor=T.+J.+Kippsauthor=V.+Leblondauthor=D.+W.+Milliganauthor=A.+Janssensauthor=A.+J.+Johnsonauthor=N.+A.+Heeremaauthor=A.+Buhlerauthor=S.+Stilgenbauerauthor=J.+Devinauthor=M.+Hallekauthor=J.+C.+Byrdauthor=M.+R.+Grever&title=Final+results+of+EFC6663%3A+a+multicenter%2C+international%2C+phase+2+study+of+alvocidib+for+patients+with+fludarabine-refractory+chronic+lymphocytic+leukemia&doi=10.1016%2Fj.leukres.2015.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Lanasa, Mark C.; Andritsos, Leslie; Brown, Jennifer R.; Gabrilove, Janice; Caligaris-Cappio, Federico; Ghia, Paolo; Larson, Richard A.; Kipps, Thomas J.; Leblond, Veronique; Milligan, Donald W.; Janssens, Ann; Johnson, Amy J.; Heerema, Nyla A.; Buhler, Andreas; Stilgenbauer, Stephan; Devin, Jeanne; Hallek, Michael; Byrd, John C.; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-500</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine.  A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results.  Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib.  The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration.  One hundred and sixty five patients were enrolled and 159 patients were treated.  The median age was 61 years, the median no. of prior therapies was 4, and 96% of patients were fludarabine refractory.  The investigator-assessed overall response rate was 25%; the majority of responses were partial.  Response rates were lower among patients with del(17p) (14%), but equiv. in patients with del(11q) or bulky lymphadenopathy.  Median progression free and overall survival were 7.6 and 14.6 mo, resp.  Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis.  Diarrhea, fatigue, and hematol. toxicities were common.  Alvocidib has clin. activity in patients with advanced, fludarabine refractory CLL.  Future studies should focus on discovery of biomarkers of clin. response and tumor lysis, and enhanced supportive care measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLlMqLBd2m7Vg90H21EOLACvtfcHk0lgE1T78GtDCGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D&md5=3f3c902b0c772666192142ffd71d1c4f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DLeblond%26aufirst%3DV.%26aulast%3DMilligan%26aufirst%3DD.%2BW.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DBuhler%26aufirst%3DA.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFinal%2520results%2520of%2520EFC6663%253A%2520a%2520multicenter%252C%2520international%252C%2520phase%25202%2520study%2520of%2520alvocidib%2520for%2520patients%2520with%2520fludarabine-refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D495%26epage%3D500%26doi%3D10.1016%2Fj.leukres.2015.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalona-Calero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span> </span><span class="NLM_article-title">Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6012</span><span class="NLM_x">–</span> <span class="NLM_lpage">6018</span><span class="refDoi"> DOI: 10.1200/JCO.2009.22.6944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2009.22.6944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=19826119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6012-6018&author=T.+S.+Linauthor=A.+S.+Ruppertauthor=A.+J.+Johnsonauthor=B.+Fischerauthor=N.+A.+Heeremaauthor=L.+A.+Andritsosauthor=K.+A.+Blumauthor=J.+M.+Flynnauthor=J.+A.+Jonesauthor=W.+Huauthor=M.+E.+Moranauthor=S.+M.+Mitchellauthor=L.+L.+Smithauthor=A.+J.+Wagnerauthor=C.+A.+Raymondauthor=L.+J.+Schaafauthor=M.+A.+Phelpsauthor=M.+A.+Villalona-Caleroauthor=M.+R.+Greverauthor=J.+C.+Byrd&title=Phase+II+study+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia+demonstrating+high+response+rates+in+genetically+high-risk+disease&doi=10.1200%2FJCO.2009.22.6944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease</span></div><div class="casAuthors">Lin, Thomas S.; Ruppert, Amy S.; Johnson, Amy J.; Fischer, Beth; Heerema, Nyla A.; Andritsos, Leslie A.; Blum, Kristie A.; Flynn, Joseph M.; Jones, Jeffrey A.; Hu, Weihong; Moran, Mollie E.; Mitchell, Sarah M.; Smith, Lisa L.; Wagner, Amy J.; Raymond, Chelsey A.; Schaaf, Larry J.; Phelps, Mitch A.; Villalona-Calero, Miguel A.; Grever, Michael R.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6012-6018</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies.  A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irresp. of high-risk features.  Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated.  Patients and Methods: Patients with relapsed CLL were treated with single-agent flavopiridol, with subsequent addn. of dexamethasone to suppress cytokine release syndrome (CRS).  High-risk genomic features were prospectively assessed for response to therapy.  Results: Sixty-four patients were enrolled.  Median age was 60 years, median no. of prior therapies was four, and all patients had received prior purine analog therapy.  If patients tolerated treatment during week 1, dose escalation occurred during week 2.  Dose escalation did not occur in four patients, as a result of severe tumor lysis syndrome; three of these patients required hemodialysis.  Thirty-four patients (53%) achieved response, including 30 partial responses (PRs; 47%), three nodular PRs (5%), and one complete response (1.6%).  A majority of high-risk patients responded; 12 (57%) of 21 patients with del(17p13.1) and 14 (50%) of 28 patients with del(11q22.3) responded irresp. of lymph node size.  Median progression-free survival among responders was 10 to 12 mo across all cytogenetic risk groups.  Reducing the no. of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P ≤ .01), resulted in improved tolerability and treatment delivery.  Conclusion: Flavopiridol achieves significant clin. activity in patients with relapsed CLL, including those with high-risk genomic features and bulky lymphadenopathy.  Subsequent clin. trials should use the amended treatment schedule developed herein and prophylactic corticosteroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8rg3AnSwf4rVg90H21EOLACvtfcHk0lgE1T78GtDCGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWisLs%253D&md5=5068ee1b36a882f0609ae5f89f6efe4f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.6944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.6944%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DAndritsos%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFlynn%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DRaymond%26aufirst%3DC.%2BA.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DVillalona-Calero%26aufirst%3DM.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520II%2520study%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%2520demonstrating%2520high%2520response%2520rates%2520in%2520genetically%2520high-risk%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6012%26epage%3D6018%26doi%3D10.1200%2FJCO.2009.22.6944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozewski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarjoura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1182/blood-2008-07-168583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1182%2Fblood-2008-07-168583" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=2637-2645&author=M.+A.+Phelpsauthor=T.+S.+Linauthor=A.+J.+Johnsonauthor=E.+Hurhauthor=D.+M.+Rozewskiauthor=K.+L.+Farleyauthor=D.+Wuauthor=K.+A.+Blumauthor=B.+Fischerauthor=S.+M.+Mitchellauthor=M.+E.+Moranauthor=M.+Brooker-McEldowneyauthor=N.+A.+Heeremaauthor=D.+Jarjouraauthor=L.+J.+Schaafauthor=J.+C.+Byrdauthor=M.+R.+Greverauthor=J.+T.+Dalton&title=Clinical+response+and+pharmacokinetics+from+a+phase+1+study+of+an+active+dosing+schedule+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2008-07-168583"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-168583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-168583%26sid%3Dliteratum%253Aachs%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHurh%26aufirst%3DE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DFarley%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520response%2520and%2520pharmacokinetics%2520from%2520a%2520phase%25201%2520study%2520of%2520an%2520active%2520dosing%2520schedule%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D2637%26epage%3D2645%26doi%3D10.1182%2Fblood-2008-07-168583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Zeidner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litzow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gocke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7 + 3) in newly diagnosed acute myeloid leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">–</span> <span class="NLM_lpage">1179</span><span class="refDoi"> DOI: 10.3324/haematol.2015.125849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3324%2Fhaematol.2015.125849" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1172-1179&author=J.+Zeidnerauthor=M.+Fosterauthor=A.+Blackfordauthor=M.+R.+Litzowauthor=L.+E.+Morrisauthor=S.+A.+Stricklandauthor=J.+E.+Lancetauthor=P.+Boseauthor=M.+Y.+Levyauthor=R.+Tibesauthor=I.+Gojoauthor=C.+D.+Gockeauthor=G.+L.+Rosnerauthor=R.+F.+Littleauthor=J.+J.+Wrightauthor=L.+A.+Doyleauthor=B.+D.+Smithauthor=J.+E.+Karp&title=Randomized+multicenter+phase+II+study+of+flavopiridol+%28alvocidib%29%2C+cytarabine%2C+and+mitoxantrone+%28FLAM%29+versus+cytarabine%2Fdaunorubicin+%287+%2B+3%29+in+newly+diagnosed+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2015.125849"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2015.125849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2015.125849%26sid%3Dliteratum%253Aachs%26aulast%3DZeidner%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DM.%26aulast%3DBlackford%26aufirst%3DA.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DMorris%26aufirst%3DL.%2BE.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DBose%26aufirst%3DP.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DGocke%26aufirst%3DC.%2BD.%26aulast%3DRosner%26aufirst%3DG.%2BL.%26aulast%3DLittle%26aufirst%3DR.%2BF.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DRandomized%2520multicenter%2520phase%2520II%2520study%2520of%2520flavopiridol%2520%2528alvocidib%2529%252C%2520cytarabine%252C%2520and%2520mitoxantrone%2520%2528FLAM%2529%2520versus%2520cytarabine%252Fdaunorubicin%2520%25287%2520%252B%25203%2529%2520in%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1172%26epage%3D1179%26doi%3D10.3324%2Fhaematol.2015.125849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drye, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorcy, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carraway, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladstone, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Othus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagel, J. M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span><span class="refDoi"> DOI: 10.3324/haematol.2012.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3324%2Fhaematol.2012.062539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=1736-1742&author=J.+E.+Karpauthor=E.+Garrett-Mayerauthor=E.+H.+Esteyauthor=M.+A.+Rudekauthor=B.+D.+Smithauthor=J.+M.+Greerauthor=D.+M.+Dryeauthor=K.+Mackeyauthor=K.+S.+Dorcyauthor=S.+D.+Goreauthor=M.+J.+Levisauthor=M.+A.+McDevittauthor=H.+E.+Carrawayauthor=K.+W.+Pratzauthor=D.+E.+Gladstoneauthor=M.+M.+Showelauthor=M.+Othusauthor=L.+A.+Doyleauthor=J.+J.+Wrightauthor=J.+M.+Pagel&title=Randomized+phase+II+study+of+two+schedules+of+flavopiridol+given+as+timed+sequential+therapy+with+cytosine+arabinoside+and+mitoxantrone+for+adults+with+newly+diagnosed%2C+poor-risk+acute+myelogenous+leukemia&doi=10.3324%2Fhaematol.2012.062539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2012.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2012.062539%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DDrye%26aufirst%3DD.%2BM.%26aulast%3DMackey%26aufirst%3DK.%26aulast%3DDorcy%26aufirst%3DK.%2BS.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DMcDevitt%26aufirst%3DM.%2BA.%26aulast%3DCarraway%26aufirst%3DH.%2BE.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DGladstone%26aufirst%3DD.%2BE.%26aulast%3DShowel%26aufirst%3DM.%2BM.%26aulast%3DOthus%26aufirst%3DM.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520two%2520schedules%2520of%2520flavopiridol%2520given%2520as%2520timed%2520sequential%2520therapy%2520with%2520cytosine%2520arabinoside%2520and%2520mitoxantrone%2520for%2520adults%2520with%2520newly%2520diagnosed%252C%2520poor-risk%2520acute%2520myelogenous%2520leukemia%26jtitle%3DHaematologica%26date%3D2012%26volume%3D97%26spage%3D1736%26epage%3D1742%26doi%3D10.3324%2Fhaematol.2012.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zeidner, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1318</span><span class="refDoi"> DOI: 10.1016/j.leukres.2015.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.leukres.2015.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26521988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=1312-1318&author=J.+F.+Zeidnerauthor=J.+E.+Karp&title=Clinical+activity+of+alvocidib+%28flavopiridol%29+in+acute+myeloid+leukemia&doi=10.1016%2Fj.leukres.2015.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia</span></div><div class="casAuthors">Zeidner, Joshua F.; Karp, Judith E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1312-1318</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory.  Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clin. activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone).  FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, resp., with encouraging findings in both patient populations warranting further investigation.  This review highlights the mechanism of action of alvocidib, pre-clin. studies of alvocidib in AML, and the clin. trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsjt81Z_94g7Vg90H21EOLACvtfcHk0lh8tmCR_Lqtdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgs77N&md5=fc79799812a30d42a31f647f98445b95</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DClinical%2520activity%2520of%2520alvocidib%2520%2528flavopiridol%2529%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D1312%26epage%3D1318%26doi%3D10.1016%2Fj.leukres.2015.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Wiernik, P. H.</span><span> </span><span class="NLM_article-title">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span><span class="refDoi"> DOI: 10.1517/13543784.2016.1169273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1517%2F13543784.2016.1169273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=729-734&author=P.+H.+Wiernik&title=Alvocidib+%28flavopiridol%29+for+the+treatment+of+chronic+lymphocytic+leukemia&doi=10.1517%2F13543784.2016.1169273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1169273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1169273%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DAlvocidib%2520%2528flavopiridol%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D729%26epage%3D734%26doi%3D10.1517%2F13543784.2016.1169273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Shirsath, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">P276–00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="refDoi"> DOI: 10.1186/1476-4598-11-77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1186%2F1476-4598-11-77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=23075291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVeitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=77&author=N.+P.+Shirsathauthor=S.+M.+Manoharauthor=K.+S.+Joshi&title=P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+modulates+cell+cycle+and+induces+apoptosis+in+vitro+and+in+vivo+in+mantle+cell+lymphoma+cell+lines&doi=10.1186%2F1476-4598-11-77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines</span></div><div class="casAuthors">Shirsath, Nitesh P.; Manohar, Sonal M.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mantle cell lymphoma (MCL) is a well-defined aggressive lymphoid neoplasm characterized by proliferation of mature B-lymphocytes that have a remarkable tendency to disseminate.  This tumor is considered as one of the most aggressive lymphoid neoplasms with poor responses to conventional chemotherapy and relatively short survival.  Since cyclin D1 and cell cycle control appears as a natural target, small-mol. inhibitors of cyclin-dependent kinases (Cdks) and cyclins may play important role in the therapy of this disorder.  We explored P276-00, a novel selective potent Cdk4-D1, Cdk1-B and Cdk9-T1 inhibitor discovered by us against MCL and elucidated its potential mechanism of action.  Methods: The cytotoxic effect of P276-00 in three human MCL cell lines was evaluated in vitro.  The effect of P276-00 on the regulation of cell cycle, apoptosis and transcription was assessed, which are implied in the pathogenesis of MCL.  Flow cytometry, western blot, immunoflourescence and siRNA studies were performed.  The in vivo efficacy and effect on survival of P276-00 was evaluated in a Jeko-1 xenograft model developed in SCID mice.  PK/PD anal. of tumors were performed using LC-MS and western blot anal.  Results: P276-00 showed a potent cytotoxic effect against MCL cell lines.  Mechanistic studies confirmed down regulation of cell cycle regulatory proteins with apoptosis.  P276-00 causes time and dose dependent increase in the sub G1 population as early as from 24 h.  Reverse transcription PCR studies provide evidence that P276-00 treatment down regulated transcription of antiapoptotic protein Mcl-1 which is a potential pathogenic protein for MCL.  Most importantly, in vivo studies have revealed significant efficacy as a single agent with increased survival period compared to vehicle treated.  Further, preliminary combination studies of P276-00 with doxorubicin and bortezomib showed in vitro synergism.  Conclusion: Our studies thus provide evidence and rational that P276-00 alone or in combination is a potential therapeutic mol. to improve patients' outcome in mantle cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6o4aP0rgOLVg90H21EOLACvtfcHk0ljAZX7wvONJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVeitL8%253D&md5=d9fb611081f55e30556484dec7d0994b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-11-77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-11-77%26sid%3Dliteratum%253Aachs%26aulast%3DShirsath%26aufirst%3DN.%2BP.%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520modulates%2520cell%2520cycle%2520and%2520induces%2520apoptosis%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520mantle%2520cell%2520lymphoma%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%26date%3D2012%26volume%3D11%26spage%3D77%26doi%3D10.1186%2F1476-4598-11-77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.+H.+Fiebigauthor=S.+Sharma&title=P276%E2%80%9300%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models&doi=10.1158%2F1535-7163.MCT-06-0614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0ljAZX7wvONJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934%26doi%3D10.1158%2F1535-7163.MCT-06-0614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300&doi=10.1158%2F1535-7163.MCT-06-0613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0ljAZX7wvONJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D918%26epage%3D925%26doi%3D10.1158%2F1535-7163.MCT-06-0613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanwalkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276–00 in pancreatic cancers</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="refDoi"> DOI: 10.1186/1479-5876-10-161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1186%2F1479-5876-10-161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22873289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVShsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=161&author=M.+J.+Rathosauthor=K.+Joshiauthor=H.+Khanwalkarauthor=S.+M.+Manoharauthor=K.+S.+Joshi&title=Molecular+evidence+for+increased+antitumor+activity+of+gemcitabine+in+combination+with+a+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300+in+pancreatic+cancers&doi=10.1186%2F1479-5876-10-161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers</span></div><div class="casAuthors">Rathos, Maggie J.; Joshi, Kavita; Khanwalkar, Harshal; Manohar, Sonal M.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clin. trials.  Gemcitabine is a std. of care for the treatment of pancreatic cancer.  The present study investigated the effect of the combination of P276-00 and gemcitabine in five pancreatic cancer cell lines.  Methods: Cytotoxic activity was evaluated by Propidium Iodide assay.  Cell cycle and apoptosis was analyzed by flow cytometry.  Genes and proteins known to inhibit apoptosis and contribute to chemoresistance were analyzed using western blot anal. and RT-PCR.  In vivo efficacy was studied in PANC-1 xenograft model.  Results: The combination of gemcitabine followed by P276-00 was found to be highly to weakly synergistic in various pancreatic cancer cell lines as assessed by the combination index.  Enhancement of apoptosis in PANC-1 cells and decrease in the antiapoptotic protein Bcl-2 and survivin was seen.  P276-00 potentiated the gemcitabine-induced cytotoxicity by modulation of proteins involved in chemoresistance to gemcitabine and cell cycle viz. antiapoptotic proteins p8 and cox-2, proapoptotic protein BNIP3 and cell cycle related proteins Cdk4 and cyclin D1.  The above results could explain the novel mechanisms of action of the combination therapy.  We also show here that gemcitabine in combination with P276-00 is much more effective as an antitumor agent compared with either agent alone in the PANC-1 xenograft tumor model in SCID mice.  Conclusions: The chemosensitzation of pancreatic tumors to gemcitabine would likely be an important and novel strategy for treatment of pancreatic cancer and enable the use of lower and safer concns., to pave the way for a more effective treatment in this devastating disease.  Phase IIb clin. trials of P276-00 in combination with gemcitabine in pancreatic cancer patients are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgjY9v9dHnkLVg90H21EOLACvtfcHk0lhX9A_COSfDGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVShsr%252FN&md5=d15dd412f77d6af51cf3022d54b89cf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-10-161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-10-161%26sid%3Dliteratum%253Aachs%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DKhanwalkar%26aufirst%3DH.%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DMolecular%2520evidence%2520for%2520increased%2520antitumor%2520activity%2520of%2520gemcitabine%2520in%2520combination%2520with%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%2520in%2520pancreatic%2520cancers%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2012%26volume%3D10%26spage%3D161%26doi%3D10.1186%2F1479-5876-10-161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padgaonkar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalota-Badhwar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, P276–00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells</span> <span class="citation_source-journal">Prostate Cancer Prostatic Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1038/pcan.2011.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fpcan.2011.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22083267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlKhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=15-27&author=S.+M.+Manoharauthor=A.+A.+Padgaonkarauthor=A.+Jalota-Badhwarauthor=S.+V.+Raoauthor=K.+S.+Joshi&title=Cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300%2C+inhibits+HIF-1%CE%B1+and+induces+G2%2FM+arrest+under+hypoxia+in+prostate+cancer+cells&doi=10.1038%2Fpcan.2011.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells</span></div><div class="casAuthors">Manohar, S. M.; Padgaonkar, A. A.; Jalota-Badhwar, A.; Rao, S. V.; Joshi, K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate Cancer and Prostatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">PCPDFW</span>;
        ISSN:<span class="NLM_cas:issn">1365-7852</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Hypoxia-inducible factor-1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation and controls genes involved in glycolysis, angiogenesis, migration and invasion.  Overexpression of HIF-1α has been demonstrated in many common human cancers.  Methods: Luciferase reporter gene assay under hypoxia and normoxia was used to demonstrate transcriptional inhibition of HIF-1 by P276-00.  Detailed studies such as western blotting, reverse-transcriptase-PCR and immunofluorescence were carried out to elucidate its mechanism of action.  Cytotoxic potential of P276-00 under normoxia and hypoxia was detd. on prostate cancer cells using CCK-8 assay, and cell-cycle anal. was carried out using flow cytometry.  Antiangiogenic activity of P276-00 was demonstrated by migration assay and tube-formation assay.  Efficacy study of P276-00 was performed in a PC-3 xenograft model.  Results: P276-00 inhibits transcriptional activation of HIF-1 under hypoxia.  It suppressed hypoxia-mediated nuclear HIF-1α expression, as well as phosphorylation of Akt and 4E-BP1 and abrogated expression of HIF-1-inducible gene viz. vascular endothelial growth factor.  Under hypoxia, P276-00 did not exhibit enhanced cytotoxic activity in prostate cancer cells but arrested them in the G2/M phase of the cell cycle.  The tubular formation of human umbilical vein endothelial cells and migration of prostate cancer cells were also inhibited by P276-00 in vitro.  In addn., it demonstrated significant in vivo efficacy in the PC-3 xenograft model.  Conclusions: Given its low toxicity profile, its demonstrated antitumor activity and its potential to inhibit the HIF-1 pathway, P276-00 should be considered as antiangiogenic chemotherapy for prostate cancer.  Prostate Cancer and Prostatic Diseases (2012) 15, 15-27; doi:10.1038/pcan.2011.51; published online 15 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbySLd0vaYPbVg90H21EOLACvtfcHk0lhX9A_COSfDGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlKhsbg%253D&md5=cd2498cc0a8c39b336deebe12beab925</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fpcan.2011.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fpcan.2011.51%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DPadgaonkar%26aufirst%3DA.%2BA.%26aulast%3DJalota-Badhwar%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%252C%2520inhibits%2520HIF-1%25CE%25B1%2520and%2520induces%2520G2%252FM%2520arrest%2520under%2520hypoxia%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DProstate%2520Cancer%2520Prostatic%2520Dis.%26date%3D2012%26volume%3D15%26spage%3D15%26epage%3D27%26doi%3D10.1038%2Fpcan.2011.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhetri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirstea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scadden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Preclinical activity of P276–00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1038/leu.2008.378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fleu.2008.378" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=961-970&author=N.+Rajeauthor=T.+Hideshimaauthor=S.+Mukherjeeauthor=M.+Raabauthor=S.+Valletauthor=S.+Chhetriauthor=D.+Cirsteaauthor=S.+Pozziauthor=C.+Mitsiadesauthor=M.+Rooneyauthor=T.+Kiziltepeauthor=K.+Podarauthor=Y.+Okawaauthor=H.+Ikedaauthor=R.+Carrascoauthor=P.+G.+Richardsonauthor=D.+Chauhanauthor=N.+C.+Munshiauthor=S.+Sharmaauthor=H.+Parikhauthor=B.+Chabnerauthor=D.+Scaddenauthor=K.+C.+Anderson&title=Preclinical+activity+of+P276%E2%80%9300%2C+a+novel+small-molecule+cyclin-dependent+kinase+inhibitor+in+the+therapy+of+multiple+myeloma&doi=10.1038%2Fleu.2008.378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.378%26sid%3Dliteratum%253Aachs%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DM.%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DChhetri%26aufirst%3DS.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DRooney%26aufirst%3DM.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DParikh%26aufirst%3DH.%26aulast%3DChabner%26aufirst%3DB.%26aulast%3DScadden%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPreclinical%2520activity%2520of%2520P276%25E2%2580%259300%252C%2520a%2520novel%2520small-molecule%2520cyclin-dependent%2520kinase%2520inhibitor%2520in%2520the%2520therapy%2520of%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D961%26epage%3D970%26doi%3D10.1038%2Fleu.2008.378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Cassaday, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chawla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachankar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, A. K.</span><span> </span><span class="NLM_article-title">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276–00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span> <span class="citation_source-journal">Clin. Lymphoma Myeloma Leuk.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span><span class="refDoi"> DOI: 10.1016/j.clml.2015.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.clml.2015.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25816934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=392-397&author=R.+D.+Cassadayauthor=A.+Goyauthor=S.+Advaniauthor=P.+Chawlaauthor=R.+Nachankarauthor=M.+Gandhiauthor=A.+K.+Gopal&title=A+phase+II%2C+single-arm%2C+open-label%2C+multicenter+study+to+evaluate+the+efficacy+and+safety+of+P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+in+patients+with+relapsed+or+refractory+mantle+cell+lymphoma&doi=10.1016%2Fj.clml.2015.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span></div><div class="casAuthors">Cassaday Ryan D; Goy Andre; Advani Suresh; Chawla Purvi; Nachankar Rajesh; Gandhi Mansi; Gopal Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">392-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Overexpression of cyclin D1 is a hallmark feature of mantle cell lymphoma (MCL).  Many of the oncogenic effects of cyclin D1 are mediated through cyclin-dependent kinases (CDKs).  P276-00 is a potent small molecule inhibitor of CDK4-D1, CDK1-B, and CDK9-T, with promising activity in preclinical models.  In phase I studies of P276-00 in patients with refractory solid neoplasms, it was well-tolerated with a mild trend toward single-agent efficacy.  PATIENTS AND METHODS:  A phase II study of P276-00 was conducted in patients with relapsed or refractory MCL at the recommended dose of 185 mg/m(2)/day from days 1 to 5 of a 21-day cycle.  Thirteen patients were enrolled in the present study.  RESULTS:  Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event (AE), and 1 patient died.  Also, 11 patients (84.6%) experienced a treatment-emergent AE deemed related to P276-00.  Of the 13 patients, 9 (69.2%) received ≥ 2 cycles of treatment, which was the predefined threshold to be evaluable for efficacy.  Treatment was discontinued early in 2 patients because of AEs (1 of which was attributed to P276-00 administration) and in 2 patients because of disease progression.  Finally, 2 patients experienced stable disease for an estimated median duration of 60.5 days (range, 58-63 days).  The estimated median time to progression for the predefined efficacy population was 43 days (range, 38-58 days).  CONCLUSION:  Given the results observed in the present study, if evaluation of CDK inhibition in MCL continues, it should be considered earlier in the disease course or as a part of combination strategies for relapsed or refractory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9BvQqGeRc9p6KlWarZTAzfW6udTcc2ea8-fvMq92v9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D&md5=b1062faa6262674828e4338d26e66e00</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCassaday%26aufirst%3DR.%2BD.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DS.%26aulast%3DChawla%26aufirst%3DP.%26aulast%3DNachankar%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26atitle%3DA%2520phase%2520II%252C%2520single-arm%252C%2520open-label%252C%2520multicenter%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520P276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26spage%3D392%26epage%3D397%26doi%3D10.1016%2Fj.clml.2015.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Vishwakarma, R. A.; Bharate, S. B.; Bhushan, S.; Mondhe, D. M.; Jain, S. K.; Meena, S.; Guru, S. K.; Pathania, A. S.; Kumar, S.; Behl, A.; Mintoo, M. J.; Bharate, S. S.; Joshi, P.</span><span> </span><span class="NLM_article-title">Rohitukine Analogs as Cyclin-dependent Kinase Inhibitors and a Process for the Preparation Thereof</span>. WO2014170914A1, US20160052915, EP2986605, CA2908084, IN2013DE01142, October 23,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+A.+Vishwakarma&author=S.+B.+Bharate&author=S.+Bhushan&author=D.+M.+Mondhe&author=S.+K.+Jain&author=S.+Meena&author=S.+K.+Guru&author=A.+S.+Pathania&author=S.+Kumar&author=A.+Behl&author=M.+J.+Mintoo&author=S.+S.+Bharate&author=P.+Joshi&title=Rohitukine+Analogs+as+Cyclin-dependent+Kinase+Inhibitors+and+a+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DRohitukine%2520Analogs%2520as%2520Cyclin-dependent%2520Kinase%2520Inhibitors%2520and%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Huwe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannis, A.</span><span> </span><span class="NLM_article-title">Small molecules as inhibitors of cyclin-dependent kinases</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2122</span><span class="NLM_x">–</span> <span class="NLM_lpage">2138</span><span class="refDoi"> DOI: 10.1002/anie.200200540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1002%2Fanie.200200540" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2122-2138&author=A.+Huweauthor=R.+Mazitschekauthor=A.+Giannis&title=Small+molecules+as+inhibitors+of+cyclin-dependent+kinases&doi=10.1002%2Fanie.200200540"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200540%26sid%3Dliteratum%253Aachs%26aulast%3DHuwe%26aufirst%3DA.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DGiannis%26aufirst%3DA.%26atitle%3DSmall%2520molecules%2520as%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2122%26epage%3D2138%26doi%3D10.1002%2Fanie.200200540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lolli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span><span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+%C3%89.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0lgq_yqlg2Y8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibition by flavoalkaloids</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">632</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.2174/138955712800626683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2174%2F138955712800626683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22512551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=632-649&author=S.+K.+Jainauthor=S.+B.+Bharateauthor=R.+A.+Vishwakarma&title=Cyclin-dependent+kinase+inhibition+by+flavoalkaloids&doi=10.2174%2F138955712800626683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibition by flavoalkaloids</span></div><div class="casAuthors">Jain, S. K.; Bharate, S. B.; Vishwakarma, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">632-649</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chromone alkaloids and flavoalkaloids are an important group of natural products possessing promising medicinal properties.  A chromone alkaloid rohitukine is a major bioactive chem. constituent of plant Dysoxylum binectariferum (Meliaceae) which is phylogenetically related to the Ayurvedic plant, D. malabaricum used for treatment of rheumatoid arthritis.  This chromone alkaloid led to discovery of 2 synthetic flavoalkaloids: flavopiridol (Sanofi) and P-276-00 (Piramal) which have reached to advanced stages of clin. development for cancer treatment.  Flavopiridol (Alvocidib; L868275; HMR-1275; NSC 649890 of Sanofi-Aventis + NCI) is approved as an orphan drug for treatment of chronic lymphocytic leukemia and is currently undergoing phase II studies as monotherapy and also as in combination regimes with traditional chemotherapy agents.  P-276-00 (12) is currently in phase II clin. studies for advanced refractory neoplasms and multiple myeloma.  Extensive amt. of medicinal chem. efforts were reported on these flavoalkaloids.  Flavopiridol demonstrated potent and specific in vitro inhibition of variety of cyclin-dependent kinases with clear block in cell cycle progression at the G1/S and G2/M phases.  Preclin. studies demonstrated the capacity of flavopiridol to induce programmed cell death, promote differentiation, inhibit angiogenic processes and modulate transcriptional events.  The co-crystd. structure of deschloro-flavopiridol with CDK-2 is available and key interactions in the ATP binding site were reported.  Flavopiridol was also studied for the treatment of arthritis and atherosclerotic plaque formation.  The present review comprises discovery, medicinal chem., pharmacol. and preclin./clin. development of flavoalkaloids as CDK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDQdAK15QBLLVg90H21EOLACvtfcHk0ljJJ3ziz8XxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCkurs%253D&md5=98702838814112f01f0f7585d9e6e994</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138955712800626683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712800626683%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DCyclin-dependent%2520kinase%2520inhibition%2520by%2520flavoalkaloids%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D632%26epage%3D649%26doi%3D10.2174%2F138955712800626683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">De Azevedo, W. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller-Dieckmann, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span> </span><span class="NLM_article-title">Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1073/pnas.93.7.2735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1073%2Fpnas.93.7.2735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=8610110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADyaK28XitVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=2735-2740&author=W.+F.+De+Azevedoauthor=H.+J.+Mueller-Dieckmannauthor=U.+Schulze-Gahmenauthor=P.+J.+Worlandauthor=E.+Sausvilleauthor=S.+H.+Kim&title=Structural+basis+for+specificity+and+potency+of+a+flavonoid+inhibitor+of+human+CDK2%2C+a+cell+cycle+kinase&doi=10.1073%2Fpnas.93.7.2735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase</span></div><div class="casAuthors">de Azevedo, Walter Filgueira, Jr.; Mueller-Dieckmann, Hans-Joachim; Schulze-Gahmen, Ursula; Worland, Peter J.; Sausville, Edward; Kim, Sung-Hou</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2735-40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The central role of cyclin-dependent kinases (CDKs) in cell cycle regulation makes them a promising target for study inhibitory mols. that can modify the degree of cell proliferation.  The discovery of specific inhibitors of CDKs such as polyhydroxylated flavones has opened the way to investigation and design of antimitotic compds.  A novel flavone, (-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride hemihydrate (L868276), is a potent inhibitor of CDKs.  A chlorinated form, flavopiridol, is currently in phase I clin. trials as a drug against breast tumors.  The authors detd. the crystal structure of a complex between CDK2 and L868276 at 2.33-Å resoln. and refined to an Rfactor of 20.3%.  The arom. portion of the inhibitor binds to the adenine-binding pocket of CDK2, and the position of the Ph group of the inhibitor enables the inhibitor to make contacts with the enzyme not obsd. in the ATP complex structure.  The anal. of the position of this Ph ring not only explains the great differences of kinase inhibition among the flavonoid inhibitors but also explains the specificity of L868276 to inhibit CDK2 and CDC2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgo__S6absqbVg90H21EOLACvtfcHk0ljJJ3ziz8XxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVCisLs%253D&md5=8f499ae6716cdf8f70f15d5907a69b1b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.7.2735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.7.2735%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BAzevedo%26aufirst%3DW.%2BF.%26aulast%3DMueller-Dieckmann%26aufirst%3DH.%2BJ.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26aulast%3DSausville%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DStructural%2520basis%2520for%2520specificity%2520and%2520potency%2520of%2520a%2520flavonoid%2520inhibitor%2520of%2520human%2520CDK2%252C%2520a%2520cell%2520cycle%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D2735%26epage%3D2740%26doi%3D10.1073%2Fpnas.93.7.2735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4126</span><span class="NLM_x">–</span> <span class="NLM_lpage">4134</span><span class="refDoi"> DOI: 10.1021/jm000231g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000231g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4126-4134&author=K.+S.+Kimauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=L.+Qianauthor=S.+T.+Chaoauthor=L.+Leithauthor=Y.+F.+Kellyauthor=R.+N.+Misraauthor=J.+T.+Huntauthor=S.+D.+Kimballauthor=W.+G.+Humphreysauthor=B.+S.+Wautletauthor=J.+G.+Mulheronauthor=K.+R.+Webster&title=Thio-+and+oxoflavopiridols%2C+cyclin-dependent+kinase+1-selective+inhibitors%3A+synthesis+and+biological+effects&doi=10.1021%2Fjm000231g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm000231g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000231g%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%2BT.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DY.%2BF.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DThio-%2520and%2520oxoflavopiridols%252C%2520cyclin-dependent%2520kinase%25201-selective%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Fjm000231g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Murthi, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brizuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisclair, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuri, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, K.</span><span> </span><span class="NLM_article-title">Structure-activity relationship studies of flavopiridol analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00156-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0960-894X%2800%2900156-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=1037-1041&author=K.+K.+Murthiauthor=M.+Dubayauthor=C.+McClureauthor=L.+Brizuelaauthor=M.+D.+Boisclairauthor=P.+J.+Worlandauthor=M.+M.+Mansuriauthor=K.+Pal&title=Structure-activity+relationship+studies+of+flavopiridol+analogues&doi=10.1016%2FS0960-894X%2800%2900156-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900156-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900156-6%26sid%3Dliteratum%253Aachs%26aulast%3DMurthi%26aufirst%3DK.%2BK.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DMcClure%26aufirst%3DC.%26aulast%3DBrizuela%26aufirst%3DL.%26aulast%3DBoisclair%26aufirst%3DM.%2BD.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26aulast%3DMansuri%26aufirst%3DM.%2BM.%26aulast%3DPal%26aufirst%3DK.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520flavopiridol%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D1037%26epage%3D1041%26doi%3D10.1016%2FS0960-894X%2800%2900156-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhuri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1741</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1021/jm0108348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0108348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1Ojt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1741-1747&author=J.+Schoepferauthor=H.+Fretzauthor=B.+Chaudhuriauthor=L.+Mullerauthor=E.+Seeberauthor=L.+Meijerauthor=O.+Lozachauthor=E.+Vangrevelingheauthor=P.+Furet&title=Structure-based+design+and+synthesis+of+2-benzylidene-benzofuran-3-ones+as+flavopiridol+mimics&doi=10.1021%2Fjm0108348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of 2-Benzylidene-benzofuran-3-ones as Flavopiridol Mimics</span></div><div class="casAuthors">Schoepfer, Joseph; Fretz, Heinz; Chaudhuri, Bhabatosh; Muller, Lionel; Seeber, Egge; Meijer, Laurent; Lozach, Olivier; Vangrevelinghe, Eric; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1741-1747</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 2-benzylidene-benzofuran-3-ones, e.g., I, were designed and synthesized to mimic flavopiridol, a well-established inhibitor of cyclin-dependent kinases (CDKs) which is currently undergoing clin. evaluation.  The underlying design concepts as well as the synthesis and structure-activity relationships (CDKs 1, 2, and 4 enzyme assays) of these mimics are described.  Inhibitors of CDKs 1 and 2 that are more potent and selective than flavopiridol were obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMUkviflNUZ7Vg90H21EOLACvtfcHk0ljTdMX61Qvhvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1Ojt7g%253D&md5=2c9dfd7bb0a07444e518b6706a936ed5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm0108348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0108348%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DFretz%26aufirst%3DH.%26aulast%3DChaudhuri%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DSeeber%26aufirst%3DE.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%25202-benzylidene-benzofuran-3-ones%2520as%2520flavopiridol%2520mimics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1741%26epage%3D1747%26doi%3D10.1021%2Fjm0108348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Ahn, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhapuram, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasandani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitscher, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lushington, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himes, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roby, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span> </span><span class="NLM_article-title">Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.10.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmc.2006.10.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=702-713&author=Y.+M.+Ahnauthor=L.+Vogetiauthor=C.+J.+Liuauthor=H.+K.+Santhapuramauthor=J.+M.+Whiteauthor=V.+Vasandaniauthor=L.+A.+Mitscherauthor=G.+H.+Lushingtonauthor=P.+R.+Hansonauthor=D.+R.+Powellauthor=R.+H.+Himesauthor=K.+F.+Robyauthor=Q.+Yeauthor=G.+I.+Georg&title=Design%2C+synthesis%2C+and+antiproliferative+and+CDK2-cyclin+a+inhibitory+activity+of+novel+flavopiridol+analogues&doi=10.1016%2Fj.bmc.2006.10.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.063%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%2BJ.%26aulast%3DSanthapuram%26aufirst%3DH.%2BK.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DVasandani%26aufirst%3DV.%26aulast%3DMitscher%26aufirst%3DL.%2BA.%26aulast%3DLushington%26aufirst%3DG.%2BH.%26aulast%3DHanson%26aufirst%3DP.%2BR.%26aulast%3DPowell%26aufirst%3DD.%2BR.%26aulast%3DHimes%26aufirst%3DR.%2BH.%26aulast%3DRoby%26aufirst%3DK.%2BF.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antiproliferative%2520and%2520CDK2-cyclin%2520a%2520inhibitory%2520activity%2520of%2520novel%2520flavopiridol%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D702%26epage%3D713%26doi%3D10.1016%2Fj.bmc.2006.10.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span> </span><span class="NLM_article-title">KF/alumina catalyzed regioselective benzylation and benzoylation using solvent-free grind-stone chemistry</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">8929</span><span class="NLM_x">–</span> <span class="NLM_lpage">8933</span><span class="refDoi"> DOI: 10.1039/c2ra21154h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1039%2Fc2ra21154h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlKjtbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=8929-8933&author=S.+K.+Jainauthor=S.+Meenaauthor=B.+Singhauthor=J.+B.+Bharateauthor=P.+Joshiauthor=V.+P.+Singhauthor=R.+A.+Vishwakarmaauthor=S.+B.+Bharate&title=KF%2Falumina+catalyzed+regioselective+benzylation+and+benzoylation+using+solvent-free+grind-stone+chemistry&doi=10.1039%2Fc2ra21154h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">KF/alumina catalyzed regioselective benzylation and benzoylation using solvent-free grind-stone chemistry</span></div><div class="casAuthors">Jain, Shreyans K.; Meena, Samdarshi; Singh, Baljinder; Bharate, Jaideep B.; Joshi, Prashant; Singh, Varun P.; Vishwakarma, Ram A.; Bharate, Sandip B.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8929-8933</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Potassium fluoride-impregnated on alumina catalyzes a solvent-free regioselective O-benzylation, benzoylation and cinnamylation of phenols.  Reaction proceeds simply by triturating together equiv. amts. of phenol and corresponding halide in the presence of 5 mol% of KF/alumina for 5-20 min with a mortar and pestle, without need for any additive, such as a phase-transfer catalyst or solvent.  Key features of the protocol include its efficiency also for solid-solid precursors and regioselectivity for phenolic hydroxyl groups vs. alc. hydroxy groups.  Utility of the protocol for N- and S-benzylation has also been explored.  Products were obtained in excellent yields and the catalyst can be easily recycled several times without significant loss of activity.  The synthesis of the target compds. was achieved using 5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-2-methyl-4H-1-benzopyran-4-one (chromene alkaloid rohitukine) was a starting material.  The title compds. thus formed included benzyl ethers, such as a rohitukine methoxybenzyl ether (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgV_-p46avmrVg90H21EOLACvtfcHk0ljTdMX61Qvhvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlKjtbjP&md5=9ad74c68d324cfaece9586a92788ef59</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fc2ra21154h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ra21154h%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DMeena%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DBharate%26aufirst%3DJ.%2BB.%26aulast%3DJoshi%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DV.%2BP.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26atitle%3DKF%252Falumina%2520catalyzed%2520regioselective%2520benzylation%2520and%2520benzoylation%2520using%2520solvent-free%2520grind-stone%2520chemistry%26jtitle%3DRSC%2520Adv.%26date%3D2012%26volume%3D2%26spage%3D8929%26epage%3D8933%26doi%3D10.1039%2Fc2ra21154h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span> </span><span class="NLM_article-title">Regulation of protein kinase C-epsilon and its age-dependence</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">482</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2016.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bbrc.2016.12.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=482&publication_year=2017&pages=1201-1206&author=C.+Kangauthor=J.+Qinauthor=W.+Oseiauthor=K.+Hu&title=Regulation+of+protein+kinase+C-epsilon+and+its+age-dependence&doi=10.1016%2Fj.bbrc.2016.12.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2016.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2016.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DOsei%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DK.%26atitle%3DRegulation%2520of%2520protein%2520kinase%2520C-epsilon%2520and%2520its%2520age-dependence%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D482%26spage%3D1201%26epage%3D1206%26doi%3D10.1016%2Fj.bbrc.2016.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Fabiani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosignoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Bartolomeo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuccelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozzi, G.</span><span> </span><span class="NLM_article-title">Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21(WAF1/Cip1) and p27(Kip1) and with induction of differentiation in HL60 cells</span> <span class="citation_source-journal">J. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1093/jn/138.1.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1093%2Fjn%2F138.1.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18156402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2008&pages=42-48&author=R.+Fabianiauthor=P.+Rosignoliauthor=A.+De+Bartolomeoauthor=R.+Fuccelliauthor=G.+Morozzi&title=Inhibition+of+cell+cycle+progression+by+hydroxytyrosol+is+associated+with+upregulation+of+cyclin-dependent+protein+kinase+inhibitors+p21%28WAF1%2FCip1%29+and+p27%28Kip1%29+and+with+induction+of+differentiation+in+HL60+cells&doi=10.1093%2Fjn%2F138.1.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21WAF1/Cip1 and p27Kip1 and with induction of differentiation in HL60 cells</span></div><div class="casAuthors">Fabiani, Roberto; Rosignoli, Patrizia; De Bartolomeo, Angelo; Fuccelli, Raffaela; Morozzi, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-48</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">Recent evidence indicates that the cancer preventive activity of olive oil can be mediated by the presence of minor components, such as antioxidant phenolic compds.  However, their mechanisms of action remain largely unknown.  In this study, we investigated the in vitro effects of one of the main olive oil phenols, hydroxytyrosol [3,4-dihydroxyphenylethanol (3,4-DHPEA)], on proliferation, cell cycle progression, apoptosis, and differentiation of HL60 human promyelocytic leukemia cells.  3,4-DHPEA showed a potent inhibitory activity on DNA synthesis, as evidenced by a 92% redn. of [3H]-thymidine incorporation at 100 μmol/L, and an induced apoptosis, as evidenced by the release of cytosolic nucleosomes and flow cytometry.  This phenol, 3,4-DHPEA, was also able to inhibit the progression of the cell cycle in synchronized HL60 cells, which accumulated in the G0/G1 phase of the cell cycle after 25 h of treatment.  Furthermore, 3,4-DHPEA induced differentiation on HL60 cells with a max. effect (22% of cells) at 100 μmol/L after 72 h of treatment.  Among the different proteins involved in the regulation of the cell cycle, 3,4-DHPEA reduced the level of cyclin-dependent kinase (CDK) 6 and increased that of cyclin D3.  With regard to the CDK inhibitors, p15 was not altered by 3,4-DHPEA treatment, whereas the expression of p21WAF1/Cip1 and p27Kip1 was increased at both protein and mRNA levels.  To our knowledge, these results provide the 1st evidence that 3,4-DHPEA may effect the expression of genes involved in the regulation of tumor cell proliferation and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ5ipBfVO407Vg90H21EOLACvtfcHk0ljkS4Ut4p35oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVSksA%253D%253D&md5=63513a48e2cc23c6fdc49255e65a556a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F138.1.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F138.1.42%26sid%3Dliteratum%253Aachs%26aulast%3DFabiani%26aufirst%3DR.%26aulast%3DRosignoli%26aufirst%3DP.%26aulast%3DDe%2BBartolomeo%26aufirst%3DA.%26aulast%3DFuccelli%26aufirst%3DR.%26aulast%3DMorozzi%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520cell%2520cycle%2520progression%2520by%2520hydroxytyrosol%2520is%2520associated%2520with%2520upregulation%2520of%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%2520p21%2528WAF1%252FCip1%2529%2520and%2520p27%2528Kip1%2529%2520and%2520with%2520induction%2520of%2520differentiation%2520in%2520HL60%2520cells%26jtitle%3DJ.%2520Nutr.%26date%3D2008%26volume%3D138%26spage%3D42%26epage%3D48%26doi%3D10.1093%2Fjn%2F138.1.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Xie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span> </span><span class="NLM_article-title">Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span><span class="refDoi"> DOI: 10.1038/aps.2016.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Faps.2016.49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1481-1489&author=S.+Xieauthor=H.+Jiangauthor=X.+W.+Zhaiauthor=F.+Weiauthor=S.+D.+Wangauthor=J.+Dingauthor=Y.+Chen&title=Antitumor+action+of+CDK+inhibitor+LS-007+as+a+single+agent+and+in+combination+with+ABT-199+against+human+acute+leukemia+cells&doi=10.1038%2Faps.2016.49"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.49%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhai%26aufirst%3DX.%2BW.%26aulast%3DWei%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%2BD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DAntitumor%2520action%2520of%2520CDK%2520inhibitor%2520LS-007%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520ABT-199%2520against%2520human%2520acute%2520leukemia%2520cells%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D1481%26epage%3D1489%26doi%3D10.1038%2Faps.2016.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Evers, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. A.</span><span> </span><span class="NLM_article-title">Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">G722</span><span class="NLM_x">–</span> <span class="NLM_lpage">G727</span><span class="refDoi"> DOI: 10.1152/ajpgi.1996.271.4.G722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1152%2Fajpgi.1996.271.4.G722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=G722-G727&author=B.+M.+Eversauthor=T.+C.+Koauthor=J.+Liauthor=E.+A.+Thompson&title=Cell+cycle+protein+suppression+and+p21+induction+in+differentiating+Caco-2+cells&doi=10.1152%2Fajpgi.1996.271.4.G722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.1996.271.4.G722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.1996.271.4.G722%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DB.%2BM.%26aulast%3DKo%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26atitle%3DCell%2520cycle%2520protein%2520suppression%2520and%2520p21%2520induction%2520in%2520differentiating%2520Caco-2%2520cells%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1996%26volume%3D271%26spage%3DG722%26epage%3DG727%26doi%3D10.1152%2Fajpgi.1996.271.4.G722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Determining partition coefficient (Log P), distribution coefficient (Log D) and ionization constant (pKa) in early drug discovery</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.2174/1386207319666160502123917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2174%2F1386207319666160502123917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27137915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=461-469&author=S.+S.+Bharateauthor=V.+Kumarauthor=R.+A.+Vishwakarma&title=Determining+partition+coefficient+%28Log+P%29%2C+distribution+coefficient+%28Log+D%29+and+ionization+constant+%28pKa%29+in+early+drug+discovery&doi=10.2174%2F1386207319666160502123917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery</span></div><div class="casAuthors">Bharate, Sonali S.; Kumar, Vikas; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">461-469</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">An early prediction of physicochem. properties is highly desirable during drug discovery to find out a viable lead candidate.  Although there are several methods available to det. partition coeff. (log P), distribution coeff. (log D) and ionization const. (pKa), none of them involves simple and fixed, miniaturized protocols for diverse set of compds.  Therefore, it is necessary to establish simple, uniform and medium-throughput protocols requiring small sample quantities for the detn. of these physicochem. properties.  Log P and log D were detd. by shake flask method, wherein, the compd. was partitioned between presatd. noctanol and water phase (water/PBS pH 7.4) and the concn. of compd. in each phase was detd. by HPLC.  The pKa detn. made use of UV spectrophotometric anal. in a 96-well microtiter plate contg. a series of aq. buffers ranging from pH 1.0 to 13.0.  The medium-throughput miniaturized protocols described herein, for detn. of log P, log D and pKa, are straightforward to set up and require very small quantities of sample (< 5 mg for all three properties).  All established protocols were validated using diverse set of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH4U64-_rEprVg90H21EOLACvtfcHk0ljkS4Ut4p35oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVags7w%253D&md5=6340eb95ac545ff52afedefe4d63d074</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2174%2F1386207319666160502123917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207319666160502123917%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DDetermining%2520partition%2520coefficient%2520%2528Log%2520P%2529%252C%2520distribution%2520coefficient%2520%2528Log%2520D%2529%2520and%2520ionization%2520constant%2520%2528pKa%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2016%26volume%3D19%26spage%3D461%26epage%3D469%26doi%3D10.2174%2F1386207319666160502123917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1561</span><span class="NLM_x">–</span> <span class="NLM_lpage">1567</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2015.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25740159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1561-1567&author=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=Thermodynamic+equilibrium+solubility+measurements+in+simulated+fluids+by+96-well+plate+method+in+early+drug+discovery&doi=10.1016%2Fj.bmcl.2015.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery</span></div><div class="casAuthors">Bharate, Sonali S.; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1561-1567</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An early prediction of soly. in physiol. media (PBS, SGF and SIF) is useful to predict qual. bioavailability and absorption of lead candidates.  Despite of the availability of multiple soly. estn. methods, none of the reported method involves simplified fixed protocol for diverse set of compds.  Therefore, a simple and medium-throughput soly. estn. protocol is highly desirable during lead optimization stage.  The present work introduces a rapid method for assessment of thermodn. equil. soly. of compds. in aq. media using 96-well microplate.  The developed protocol is straightforward to set up and takes advantage of the sensitivity of UV spectroscopy.  The compd., in stock soln. in methanol, is introduced in microgram quantities into microplate wells followed by drying at an ambient temp.  Microplates were shaken upon addn. of test media and the supernatant was analyzed by UV method.  A plot of absorbance vs. concn. of a sample provides satn. point, which is thermodn. equil. soly. of a sample.  The established protocol was validated using a large panel of com. available drugs and with conventional miniaturized shake flask method (r2 >0.84).  Addnl., the statistically significant QSPR models were established using exptl. soly. values of 52 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEhIADhdQd3LVg90H21EOLACvtfcHk0li0IPDGfoSdmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSrsbc%253D&md5=e118b10c67ca311ea5da994793546c11</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DThermodynamic%2520equilibrium%2520solubility%2520measurements%2520in%2520simulated%2520fluids%2520by%252096-well%2520plate%2520method%2520in%2520early%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1561%26epage%3D1567%26doi%3D10.1016%2Fj.bmcl.2015.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0li0IPDGfoSdmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lolli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span><span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0lgzEV0OgQoROQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penman, B. W.</span><span> </span><span class="NLM_article-title">Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">248</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1006/abio.1997.2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1006%2Fabio.1997.2145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1997&pages=188-190&author=C.+L.+Crespiauthor=V.+P.+Millerauthor=B.+W.+Penman&title=Microtiter+plate+assays+for+inhibition+of+human%2C+drug-metabolizing+cytochromes+P450&doi=10.1006%2Fabio.1997.2145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2145%26sid%3Dliteratum%253Aachs%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DMiller%26aufirst%3DV.%2BP.%26aulast%3DPenman%26aufirst%3DB.%2BW.%26atitle%3DMicrotiter%2520plate%2520assays%2520for%2520inhibition%2520of%2520human%252C%2520drug-metabolizing%2520cytochromes%2520P450%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D248%26spage%3D188%26epage%3D190%26doi%3D10.1006%2Fabio.1997.2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1016/j.ejps.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.ejps.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27422078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eis7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=203-211&author=V.+Kumarauthor=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=Modulating+lipophilicity+of+rohitukine+via+prodrug+approach%3A+Preparation%2C+characterization%2C+and+in+vitro+enzymatic+hydrolysis+in+biorelevant+media&doi=10.1016%2Fj.ejps.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media</span></div><div class="casAuthors">Kumar, Vikas; Bharate, Sonali S.; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rohitukine is a medicinally important natural product which has inspired the discovery of two anticancer clin. candidates.  Rohitukine is highly hydrophilic in nature which hampers its oral bioavailability.  Thus, herein our objective was to improve the drug-like properties of rohitukine via prodrug-strategy.  Various ester prodrugs were synthesized and studied for soly., lipophilicity, chem. stability and enzymic hydrolysis in plasma/esterase.  All prodrugs displayed lower aq. soly. and improved lipophilicity compared with rohitukine, which was in accordance with the criteria of compds. in drug-discovery.  The stability of synthesized prodrugs was evaluated in buffers at different pH, SGF, SIF, rat plasma and in esterase enzyme.  The rate of hydrolysis in all incubation media was dependent primarily on the acyl promoieties.  Hexanoyl ester prodrug of rohitukine, 3d, was stable under chem. conditions; however it was completely hydrolyzed to rohitukine, in plasma and in esterase in 4 h.  Hexanoate ester 3d appeared to be the most promising prodrug as it remained intact at gastric/intestinal pH and was completely transformed to the parent compd. in plasma as desired for an ideal prodrug.  The data presented herein, will help in designing prodrugs with desired physicochem. properties in future in structurally similar chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhioU_tMke-LVg90H21EOLACvtfcHk0lg998ctwHs70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eis7vL&md5=32781e4682481225bf0219d8094fd634</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DModulating%2520lipophilicity%2520of%2520rohitukine%2520via%2520prodrug%2520approach%253A%2520Preparation%252C%2520characterization%252C%2520and%2520in%2520vitro%2520enzymatic%2520hydrolysis%2520in%2520biorelevant%2520media%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D92%26spage%3D203%26epage%3D211%26doi%3D10.1016%2Fj.ejps.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tizhi Wu, Zhen Qin, Yucheng Tian, Jubo Wang, Chenxi Xu, Zhiyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Jinlei Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13228-13257. <a href="https://doi.org/10.1021/acs.jmedchem.0c00744" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00744%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BDevelopments%252Bin%252Bthe%252BBiology%252Band%252BMedicinal%252BChemistry%252Bof%252BCDK9%252BInhibitors%25253A%252BAn%252BUpdate%26aulast%3DWu%26aufirst%3DTizhi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D17092020%26date%3D31082020%26volume%3D63%26issue%3D22%26spage%3D13228%26epage%3D13257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kine Ø. Hansen, Jeanette H. Andersen, Annette Bayer, Sunil K. Pandey, Marianne Lorentzen, Kåre B. Jørgensen, Magne O. Sydnes, Yngve Guttormsen, Matthias Baumann, Uwe Koch, Bert Klebl, Jan Eickhoff, Bengt Erik Haug, Johan Isaksson, <span class="NLM_string-name hlFld-ContribAuthor">Espen H. Hansen</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Chemodiversity from the Arctic: The Breitfussins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10167-10181. <a href="https://doi.org/10.1021/acs.jmedchem.9b01006" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BChemodiversity%252Bfrom%252Bthe%252BArctic%25253A%252BThe%252BBreitfussins%26aulast%3DHansen%26aufirst%3DKine%2B%25C3%2598.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25062019%26date%3D14112019%26date%3D24102019%26volume%3D62%26issue%3D22%26spage%3D10167%26epage%3D10181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Galyna
P. Mrug, Nataliia V. Myshko, Svitlana P. Bondarenko, Vitaliy M. Sviripa, <span class="NLM_string-name hlFld-ContribAuthor">Mykhaylo S. Frasinyuk</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of B-Ring Ortho-Hydroxylated Sappanin-Type Homoisoflavonoids. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (11)
                                     , 7138-7147. <a href="https://doi.org/10.1021/acs.joc.9b00814" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00814%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BB-Ring%252BOrtho-Hydroxylated%252BSappanin-Type%252BHomoisoflavonoids%26aulast%3DMrug%26aufirst%3DGalyna%2BP.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D24052019%26date%3D15052019%26volume%3D84%26issue%3D11%26spage%3D7138%26epage%3D7147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aaron Coffin, <span class="NLM_string-name hlFld-ContribAuthor">Joseph M. Ready</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Synthesis of (+)-Dysoline. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (3)
                                     , 648-651. <a href="https://doi.org/10.1021/acs.orglett.8b03777" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03777%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSelective%252BSynthesis%252Bof%252B%252528%25252B%252529-Dysoline%26aulast%3DCoffin%26aufirst%3DAaron%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D26112018%26date%3D17012019%26volume%3D21%26issue%3D3%26spage%3D648%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vikas Kumar, Sandip B. Bharate, Ram A. Vishwakarma, <span class="NLM_string-name hlFld-ContribAuthor">Sonali S. Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Selection of a Water-Soluble Salt Form of a Preclinical Candidate, IIIM-290: Multiwell-Plate Salt Screening and Characterization. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (7)
                                     , 8365-8377. <a href="https://doi.org/10.1021/acsomega.8b00801" title="DOI URL">https://doi.org/10.1021/acsomega.8b00801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00801%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSelection%252Bof%252Ba%252BWater-Soluble%252BSalt%252BForm%252Bof%252Ba%252BPreclinical%252BCandidate%25252C%252BIIIM-290%25253A%252BMultiwell-Plate%252BSalt%252BScreening%252Band%252BCharacterization%26aulast%3DKumar%26aufirst%3DVikas%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24042018%26date%3D13072018%26volume%3D3%26issue%3D7%26spage%3D8365%26epage%3D8377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mubashir  Mintoo</span>, <span class="hlFld-ContribAuthor ">Sameer  Khan</span>, <span class="hlFld-ContribAuthor ">Abubakar  Wani</span>, <span class="hlFld-ContribAuthor ">Sumera  Malik</span>, <span class="hlFld-ContribAuthor ">Deendyal  Bhurta</span>, <span class="hlFld-ContribAuthor ">Sandip  Bharate</span>, <span class="hlFld-ContribAuthor ">Fayaz  Malik</span>, <span class="hlFld-ContribAuthor ">Dilip  Mondhe</span>. </span><span class="cited-content_cbyCitation_article-title">A rohitukine derivative IIIM‐290 induces p53 dependent mitochondrial apoptosis in acute lymphoblastic leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Carcinogenesis</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.1002/mc.23332" title="DOI URL">https://doi.org/10.1002/mc.23332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mc.23332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmc.23332%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Carcinogenesis%26atitle%3DA%252Brohitukine%252Bderivative%252BIIIM%2525E2%252580%252590290%252Binduces%252Bp53%252Bdependent%252Bmitochondrial%252Bapoptosis%252Bin%252Bacute%252Blymphoblastic%252Bleukemia%252Bcells%26aulast%3DMintoo%26aufirst%3DMubashir%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Richter</span>, <span class="hlFld-ContribAuthor ">Nina  Schoenwaelder</span>, <span class="hlFld-ContribAuthor ">Sina  Sender</span>, <span class="hlFld-ContribAuthor ">Christian  Junghanss</span>, <span class="hlFld-ContribAuthor ">Claudia  Maletzki</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (10)
                                     , 2497. <a href="https://doi.org/10.3390/cancers13102497" title="DOI URL">https://doi.org/10.3390/cancers13102497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13102497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13102497%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCyclin-Dependent%252BKinase%252BInhibitors%252Bin%252BHematological%252BMalignancies%2525E2%252580%252594Current%252BUnderstanding%25252C%252B%252528Pre-%252529Clinical%252BApplication%252Band%252BPromising%252BApproaches%26aulast%3DRichter%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D10%26spage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brilliant N.  Marak</span>, <span class="hlFld-ContribAuthor ">Jayanta  Dowarah</span>, <span class="hlFld-ContribAuthor ">Laldingluaia  Khiangte</span>, <span class="hlFld-ContribAuthor ">Ved Prakash  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112571. <a href="https://doi.org/10.1016/j.ejmech.2020.112571" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112571%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Binsight%252Bon%252Bthe%252Brecent%252Bdevelopment%252Bof%252BCyclic%252BDependent%252BKinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DMarak%26aufirst%3DBrilliant%2BN.%26date%3D2020%26volume%3D203%26spage%3D112571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bharat  Goel</span>, <span class="hlFld-ContribAuthor ">Nancy  Tripathi</span>, <span class="hlFld-ContribAuthor ">Nivedita  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">Shreyans K.  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (17)
                                     , 1535-1563. <a href="https://doi.org/10.2174/1568026620666200516152756" title="DOI URL">https://doi.org/10.2174/1568026620666200516152756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200516152756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200516152756%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BCDK%252BInhibitors%252Bfor%252Bthe%252BTherapeutic%252BManagement%252Bof%252BCancer%26aulast%3DGoel%26aufirst%3DBharat%26date%3D2020%26volume%3D20%26issue%3D17%26spage%3D1535%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nada  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Pascal  Bonnet</span>, <span class="hlFld-ContribAuthor ">Jean-Daniel  Brion</span>, <span class="hlFld-ContribAuthor ">Jean-François  Peyrat</span>, <span class="hlFld-ContribAuthor ">Jerome  Bignon</span>, <span class="hlFld-ContribAuthor ">Helene  Levaique</span>, <span class="hlFld-ContribAuthor ">Béatrice  Josselin</span>, <span class="hlFld-ContribAuthor ">Thomas  Robert</span>, <span class="hlFld-ContribAuthor ">Pierre  Colas</span>, <span class="hlFld-ContribAuthor ">Stéphane  Bach</span>, <span class="hlFld-ContribAuthor ">Samir  Messaoudi</span>, <span class="hlFld-ContribAuthor ">Mouad  Alami</span>, <span class="hlFld-ContribAuthor ">Abdallah  Hamze</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112355. <a href="https://doi.org/10.1016/j.ejmech.2020.112355" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112355%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ba%252Bnew%252Bseries%252Bof%252Bflavopiridol-like%252Bstructures%252Bas%252Bkinase%252Binhibitors%252Bwith%252Bhigh%252Bcytotoxic%252Bpotency%26aulast%3DIbrahim%26aufirst%3DNada%26date%3D2020%26volume%3D199%26spage%3D112355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junyu  Xu</span>, <span class="hlFld-ContribAuthor ">Hongmei  Li</span>, <span class="hlFld-ContribAuthor ">Xinren  Wang</span>, <span class="hlFld-ContribAuthor ">Jianhang  Huang</span>, <span class="hlFld-ContribAuthor ">Shuwen  Li</span>, <span class="hlFld-ContribAuthor ">Chenhe  Liu</span>, <span class="hlFld-ContribAuthor ">Ruinan  Dong</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Fei  Jiang</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuqin  Zhu</span>, <span class="hlFld-ContribAuthor ">Tianyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112424. <a href="https://doi.org/10.1016/j.ejmech.2020.112424" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112424%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bcoumarin%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252Bcyclin-dependent%252Bkinase%252B9%252B%252528CDK9%252529%252Binhibitors%252Bwith%252Bhigh%252Bantitumour%252Bactivity%26aulast%3DXu%26aufirst%3DJunyu%26date%3D2020%26volume%3D200%26spage%3D112424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>, <span class="hlFld-ContribAuthor ">Deendyal  Bhurta</span>, <span class="hlFld-ContribAuthor ">Mehak  Gupta</span>, <span class="hlFld-ContribAuthor ">Sumit G.  Gandhi</span>, <span class="hlFld-ContribAuthor ">Deepika  Singh</span>, <span class="hlFld-ContribAuthor ">Sundeep  Jaglan</span>, <span class="hlFld-ContribAuthor ">Ajay  Kumar</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of rohitukine-enriched fraction of Dysoxylum binectariferum Hook.f. (leaves) as anti-arthritic phytopharmaceutical candidate: Chemical standardization, in-vivo validation, formulation development and oral pharmacokinetics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ethnopharmacology</span><span> <strong>2020,</strong> <em>254 </em>, 112758. <a href="https://doi.org/10.1016/j.jep.2020.112758" title="DOI URL">https://doi.org/10.1016/j.jep.2020.112758</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jep.2020.112758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jep.2020.112758%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ethnopharmacology%26atitle%3DEvaluation%252Bof%252Brohitukine-enriched%252Bfraction%252Bof%252BDysoxylum%252Bbinectariferum%252BHook.f.%252B%252528leaves%252529%252Bas%252Banti-arthritic%252Bphytopharmaceutical%252Bcandidate%25253A%252BChemical%252Bstandardization%25252C%252Bin-vivo%252Bvalidation%25252C%252Bformulation%252Bdevelopment%252Band%252Boral%252Bpharmacokinetics%26aulast%3DKumar%26aufirst%3DVikas%26date%3D2020%26volume%3D254%26spage%3D112758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112073. <a href="https://doi.org/10.1016/j.ejmech.2020.112073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bcyclin-dependent%252Bkinase%252B%252528CDK%252529%252Band%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Bdual%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Banticancer%252Bactivity%26aulast%3DCheng%26aufirst%3DChunhui%26date%3D2020%26volume%3D189%26spage%3D112073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi-Zhuan  Li</span>, <span class="hlFld-ContribAuthor ">Qi  Tong</span>, <span class="hlFld-ContribAuthor ">Wen-Yong  Han</span>, <span class="hlFld-ContribAuthor ">Si-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Bao-Dong  Cui</span>, <span class="hlFld-ContribAuthor ">Nan-Wei  Wan</span>, <span class="hlFld-ContribAuthor ">Yong-Zheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of chromone-containing polycyclic compounds
              via
              palladium-catalyzed [2 + 2 + 1] annulation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (6)
                                     , 1112-1116. <a href="https://doi.org/10.1039/C9OB02690H" title="DOI URL">https://doi.org/10.1039/C9OB02690H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB02690H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB02690H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bchromone-containing%252Bpolycyclic%252Bcompounds%252Bvia%252Bpalladium-catalyzed%252B%25255B2%252B%25252B%252B2%252B%25252B%252B1%25255D%252Bannulation%26aulast%3DLi%26aufirst%3DMi-Zhuan%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D6%26spage%3D1112%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna P.  Mrug</span>, <span class="hlFld-ContribAuthor ">Iryna M.  Biletska</span>, <span class="hlFld-ContribAuthor ">Svitlana P.  Bondarenko</span>, <span class="hlFld-ContribAuthor ">Vitaliy M.  Sviripa</span>, <span class="hlFld-ContribAuthor ">Mykhaylo S.  Frasinyuk</span>. </span><span class="cited-content_cbyCitation_article-title">Trifluoroacetylation of 2‐Methyl‐ and 2‐Ethylchromones: A Convenient Access to 2‐Trifluoroacetonyl Chromones. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (39)
                                     , 11506-11510. <a href="https://doi.org/10.1002/slct.201903629" title="DOI URL">https://doi.org/10.1002/slct.201903629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201903629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201903629%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DTrifluoroacetylation%252Bof%252B2%2525E2%252580%252590Methyl%2525E2%252580%252590%252Band%252B2%2525E2%252580%252590Ethylchromones%25253A%252BA%252BConvenient%252BAccess%252Bto%252B2%2525E2%252580%252590Trifluoroacetonyl%252BChromones%26aulast%3DMrug%26aufirst%3DGalyna%2BP.%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D39%26spage%3D11506%26epage%3D11510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Mubashir J.  Mintoo</span>, <span class="hlFld-ContribAuthor ">Dilip M.  Mondhe</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2019,</strong> <em>570 </em>, 118683. <a href="https://doi.org/10.1016/j.ijpharm.2019.118683" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2019.118683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2019.118683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2019.118683%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DBinary%252Band%252Bternary%252Bsolid%252Bdispersions%252Bof%252Ban%252Banticancer%252Bpreclinical%252Blead%25252C%252BIIIM-290%25253A%252BIn%252Bvitro%252Band%252Bin%252Bvivo%252Bstudies%26aulast%3DKumar%26aufirst%3DVikas%26date%3D2019%26volume%3D570%26spage%3D118683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lulu  Zhao</span>, <span class="hlFld-ContribAuthor ">Xinyu  Yuan</span>, <span class="hlFld-ContribAuthor ">Jubo  Wang</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Fei  Ji</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (5)
                                     , 677-685. <a href="https://doi.org/10.1016/j.bmc.2019.01.027" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.01.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.01.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bflavones%252Btargeting%252Bserine%25252Fthreonine%252Bprotein%252Bkinases%252Bfor%252Bpotential%252Banticancer%252Bdrugs%26aulast%3DZhao%26aufirst%3DLulu%26date%3D2019%26volume%3D27%26issue%3D5%26spage%3D677%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Deendyal  Bhurta</span>, <span class="hlFld-ContribAuthor ">Ankita  Sharma</span>, <span class="hlFld-ContribAuthor ">Puneet  Kumar</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Impurity profiling of anticancer preclinical candidate, IIIM-290. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2019,</strong> <em>166 </em>, 1-5. <a href="https://doi.org/10.1016/j.jpba.2018.12.027" title="DOI URL">https://doi.org/10.1016/j.jpba.2018.12.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2018.12.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2018.12.027%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DImpurity%252Bprofiling%252Bof%252Banticancer%252Bpreclinical%252Bcandidate%25252C%252BIIIM-290%26aulast%3DKumar%26aufirst%3DVikas%26date%3D2019%26volume%3D166%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramesh  Mudududdla</span>, <span class="hlFld-ContribAuthor ">Dinesh  Mohanakrishnan</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Dinkar  Sahal</span>, <span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>. </span><span class="cited-content_cbyCitation_article-title">Orally Effective Aminoalkyl 10
              H
              ‐Indolo[3,2‐
              b
              ]quinoline‐11‐carboxamide Kills the Malaria Parasite by Inhibiting Host Hemoglobin Uptake. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (23)
                                     , 2581-2598. <a href="https://doi.org/10.1002/cmdc.201800579" title="DOI URL">https://doi.org/10.1002/cmdc.201800579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800579%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DOrally%252BEffective%252BAminoalkyl%252B10%252BH%252B%2525E2%252580%252590Indolo%25255B3%25252C2%2525E2%252580%252590%252Bb%252B%25255Dquinoline%2525E2%252580%25259011%2525E2%252580%252590carboxamide%252BKills%252Bthe%252BMalaria%252BParasite%252Bby%252BInhibiting%252BHost%252BHemoglobin%252BUptake%26aulast%3DMudududdla%26aufirst%3DRamesh%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D23%26spage%3D2581%26epage%3D2598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of rohitukine (<b>1</b>) and its inspired anticancer candidates <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of four different series A–D of rohitukine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Rohitukine Derivatives <b>8a</b>–<b>h</b>, <b>9a</b>–<b>o</b>, <b>10a</b>–<b>n</b>, and <b>11a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a). KF/alumina (5 mol %); grinding, substituted benzyl halide, 5–15 min, rt, 42–62%; (b) formalin solution (1.7 equiv), secondary amine, DMSO, 60 °C, 5 h, 34–52%; (c) DABCO (1.2 equiv), substituted aldehydes (1.2 equiv), MeOH, rt, 15 days, 36–65%; (d) KOH (10 equiv), substituted aldehydes (1.2 equiv), MeOH, 110 °C, 10 h, 45–61%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure–activity relationship of rohitukine scaffold for Cdk inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Interactions of <b>11d</b> with the ATP-binding site of Cdk-9 kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>). (a) Surface view of the ATP-binding site of Cdk-9 showing orientation of <b>11d</b> inside the cavity; (b) two-dimensional view of the key interactions of <b>11d</b> with active site residues; (c) overlay of flavopiridol (green) with <b>11d</b> (red) in the active site; (d) key interactions of <b>11d</b> with binding site residues in the 3D view.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Percent inhibition profile (TREEspot Interaction Map) in the DiscoverX ScanMax kinome scan for compound <b>11d</b>. The kinase groups and number of kinases in the panel: TK, tyrosine kinases (87); TKL, tyrosine kinase like (31); STE, STE kinases (43); CK1, cell kinase 1 (8); AGC, PKA, PKG, PKC kinases (46); CAMK, calcium and calmodulin regulated kinases (46); CMGC, Cdk, MAP, GSK, Cdk-like kinases (54); other, other kinases (54); mutant kinases (60); atypical kinases (8); lipid kinases (13); pathogen kinases (3). The red (and blue) circles indicate the kinases where compound <b>11d</b> has reduced the kinase activity to less than 35% of control. Two blue circles indicates Cdk-4 and Cdk-9 kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compound <b>11d</b> on cell cycle (a), apoptosis via scanning electron microscopy (b), and DAPI staining (c), and mitochondrial membrane potential loss (using Rh123 dye) (d) in MIAPaCa-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>11d</b> on PARP, caspase-3, and caspase-7 using western-blot analysis in MIAPaCa-2 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmacokinetic analysis of <b>11d</b> in BALB/c mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/medium/jm-2017-01765x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor effect of styryl derivative <b>11d</b> in human pancreatic (MIAPaCa-2), colon (HCT-116), and leukemia (Molt-4) xenograft nude mice models. (a,b) Graph showing the effect of <b>11d</b> on the MIAPaCa-2 tumor growth along with representative tumor images. (c,d) Graph showing the effect of <b>11d</b> on the HCT-116 tumor growth along with representative tumor images. (e,f) Graph showing the effect of <b>11d</b> on the Molt-4 tumor growth along with representative images of Molt-4 xenograft studies. Data represent the mean (<i>n</i> = 6) ± SEM. Statistical significance (*<i>p</i> < 0.05) was determined by one-way analysis of variance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01765/20180215/images/large/jm-2017-01765x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01765&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i100">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 62 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ingham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Cell-cycle therapeutics come of age</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2949</span><span class="NLM_x">–</span> <span class="NLM_lpage">2959</span><span class="refDoi"> DOI: 10.1200/JCO.2016.69.0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2016.69.0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28580868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVemtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2949-2959&author=M.+Inghamauthor=G.+K.+Schwartz&title=Cell-cycle+therapeutics+come+of+age&doi=10.1200%2FJCO.2016.69.0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-cycle therapeutics come of age</span></div><div class="casAuthors">Ingham, Matthew; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2949-2959</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The ability to sustain unscheduled proliferation is a hallmark of cancer.  The normal process of cell division occurs via the cell cycle, a series of highly regulated steps that are orchestrated at the mol. level by specific cyclins that act in assocn. with cyclin-dependent kinases (CDKs).  Cyclin D and CDK4/6 play a key role in cell-cycle progression by phosphorylating and inactivating the retinoblastoma protein, a tumor suppressor that restrains G1- to S-phase progression.  The first-generation CDK inhibitors demonstrated broad activity upon several CDKs, which likely explains their considerable toxicities and limited efficacy.  Palbociclib, ribociclib, and abemaciclib represent a new class of highly specific ATP-competitive CDK4/6 inhibitors that induce reversible G1-phase cell-cycle arrest in retinoblastoma-pos. tumor models.  Both palbociclib and ribociclib have been approved in combination with hormone-based therapy for the treatment of na.ovrddot.ive hormone receptor-pos. advanced breast cancer on the basis of an improvement in progression-free survival.  In general, CDK4/6 inhibitors are cytostatic as monotherapy but demonstrate favorable tolerability, which has prompted interest in combination approaches.  Combinations with phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitors in breast cancer, and inhibitors of the RAS/RAF/mitogen-activated protein kinase pathway in RAS-mutant cancers are particularly promising approaches that are currently being evaluated.  Although the subject of intense preclin. study, predictive biomarkers for response and resistance to these drugs remain largely undefined.  CDK4/6 inhibitors have emerged as the most promising of the cell-cycle therapeutics and intense efforts are now underway to expand the reach of this paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy_vAO4ZbR8LVg90H21EOLACvtfcHk0lhL6Qw80AH3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVemtrzI&md5=167767d50f9089b730514d9a8f8f1cb5</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.69.0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.69.0032%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DCell-cycle%2520therapeutics%2520come%2520of%2520age%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2949%26epage%3D2959%26doi%3D10.1200%2FJCO.2016.69.0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Abou Zahr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span> </span><span class="NLM_article-title">Emerging cell cycle inhibitors for acute myeloid leukemia</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1080/14728214.2017.1330885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1080%2F14728214.2017.1330885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28506135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1ars7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=137-148&author=A.+Abou+Zahrauthor=G.+Borthakur&title=Emerging+cell+cycle+inhibitors+for+acute+myeloid+leukemia&doi=10.1080%2F14728214.2017.1330885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging cell cycle inhibitors for acute myeloid leukemia</span></div><div class="casAuthors">Abou Zahr, Abdallah; Borthakur, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-148</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: AML therapy remains very challenging despite our increased understanding of its mol. heterogeneity.  Outcomes with chemotherapy and targeted therapy remain poor.  Targeting cell cycle regulators might complement chemotherapy and targeted therapy and help in improving outcomes.: Here we cover the pre-clin. and clin. data for both for cyclin dependent kinase (CDK) and cell-cycle checkpoint inhibitors.  While CDK inhibition can inhibit proliferation, checkpoint inhibitors can facilitate cell cycle progression in presence of DNA damage and can induce mitotic catastrophe.: Though the preclin. data for cell cycle inhibitors in AML is compelling, the clin. translation so far has proven to be challenging.  This is a reflection of the complexity of both, AML and cell cycle regulators.  However, early introduction of cell-cycle active agents in combination with chemotherapy or targeted agents, identifying right sequence of use and identifying right biomarkers might pave the way into successful clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGO9l8La2YvrVg90H21EOLACvtfcHk0lhL6Qw80AH3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1ars7s%253D&md5=cd3510a43222380a602f4bb343b6c955</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F14728214.2017.1330885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2017.1330885%26sid%3Dliteratum%253Aachs%26aulast%3DAbou%2BZahr%26aufirst%3DA.%26aulast%3DBorthakur%26aufirst%3DG.%26atitle%3DEmerging%2520cell%2520cycle%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2017%26volume%3D22%26spage%3D137%26epage%3D148%26doi%3D10.1080%2F14728214.2017.1330885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Michalides, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Veelen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loftus, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wientjens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balm, A.</span><span> </span><span class="NLM_article-title">Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=975-978&author=R.+Michalidesauthor=N.+van+Veelenauthor=A.+Hartauthor=B.+Loftusauthor=E.+Wientjensauthor=A.+Balm&title=Overexpression+of+cyclin+D1+correlates+with+recurrence+in+a+group+of+forty-seven+operable+squamous+cell+carcinomas+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichalides%26aufirst%3DR.%26aulast%3Dvan%2BVeelen%26aufirst%3DN.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DLoftus%26aufirst%3DB.%26aulast%3DWientjens%26aufirst%3DE.%26aulast%3DBalm%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520cyclin%2520D1%2520correlates%2520with%2520recurrence%2520in%2520a%2520group%2520of%2520forty-seven%2520operable%2520squamous%2520cell%2520carcinomas%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Roskoski, R.,  Jr.</span><span> </span><span class="NLM_article-title">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1016/j.phrs.2016.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.phrs.2016.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26995305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=249-275&author=R.+Roskoski&title=Cyclin-dependent+protein+kinase+inhibitors+including+palbociclib+as+anticancer+drugs&doi=10.1016%2Fj.phrs.2016.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-275</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle progression.  The levels of the cell cycle CDKs are generally const. and their activities are controlled by cyclins, proteins whose levels oscillate during each cell cycle.  Addnl. CDK family members were subsequently discovered that play significant roles in a wide range of activities including the control of gene transcription, metab., and neuronal function.  In response to mitogenic stimuli, cells in the G1 phase of the cell cycle produce cyclins of the D type that activate CDK4/6.  These activated enzymes catalyze the monophosphorylation of the retinoblastoma protein.  Then CDK2-cyclin E catalyzes the hyperphosphorylation of Rb that promotes the release and activation of the E2F transcription factors, which in turn lead to the generation of several proteins required for cell cycle progression.  As a result, cells pass through the G1-restriction point and are committed to complete cell division.  CDK2-cyclin A, CDK1-cyclin A, and CDK1-cyclin B are required for S, G2, and M-phase progression.  Increased cyclin or CDK expression or decreased levels of endogenous CDK inhibitors such as INK4 or CIP/KIP have been obsd. in various cancers.  In contrast to the mutational activation of EGFR, Kit, or B-Raf in the pathogenesis of malignancies, mutations in the CDKs that cause cancers are rare.  Owing to their role in cell proliferation, CDKs represent natural targets for anticancer therapies.  Abemaciclib (LY2835219), ribociclib (Lee011), and palbociclib (Ibrance or PD0332991) target CDK4/6 with IC50 values in the low nanomolar range.  Palbociclib and other CDK inhibitors bind in the cleft between the small and large lobes of the CDKs and inhibit the binding of ATP.  Like ATP, palbociclib forms hydrogen bonds with residues in the hinge segment of the cleft.  Like the adenine base of ATP, palbociclib interacts with catalytic spine residues CS6 and CS7.  CDK antagonists are in clin. trials for the treatment of a variety of malignancies.  Significantly, palbociclib has been approved by the FDA for the treatment of hormone-receptor pos./human epidermal growth factor receptor-2 neg. breast cancer in conjunction with letrozole as a first-line therapy and with fulvestrant as a second-line treatment.  As inhibitors of the cell cycle, it is not surprising that one of their most common toxicities is myelosuppression with decreased neutrophil prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol0On7HAFtl7Vg90H21EOLACvtfcHk0lijHT6S-PZehQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOjt7o%253D&md5=0356807b16735e3903706eac10635bc7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DCyclin-dependent%2520protein%2520kinase%2520inhibitors%2520including%2520palbociclib%2520as%2520anticancer%2520drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D107%26spage%3D249%26epage%3D275%26doi%3D10.1016%2Fj.phrs.2016.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Burki, T. K.</span><span> </span><span class="NLM_article-title">Palbociclib improves survival in advanced breast cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30619-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS1470-2045%2816%2930619-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27890465" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=e1&author=T.+K.+Burki&title=Palbociclib+improves+survival+in+advanced+breast+cancer&doi=10.1016%2FS1470-2045%2816%2930619-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930619-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930619-2%26sid%3Dliteratum%253Aachs%26aulast%3DBurki%26aufirst%3DT.%2BK.%26atitle%3DPalbociclib%2520improves%2520survival%2520in%2520advanced%2520breast%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3De1%26doi%3D10.1016%2FS1470-2045%2816%2930619-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zerdes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziogas, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lykoudis, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roukos, D. H.</span><span> </span><span class="NLM_article-title">Palbociclib: an approval at last for HER2-negative breast cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1097</span><span class="NLM_x">–</span> <span class="NLM_lpage">1100</span><span class="refDoi"> DOI: 10.2217/fon-2015-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2217%2Ffon-2015-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26987714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVamuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1097-1100&author=I.+Zerdesauthor=D.+E.+Ziogasauthor=E.+G.+Lykoudisauthor=D.+H.+Roukos&title=Palbociclib%3A+an+approval+at+last+for+HER2-negative+breast+cancer&doi=10.2217%2Ffon-2015-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: an approval at last for HER2-negative breast cancer</span></div><div class="casAuthors">Zerdes, Ioannis; Ziogas, Demosthenes E.; Lykoudis, Efstathios G.; Roukos, Dimitrios H.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1097-1100</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXtnt5nV1mebVg90H21EOLACvtfcHk0lijHT6S-PZehQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVamuro%253D&md5=c80b4ea7ef0e38d3694d29bdf3ce0a39</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Ffon-2015-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2015-0056%26sid%3Dliteratum%253Aachs%26aulast%3DZerdes%26aufirst%3DI.%26aulast%3DZiogas%26aufirst%3DD.%2BE.%26aulast%3DLykoudis%26aufirst%3DE.%2BG.%26aulast%3DRoukos%26aufirst%3DD.%2BH.%26atitle%3DPalbociclib%253A%2520an%2520approval%2520at%2520last%2520for%2520HER2-negative%2520breast%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2016%26volume%3D12%26spage%3D1097%26epage%3D1100%26doi%3D10.2217%2Ffon-2015-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Palanisamy, R. P.</span><span> </span><span class="NLM_article-title">Palbociclib: A new hope in the treatment of breast cancer</span> <span class="citation_source-journal">J. Cancer Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1223</span><span class="refDoi"> DOI: 10.4103/0973-1482.168988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.4103%2F0973-1482.168988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28169231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1220-1223&author=R.+P.+Palanisamy&title=Palbociclib%3A+A+new+hope+in+the+treatment+of+breast+cancer&doi=10.4103%2F0973-1482.168988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: A new hope in the treatment of breast cancer</span></div><div class="casAuthors">Palanisamy R Priyadharsini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cancer research and therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1220-1223</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer being one of the common cancers has high morbidity and mortality.  Despite the conventional treatment, the burden of the disease increases year after year.  There is a need for newer drugs that target the different mechanisms in the pathogenesis.  The interaction of cyclins with cyclin dependent kinases (CDKs) plays a major role in the abnormal cell cycle in cancer and it is considered to be an important target.  Palbociclib is a CDK inhibitor currently approved for the treatment of breast cancer.  The preclinical studies with breast cancer lines were sensitive to palbociclib and the clinical trials phase I, phase II (PALOMA 1), and phase III (PALOMA 2, 3, PENTELOPE, PEARL) showed that the drug was efficacious when combined other conventional drugs for breast cancer.  Palbociclib was also been tested in various other germ cell tumors, melanoma, multiple myeloma, glioblastoma multiforme etc., The major adverse effect of the drug includes hematological toxicity mainly neutropenia, gastrointestinal adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnC9U-jJOxSoJKJbLTgsvCfW6udTcc2eZF3sOxBulNjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jvFWitQ%253D%253D&md5=5078e0a51063f7a427461baeb4be57b6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.4103%2F0973-1482.168988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0973-1482.168988%26sid%3Dliteratum%253Aachs%26aulast%3DPalanisamy%26aufirst%3DR.%2BP.%26atitle%3DPalbociclib%253A%2520A%2520new%2520hope%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Cancer%2520Res.%2520Ther.%26date%3D2016%26volume%3D12%26spage%3D1220%26epage%3D1223%26doi%3D10.4103%2F0973-1482.168988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gupta, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashier, D. B.</span><span> </span><span class="NLM_article-title">Palbociclib: A breakthrough in breast carcinoma in women</span> <span class="citation_source-journal">Med. J. Armed Forces India</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">S37</span><span class="NLM_x">–</span> <span class="NLM_lpage">S42</span><span class="refDoi"> DOI: 10.1016/j.mjafi.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.mjafi.2015.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28050067" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2016&pages=S37-S42&author=A.+K.+Guptaauthor=S.+Sharmaauthor=N.+Dahiyaauthor=D.+B.+Brashier&title=Palbociclib%3A+A+breakthrough+in+breast+carcinoma+in+women&doi=10.1016%2Fj.mjafi.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.mjafi.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mjafi.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DDahiya%26aufirst%3DN.%26aulast%3DBrashier%26aufirst%3DD.%2BB.%26atitle%3DPalbociclib%253A%2520A%2520breakthrough%2520in%2520breast%2520carcinoma%2520in%2520women%26jtitle%3DMed.%2520J.%2520Armed%2520Forces%2520India%26date%3D2016%26volume%3D72%26spage%3DS37%26epage%3DS42%26doi%3D10.1016%2Fj.mjafi.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>Ribociclib (Kisqali). <a href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm" class="extLink">https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm</a> (accessed on July 11,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ribociclib+%28Kisqali%29.+https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm546438.htm+%28accessed+on+July+11%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Torres-Guzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calsina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermoso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baquero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehnke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lallena, M. J.</span><span> </span><span class="NLM_article-title">Preclinical characterization of abemaciclib in hormone receptor positive breast cancer</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">69493</span><span class="NLM_x">–</span> <span class="NLM_lpage">69507</span><span class="refDoi"> DOI: 10.18632/oncotarget.17778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.17778" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=69493-69507&author=R.+Torres-Guzmanauthor=B.+Calsinaauthor=A.+Hermosoauthor=C.+Baqueroauthor=B.+Alvarezauthor=J.+Amatauthor=A.+M.+McNultyauthor=X.+Gongauthor=K.+Boehnkeauthor=J.+Duauthor=A.+de+Diosauthor=R.+P.+Beckmannauthor=S.+Buchananauthor=M.+J.+Lallena&title=Preclinical+characterization+of+abemaciclib+in+hormone+receptor+positive+breast+cancer&doi=10.18632%2Foncotarget.17778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17778%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Guzman%26aufirst%3DR.%26aulast%3DCalsina%26aufirst%3DB.%26aulast%3DHermoso%26aufirst%3DA.%26aulast%3DBaquero%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DB.%26aulast%3DAmat%26aufirst%3DJ.%26aulast%3DMcNulty%26aufirst%3DA.%2BM.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DBoehnke%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26atitle%3DPreclinical%2520characterization%2520of%2520abemaciclib%2520in%2520hormone%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D69493%26epage%3D69507%26doi%3D10.18632%2Foncotarget.17778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Sledge, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neven, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pivot, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdaeva, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grischke, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barriga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourayou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llombart-Cussac, A.</span><span> </span><span class="NLM_article-title">MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2875</span><span class="NLM_x">–</span> <span class="NLM_lpage">2884</span><span class="refDoi"> DOI: 10.1200/JCO.2017.73.7585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2017.73.7585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=28580882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC1cnkvFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2875-2884&author=G.+W.+Sledgeauthor=M.+Toiauthor=P.+Nevenauthor=J.+Sohnauthor=K.+Inoueauthor=X.+Pivotauthor=O.+Burdaevaauthor=M.+Okeraauthor=N.+Masudaauthor=P.+A.+Kaufmanauthor=H.+Kohauthor=E.+M.+Grischkeauthor=M.+Frenzelauthor=Y.+Linauthor=S.+Barrigaauthor=I.+C.+Smithauthor=N.+Bourayouauthor=A.+Llombart-Cussac&title=MONARCH+2%3A+Abemaciclib+in+combination+with+fulvestrant+in+women+with+HR%2B%2FHER2-+advanced+breast+cancer+who+had+progressed+while+receiving+endocrine+therapy&doi=10.1200%2FJCO.2017.73.7585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy</span></div><div class="casAuthors">Sledge George W Jr; Toi Masakazu; Neven Patrick; Sohn Joohyuk; Inoue Kenichi; Pivot Xavier; Burdaeva Olga; Okera Meena; Masuda Norikazu; Kaufman Peter A; Koh Han; Grischke Eva-Maria; Frenzel Martin; Lin Yong; Barriga Susana; Smith Ian C; Bourayou Nawel; Llombart-Cussac Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2875-2884</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).  Patients and Methods MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic disease.  Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label).  The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clinical benefit rate, quality of life, and safety.  Results Between August 2014 and December 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223).  Abemaciclib plus fulvestrant significantly extended PFS versus fulvestrant alone (median, 16.4 v 9.3 months; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001).  In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm.  The most common adverse events in the abemaciclib versus placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%).  Conclusions Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCflt1Gxh1HszK395ZObgVfW6udTcc2eZ3uHqIye_eZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnkvFWhsA%253D%253D&md5=7a305322c71231a877aa099acfaec522</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.73.7585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.73.7585%26sid%3Dliteratum%253Aachs%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DPivot%26aufirst%3DX.%26aulast%3DBurdaeva%26aufirst%3DO.%26aulast%3DOkera%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DKaufman%26aufirst%3DP.%2BA.%26aulast%3DKoh%26aufirst%3DH.%26aulast%3DGrischke%26aufirst%3DE.%2BM.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DBarriga%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DI.%2BC.%26aulast%3DBourayou%26aufirst%3DN.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26atitle%3DMONARCH%25202%253A%2520Abemaciclib%2520in%2520combination%2520with%2520fulvestrant%2520in%2520women%2520with%2520HR%252B%252FHER2-%2520advanced%2520breast%2520cancer%2520who%2520had%2520progressed%2520while%2520receiving%2520endocrine%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D2875%26epage%3D2884%26doi%3D10.1200%2FJCO.2017.73.7585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schade, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulford, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulanthaivel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronier, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F2159-8290.CD-16-0095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=740-753&author=A.+Patnaikauthor=L.+S.+Rosenauthor=S.+M.+Tolaneyauthor=A.+W.+Tolcherauthor=J.+W.+Goldmanauthor=L.+Gandhiauthor=K.+P.+Papadopoulosauthor=M.+Beeramauthor=D.+W.+Rascoauthor=J.+F.+Hiltonauthor=A.+Nasirauthor=R.+P.+Beckmannauthor=A.+E.+Schadeauthor=A.+D.+Fulfordauthor=T.+S.+Nguyenauthor=R.+Martinezauthor=P.+Kulanthaivelauthor=L.+Q.+Liauthor=M.+Frenzelauthor=D.+M.+Cronierauthor=E.+M.+Chanauthor=K.+T.+Flahertyauthor=P.+Y.+Wenauthor=G.+I.+Shapiro&title=Efficacy+and+safety+of+abemaciclib%2C+an+inhibitor+of+CDK4+and+CDK6%2C+for+patients+with+breast+cancer%2C+non-small+cell+lung+cancer%2C+and+other+solid+tumors&doi=10.1158%2F2159-8290.CD-16-0095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0095%26sid%3Dliteratum%253Aachs%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DHilton%26aufirst%3DJ.%2BF.%26aulast%3DNasir%26aufirst%3DA.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DSchade%26aufirst%3DA.%2BE.%26aulast%3DFulford%26aufirst%3DA.%2BD.%26aulast%3DNguyen%26aufirst%3DT.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DKulanthaivel%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DL.%2BQ.%26aulast%3DFrenzel%26aufirst%3DM.%26aulast%3DCronier%26aufirst%3DD.%2BM.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520abemaciclib%252C%2520an%2520inhibitor%2520of%2520CDK4%2520and%2520CDK6%252C%2520for%2520patients%2520with%2520breast%2520cancer%252C%2520non-small%2520cell%2520lung%2520cancer%252C%2520and%2520other%2520solid%2520tumors%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D740%26epage%3D753%26doi%3D10.1158%2F2159-8290.CD-16-0095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a> (accessed on August 23,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov+%28accessed+on+August+23%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rahaman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekonnen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">T211</span><span class="NLM_x">–</span> <span class="NLM_lpage">T226</span><span class="refDoi"> DOI: 10.1530/ERC-16-0299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1530%2FERC-16-0299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27582311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=T211-T226&author=M.+H.+Rahamanauthor=M.+Kumarasiriauthor=L.+B.+Mekonnenauthor=M.+Yuauthor=S.+Diabauthor=H.+Albrechtauthor=R.+W.+Milneauthor=S.+Wang&title=Targeting+CDK9%3A+a+promising+therapeutic+opportunity+in+prostate+cancer&doi=10.1530%2FERC-16-0299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK9: a promising therapeutic opportunity in prostate cancer</span></div><div class="casAuthors">Rahaman, Muhammed H.; Kumarasiri, Malika; Mekonnen, Laychiluh B.; Yu, Mingfeng; Diab, Sarah; Albrecht, Hugo; Milne, Robert W.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">T211-T226</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment.  Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression.  In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen.  CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and antiapoptotic proteins, improving the chances of pos. outcomes, esp. in patients with the advanced disease.  This review focuses on biol. functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJmSh9D9_op7Vg90H21EOLACvtfcHk0ljxqQMJsskwuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSlu78%253D&md5=cea302eeb765840884f60cb170ec1640</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1530%2FERC-16-0299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-16-0299%26sid%3Dliteratum%253Aachs%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DMekonnen%26aufirst%3DL.%2BB.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DMilne%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK9%253A%2520a%2520promising%2520therapeutic%2520opportunity%2520in%2520prostate%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2016%26volume%3D23%26spage%3DT211%26epage%3DT226%26doi%3D10.1530%2FERC-16-0299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sonawane, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napoleon, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contreras, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, A.</span><span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 knhibitors for cancer therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8667</span><span class="NLM_x">–</span> <span class="NLM_lpage">8684</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+knhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520knhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Morales, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Overview of CDK9 as a target in cancer research</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span><span class="refDoi"> DOI: 10.1080/15384101.2016.1138186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1080%2F15384101.2016.1138186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26766294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=519-527&author=F.+Moralesauthor=A.+Giordano&title=Overview+of+CDK9+as+a+target+in+cancer+research&doi=10.1080%2F15384101.2016.1138186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of CDK9 as a target in cancer research</span></div><div class="casAuthors">Morales, Fatima; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">CDK9 is a protein in const. development in cancer therapy.  Herein we present an overview of the enzyme as a target for cancer therapy.  We provide data on its characteristics and mechanism of action.  In recent years, CDK9 inhibitors that have been designed with mol. modeling have demonstrated good antitumoral activity in vitro.  Clin. studies of the drugs flavopiridol, dinaciclib, seliciclib, SNS-032 and RGB-286638 used as CDK9 inhibitors are also reviewed, with their addnl. targets and their relative IC50 values.  Unfortunately, treatment with these drugs remains unsuccessful and involves many adverse effects.  We could conclude that there are many small mols. that bind to CDK9, but their lack of selectivity against other CDKs do not allow them to get to the clin. use.  However, drug designers currently have the tools needed to improve the selectivity of CDK9 inhibitors and to make successful treatment available to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTT9RDBXneVrVg90H21EOLACvtfcHk0ljxqQMJsskwuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCitro%253D&md5=4380763f74e91d5ea6d2d9b38ec6fd5e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F15384101.2016.1138186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2016.1138186%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DOverview%2520of%2520CDK9%2520as%2520a%2520target%2520in%2520cancer%2520research%26jtitle%3DCell%2520Cycle%26date%3D2016%26volume%3D15%26spage%3D519%26epage%3D527%26doi%3D10.1080%2F15384101.2016.1138186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span><span class="refDoi"> DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure-activity+relationship%2C+and+anticancer+activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure-activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Nemeth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekely, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebestyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaszay, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirat, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virieux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyuris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelemenics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ay, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szathmary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3939</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span><span class="refDoi"> DOI: 10.1021/jm401742r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401742r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3939-3965&author=G.+Nemethauthor=Z.+Greffauthor=A.+Siposauthor=Z.+Vargaauthor=R.+Szekelyauthor=M.+Sebestyenauthor=Z.+Jaszayauthor=S.+Beniauthor=Z.+Nemesauthor=J.+L.+Piratauthor=J.+N.+Volleauthor=D.+Virieuxauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=E.+Ayauthor=J.+Minarovitsauthor=S.+Szathmaryauthor=G.+Keriauthor=L.+Orfi&title=Synthesis+and+evaluation+of+phosphorus+containing%2C+specific+CDK9%2FCycT1+inhibitors&doi=10.1021%2Fjm401742r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm401742r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401742r%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DSzekely%26aufirst%3DR.%26aulast%3DSebestyen%26aufirst%3DM.%26aulast%3DJaszay%26aufirst%3DZ.%26aulast%3DBeni%26aufirst%3DS.%26aulast%3DNemes%26aufirst%3DZ.%26aulast%3DPirat%26aufirst%3DJ.%2BL.%26aulast%3DVolle%26aufirst%3DJ.%2BN.%26aulast%3DVirieux%26aufirst%3DD.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DAy%26aufirst%3DE.%26aulast%3DMinarovits%26aufirst%3DJ.%26aulast%3DSzathmary%26aufirst%3DS.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520phosphorus%2520containing%252C%2520specific%2520CDK9%252FCycT1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3939%26epage%3D3965%26doi%3D10.1021%2Fjm401742r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span> </span><span class="NLM_article-title">Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3231</span><span class="NLM_x">–</span> <span class="NLM_lpage">3237</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2017.06.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2017.06.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=3231-3237&author=Y.+Liauthor=Q.+Guoauthor=C.+Zhangauthor=Z.+Huangauthor=T.+Wangauthor=X.+Wangauthor=X.+Wangauthor=G.+Xuauthor=Y.+Liuauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=Discovery+of+a+highly+potent%2C+selective+and+novel+CDK9+inhibitor+as+an+anticancer+drug+candidate&doi=10.1016%2Fj.bmcl.2017.06.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.06.041%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%252C%2520selective%2520and%2520novel%2520CDK9%2520inhibitor%2520as%2520an%2520anticancer%2520drug%2520candidate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D3231%26epage%3D3237%26doi%3D10.1016%2Fj.bmcl.2017.06.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Tong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeranki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mejia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstetter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maru, D.</span><span> </span><span class="NLM_article-title">Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">28696</span><span class="NLM_x">–</span> <span class="NLM_lpage">28710</span><span class="refDoi"> DOI: 10.18632/oncotarget.15645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.15645" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=28696-28710&author=Z.+Tongauthor=D.+Chatterjeeauthor=D.+Dengauthor=O.+Veerankiauthor=A.+Mejiaauthor=J.+A.+Ajaniauthor=W.+Hofstetterauthor=S.+Linauthor=S.+Guhaauthor=S.+Kopetzauthor=S.+Krishnanauthor=D.+Maru&title=Antitumor+effects+of+cyclin+dependent+kinase+9+inhibition+in+esophageal+adenocarcinoma&doi=10.18632%2Foncotarget.15645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15645%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DVeeranki%26aufirst%3DO.%26aulast%3DMejia%26aufirst%3DA.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DHofstetter%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DGuha%26aufirst%3DS.%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DMaru%26aufirst%3DD.%26atitle%3DAntitumor%2520effects%2520of%2520cyclin%2520dependent%2520kinase%25209%2520inhibition%2520in%2520esophageal%2520adenocarcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D28696%26epage%3D28710%26doi%3D10.18632%2Foncotarget.15645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Yeh, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoney, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span> </span><span class="NLM_article-title">Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2667</span><span class="NLM_x">–</span> <span class="NLM_lpage">2679</span><span class="refDoi"> DOI: 10.18632/oncotarget.2096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.18632%2Foncotarget.2096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=2667-2679&author=Y.+Y.+Yehauthor=R.+Chenauthor=J.+Hesslerauthor=E.+Mahoneyauthor=A.+M.+Lehmanauthor=N.+A.+Heeremaauthor=M.+R.+Greverauthor=W.+Plunkettauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Up-regulation+of+CDK9+kinase+activity+and+Mcl-1+stability+contributes+to+the+acquired+resistance+to+cyclin-dependent+kinase+inhibitors+in+leukemia&doi=10.18632%2Foncotarget.2096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2096%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DLehman%26aufirst%3DA.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DUp-regulation%2520of%2520CDK9%2520kinase%2520activity%2520and%2520Mcl-1%2520stability%2520contributes%2520to%2520the%2520acquired%2520resistance%2520to%2520cyclin-dependent%2520kinase%2520inhibitors%2520in%2520leukemia%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D2667%26epage%3D2679%26doi%3D10.18632%2Foncotarget.2096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span> </span><span class="NLM_article-title">Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2513</span><span class="NLM_x">–</span> <span class="NLM_lpage">2519</span><span class="refDoi"> DOI: 10.1182/blood-2005-04-1678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1182%2Fblood-2005-04-1678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=15972445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=2513-2519&author=R.+Chenauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Transcription+inhibition+by+flavopiridol%3A+mechanism+of+chronic+lymphocytic+leukemia+cell+death&doi=10.1182%2Fblood-2005-04-1678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death</span></div><div class="casAuthors">Chen, Rong; Keating, Michael J.; Gandhi, Varsha; Plunkett, William</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2513-2519</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Flavopiridol is active against chronic lymphocytic leukemia (CLL) cells in vitro and in the treatment of advanced stage disease, but the mechanisms of these actions remain unclear.  Originally developed as a general cyclin-dependent kinase inhibitor, flavopiridol is a potent transcriptional suppressor through the inhibition of pos. transcription elongation factor b (P-TEFb; CDK9/cyclin T).  P-TEFb phosphorylates the C-terminal domain (CTD) of RNA polymerase II to promote transcriptional elongation.  Because most CLL cells are not actively cycling, and their viability is dependent upon the continuous expression of antiapoptotic proteins, we hypothesized that flavopiridol induces apoptosis in CLL cells through the transcriptional down-regulation of such proteins.  This study demonstrated that flavopiridol inhibited the phosphorylation of the CTD of RNA polymerase II in primary CLL cells and reduced RNA synthesis.  This was assocd. with a decline of the transcripts and the levels of short-lived antiapoptotic proteins such as myeloid cell leukemia 1 (Mcl-1), and resulted in the induction of apoptosis.  The B-cell lymphoma 2 (Bcl-2) protein level remained stable, although its mRNA was consistently reduced, suggesting that the outcome of transcriptional inhibition by flavopiridol is governed by the intrinsic stability of the individual transcripts and proteins.  The dependence of CLL-cell survival on short-lived oncoproteins may provide the biochem. basis for the therapeutic index in response to flavopiridol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Pk8ThZIWabVg90H21EOLACvtfcHk0lhlhEAad4_myA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKqt7rN&md5=428335b578ab40e36c8956905ebf0bea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-04-1678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-04-1678%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DTranscription%2520inhibition%2520by%2520flavopiridol%253A%2520mechanism%2520of%2520chronic%2520lymphocytic%2520leukemia%2520cell%2520death%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D2513%26epage%3D2519%26doi%3D10.1182%2Fblood-2005-04-1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Harmon, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, U.</span><span> </span><span class="NLM_article-title">The structure of rohitukine, the main alkaloid of <i>Amoora rohituka</i> (Syn. <i>Aphanamixis polystachya</i>) (Meliaceae)</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)93556-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0040-4039%2801%2993556-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=721-724&author=A.+D.+Harmonauthor=U.+Weiss&title=The+structure+of+rohitukine%2C+the+main+alkaloid+of+Amoora+rohituka+%28Syn.+Aphanamixis+polystachya%29+%28Meliaceae%29&doi=10.1016%2FS0040-4039%2801%2993556-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2993556-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252993556-7%26sid%3Dliteratum%253Aachs%26aulast%3DHarmon%26aufirst%3DA.%2BD.%26aulast%3DWeiss%26aufirst%3DU.%26atitle%3DThe%2520structure%2520of%2520rohitukine%252C%2520the%2520main%2520alkaloid%2520of%2520Amoora%2520rohituka%2520%2528Syn.%2520Aphanamixis%2520polystachya%2529%2520%2528Meliaceae%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26spage%3D721%26epage%3D724%26doi%3D10.1016%2FS0040-4039%2801%2993556-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Naik, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kattige, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alreja, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Souza, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupp, R. H.</span><span> </span><span class="NLM_article-title">An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span><span class="refDoi"> DOI: 10.1016/S0040-4020(01)90352-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0040-4020%2801%2990352-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1988&pages=2081-2086&author=R.+G.+Naikauthor=S.+L.+Kattigeauthor=S.+V.+Bhatauthor=B.+Alrejaauthor=N.+J.+de+Souzaauthor=R.+H.+Rupp&title=An+antiinflammatory+cum+immunomodulatory+piperidinylbenzopyranone+from+dysoxylum+binectariferum%3A+isolation%2C+structure+and+total+synthesis&doi=10.1016%2FS0040-4020%2801%2990352-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2990352-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252990352-7%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DR.%2BG.%26aulast%3DKattige%26aufirst%3DS.%2BL.%26aulast%3DBhat%26aufirst%3DS.%2BV.%26aulast%3DAlreja%26aufirst%3DB.%26aulast%3Dde%2BSouza%26aufirst%3DN.%2BJ.%26aulast%3DRupp%26aufirst%3DR.%2BH.%26atitle%3DAn%2520antiinflammatory%2520cum%2520immunomodulatory%2520piperidinylbenzopyranone%2520from%2520dysoxylum%2520binectariferum%253A%2520isolation%252C%2520structure%2520and%2520total%2520synthesis%26jtitle%3DTetrahedron%26date%3D1988%26volume%3D44%26spage%3D2081%26epage%3D2086%26doi%3D10.1016%2FS0040-4020%2801%2990352-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Mohanakumara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sreejayan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramesha, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganeshaiah, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudeva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhoshkumar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishra, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uma Shaanker, R.</span><span> </span><span class="NLM_article-title"><i>Dysoxylum binectariferum</i> Hook.f (Meliaceae), a rich source of rohitukine</span> <span class="citation_source-journal">Fitoterapia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.fitote.2009.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.fitote.2009.08.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2010&pages=145-148&author=P.+Mohanakumaraauthor=N.+Sreejayanauthor=V.+Pritiauthor=B.+T.+Rameshaauthor=G.+Ravikanthauthor=K.+N.+Ganeshaiahauthor=R.+Vasudevaauthor=J.+Mohanauthor=T.+R.+Santhoshkumarauthor=P.+D.+Mishraauthor=R.+A.+Vishwakarmaauthor=R.+Uma+Shaanker&title=Dysoxylum+binectariferum+Hook.f+%28Meliaceae%29%2C+a+rich+source+of+rohitukine&doi=10.1016%2Fj.fitote.2009.08.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.fitote.2009.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fitote.2009.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DMohanakumara%26aufirst%3DP.%26aulast%3DSreejayan%26aufirst%3DN.%26aulast%3DPriti%26aufirst%3DV.%26aulast%3DRamesha%26aufirst%3DB.%2BT.%26aulast%3DRavikanth%26aufirst%3DG.%26aulast%3DGaneshaiah%26aufirst%3DK.%2BN.%26aulast%3DVasudeva%26aufirst%3DR.%26aulast%3DMohan%26aufirst%3DJ.%26aulast%3DSanthoshkumar%26aufirst%3DT.%2BR.%26aulast%3DMishra%26aufirst%3DP.%2BD.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DUma%2BShaanker%26aufirst%3DR.%26atitle%3DDysoxylum%2520binectariferum%2520Hook.f%2520%2528Meliaceae%2529%252C%2520a%2520rich%2520source%2520of%2520rohitukine%26jtitle%3DFitoterapia%26date%3D2010%26volume%3D81%26spage%3D145%26epage%3D148%26doi%3D10.1016%2Fj.fitote.2009.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guru, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhushan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">A chromatography-free isolation of rohitukine from leaves of <i>Dysoxylum binectariferum</i>: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3457</span><span class="NLM_x">–</span> <span class="NLM_lpage">3463</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2016.06.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3457-3463&author=V.+Kumarauthor=S.+K.+Guruauthor=S.+K.+Jainauthor=P.+Joshiauthor=S.+G.+Gandhiauthor=S.+B.+Bharateauthor=S.+Bhushanauthor=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=A+chromatography-free+isolation+of+rohitukine+from+leaves+of+Dysoxylum+binectariferum%3A+Evaluation+for+in+vitro+cytotoxicity%2C+Cdk+inhibition+and+physicochemical+properties&doi=10.1016%2Fj.bmcl.2016.06.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DGuru%26aufirst%3DS.%2BK.%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DJoshi%26aufirst%3DP.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DBhushan%26aufirst%3DS.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DA%2520chromatography-free%2520isolation%2520of%2520rohitukine%2520from%2520leaves%2520of%2520Dysoxylum%2520binectariferum%253A%2520Evaluation%2520for%2520in%2520vitro%2520cytotoxicity%252C%2520Cdk%2520inhibition%2520and%2520physicochemical%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3457%26epage%3D3463%26doi%3D10.1016%2Fj.bmcl.2016.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Mahajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhardwaj, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khajuria, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedi, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, S. G.</span><span> </span><span class="NLM_article-title">Production of rohitukine in leaves and seeds of <i>Dysoxylum binectariferum</i>: an alternate renewable resource</span> <span class="citation_source-journal">Pharm. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.3109/13880209.2014.923006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3109%2F13880209.2014.923006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25472605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFCiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2015&pages=446-450&author=V.+Mahajanauthor=N.+Sharmaauthor=S.+Kumarauthor=V.+Bhardwajauthor=A.+Aliauthor=R.+K.+Khajuriaauthor=Y.+S.+Bediauthor=R.+A.+Vishwakarmaauthor=S.+G.+Gandhi&title=Production+of+rohitukine+in+leaves+and+seeds+of+Dysoxylum+binectariferum%3A+an+alternate+renewable+resource&doi=10.3109%2F13880209.2014.923006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Production of rohitukine in leaves and seeds of Dysoxylum binectariferum: An alternate renewable resource</span></div><div class="casAuthors">Mahajan, Vidushi; Sharma, Neha; Kumar, Sunil; Bhardwaj, Vikram; Ali, Asif; Khajuria, R. K.; Bedi, Y. S.; Vishwakarma, Ram A.; Gandhi, Sumit G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Biology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-450</span>CODEN:
                <span class="NLM_cas:coden">PHBIFC</span>;
        ISSN:<span class="NLM_cas:issn">1388-0209</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Rohitukine is an important precursor for the synthesis of potential anticancer drugs flavopiridol (Sanofi-Aventis) and P-276-00 (Piramal Healthcare Limited, Mumbai, India).  Trunk bark of Dysoxylum binectariferum (Roxb.) Hook. f. ex Bedd. (Meliaceae) is the widely used source for isolation of rohitukine.  However, removal of trunk bark threatens the survival of the tree.  The aim was to investigate the amt. of rohitukine accumulated in other tissues of D. binectariferum.  Materials and methods: Rohitukine std. was isolated from leaves of D. binectariferum.  Its purity was ascertained using HR-MS and NMR.  Crude exts. were prepd. from different tissues of D. binectariferum.  Rohitukine content in all the tissues was quantified by HPLC.  Rohitukine accumulates in a significant amt. in seeds, trunk bark, leaves, twigs, and fruits of D. binectariferum.  Seeds have the highest rohitukine content (2.42%, dry wt.) followed by trunk bark (1.34%, dry wt.), leaves (1.064%, dry wt.), twigs (0.844% dry wt.), and fruits (0.4559% dry wt.).  Discussion and conclusion: Seeds and leaves of D. binectariferum could be used as alternate renewable sources for isolation of rohitukine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobpkFXP3CHDLVg90H21EOLACvtfcHk0lhpb6_D7kEy7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFCiurc%253D&md5=bd502e873aa1802768c71ca03754c62b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3109%2F13880209.2014.923006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F13880209.2014.923006%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DV.%26aulast%3DSharma%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBhardwaj%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DKhajuria%26aufirst%3DR.%2BK.%26aulast%3DBedi%26aufirst%3DY.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DGandhi%26aufirst%3DS.%2BG.%26atitle%3DProduction%2520of%2520rohitukine%2520in%2520leaves%2520and%2520seeds%2520of%2520Dysoxylum%2520binectariferum%253A%2520an%2520alternate%2520renewable%2520resource%26jtitle%3DPharm.%2520Biol.%26date%3D2015%26volume%3D53%26spage%3D446%26epage%3D450%26doi%3D10.3109%2F13880209.2014.923006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyoshi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, Y.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing’s family tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1218</span><span class="refDoi"> DOI: 10.1002/ijc.22820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1002%2Fijc.22820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17520676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSmt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2007&pages=1212-1218&author=Y.+Liauthor=K.+Tanakaauthor=X.+Liauthor=T.+Okadaauthor=T.+Nakamuraauthor=M.+Takasakiauthor=S.+Yamamotoauthor=Y.+Odaauthor=M.+Tsuneyoshiauthor=Y.+Iwamoto&title=Cyclin-dependent+kinase+inhibitor%2C+flavopiridol%2C+induces+apoptosis+and+inhibits+tumor+growth+in+drug-resistant+osteosarcoma+and+Ewing%E2%80%99s+family+tumor+cells&doi=10.1002%2Fijc.22820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant Osteosarcoma and Ewing's family tumor cells</span></div><div class="casAuthors">Li, Yan; Tanaka, Kazuhiro; Li, Xu; Okada, Takamitsu; Nakamura, Tomoyuki; Takasaki, Minoru; Yamamoto, Shunsaku; Oda, Yoshinao; Tsuneyoshi, Masazumi; Iwamoto, Yukihide</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1212-1218</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Multimodal therapies play important roles in the treatment of osteosarcoma (OS) and Ewing's family of tumors (EFTs), two most frequent malignant bone tumors.  Although the clin. outcome of primary OS and EFTs is greatly improved, the relapsed cases often are assocd. with multidrug resistance of the tumors and the prognosis of these patients is still poor.  Flavopiridol, a pan cyclin-dependent kinase (CDK) inhibitor is a novel antitumor agent that can induce cell cycle arrest and apoptosis in many cancer cells.  However, there have been no studies about the effects of flavopiridol on drug-resistant OS and EFTs.  Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-assocd. protein 1 (MRP1) as effectively as in their parental cells.  Our data also showed that flavopiridol caused the release of mitochondrial cytochrome c and the activation of caspase-9, caspase-8 and caspase-3, with an increase ratio of the proapoptotic protein level (Bax) to the antiapoptotic protein level (Bcl-2 and Bcl-XL), while apoptosis was inhibited by pan caspase inhibitor (Z-VAD-FMK) and caspase-3 inhibitor (Z-DEVD-FMK), not by caspase-8 inhibitor (Z-IETD-FMK).  The treatment with flavopiridol further inhibited the tumor growth in mouse models of the drug-resistant OS and EFTs.  These results suggest that flavopiridol might be promising in clin. therapy for the relapsed OS and EFTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj6WI4ypRZh7Vg90H21EOLACvtfcHk0lhpb6_D7kEy7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSmt7fL&md5=19abe5cc41bf20c5466e574982ef54dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fijc.22820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22820%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DTakasaki%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DY.%26aulast%3DTsuneyoshi%26aufirst%3DM.%26aulast%3DIwamoto%26aufirst%3DY.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520flavopiridol%252C%2520induces%2520apoptosis%2520and%2520inhibits%2520tumor%2520growth%2520in%2520drug-resistant%2520osteosarcoma%2520and%2520Ewing%25E2%2580%2599s%2520family%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2007%26volume%3D121%26spage%3D1212%26epage%3D1218%26doi%3D10.1002%2Fijc.22820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Lanasa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrilove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligaris-Cappio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblond, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stilgenbauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span> </span><span class="NLM_article-title">Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.leukres.2015.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.leukres.2015.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25804339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=495-500&author=M.+C.+Lanasaauthor=L.+Andritsosauthor=J.+R.+Brownauthor=J.+Gabriloveauthor=F.+Caligaris-Cappioauthor=P.+Ghiaauthor=R.+A.+Larsonauthor=T.+J.+Kippsauthor=V.+Leblondauthor=D.+W.+Milliganauthor=A.+Janssensauthor=A.+J.+Johnsonauthor=N.+A.+Heeremaauthor=A.+Buhlerauthor=S.+Stilgenbauerauthor=J.+Devinauthor=M.+Hallekauthor=J.+C.+Byrdauthor=M.+R.+Grever&title=Final+results+of+EFC6663%3A+a+multicenter%2C+international%2C+phase+2+study+of+alvocidib+for+patients+with+fludarabine-refractory+chronic+lymphocytic+leukemia&doi=10.1016%2Fj.leukres.2015.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Lanasa, Mark C.; Andritsos, Leslie; Brown, Jennifer R.; Gabrilove, Janice; Caligaris-Cappio, Federico; Ghia, Paolo; Larson, Richard A.; Kipps, Thomas J.; Leblond, Veronique; Milligan, Donald W.; Janssens, Ann; Johnson, Amy J.; Heerema, Nyla A.; Buhler, Andreas; Stilgenbauer, Stephan; Devin, Jeanne; Hallek, Michael; Byrd, John C.; Grever, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-500</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine.  A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results.  Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib.  The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration.  One hundred and sixty five patients were enrolled and 159 patients were treated.  The median age was 61 years, the median no. of prior therapies was 4, and 96% of patients were fludarabine refractory.  The investigator-assessed overall response rate was 25%; the majority of responses were partial.  Response rates were lower among patients with del(17p) (14%), but equiv. in patients with del(11q) or bulky lymphadenopathy.  Median progression free and overall survival were 7.6 and 14.6 mo, resp.  Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis.  Diarrhea, fatigue, and hematol. toxicities were common.  Alvocidib has clin. activity in patients with advanced, fludarabine refractory CLL.  Future studies should focus on discovery of biomarkers of clin. response and tumor lysis, and enhanced supportive care measures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLlMqLBd2m7Vg90H21EOLACvtfcHk0ljG1GGXDNmktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFCis7c%253D&md5=3f3c902b0c772666192142ffd71d1c4f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DLanasa%26aufirst%3DM.%2BC.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DLeblond%26aufirst%3DV.%26aulast%3DMilligan%26aufirst%3DD.%2BW.%26aulast%3DJanssens%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DBuhler%26aufirst%3DA.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DHallek%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFinal%2520results%2520of%2520EFC6663%253A%2520a%2520multicenter%252C%2520international%252C%2520phase%25202%2520study%2520of%2520alvocidib%2520for%2520patients%2520with%2520fludarabine-refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D495%26epage%3D500%26doi%3D10.1016%2Fj.leukres.2015.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruppert, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalona-Calero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span> </span><span class="NLM_article-title">Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6012</span><span class="NLM_x">–</span> <span class="NLM_lpage">6018</span><span class="refDoi"> DOI: 10.1200/JCO.2009.22.6944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1200%2FJCO.2009.22.6944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=19826119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6012-6018&author=T.+S.+Linauthor=A.+S.+Ruppertauthor=A.+J.+Johnsonauthor=B.+Fischerauthor=N.+A.+Heeremaauthor=L.+A.+Andritsosauthor=K.+A.+Blumauthor=J.+M.+Flynnauthor=J.+A.+Jonesauthor=W.+Huauthor=M.+E.+Moranauthor=S.+M.+Mitchellauthor=L.+L.+Smithauthor=A.+J.+Wagnerauthor=C.+A.+Raymondauthor=L.+J.+Schaafauthor=M.+A.+Phelpsauthor=M.+A.+Villalona-Caleroauthor=M.+R.+Greverauthor=J.+C.+Byrd&title=Phase+II+study+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia+demonstrating+high+response+rates+in+genetically+high-risk+disease&doi=10.1200%2FJCO.2009.22.6944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease</span></div><div class="casAuthors">Lin, Thomas S.; Ruppert, Amy S.; Johnson, Amy J.; Fischer, Beth; Heerema, Nyla A.; Andritsos, Leslie A.; Blum, Kristie A.; Flynn, Joseph M.; Jones, Jeffrey A.; Hu, Weihong; Moran, Mollie E.; Mitchell, Sarah M.; Smith, Lisa L.; Wagner, Amy J.; Raymond, Chelsey A.; Schaaf, Larry J.; Phelps, Mitch A.; Villalona-Calero, Miguel A.; Grever, Michael R.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6012-6018</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies.  A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irresp. of high-risk features.  Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated.  Patients and Methods: Patients with relapsed CLL were treated with single-agent flavopiridol, with subsequent addn. of dexamethasone to suppress cytokine release syndrome (CRS).  High-risk genomic features were prospectively assessed for response to therapy.  Results: Sixty-four patients were enrolled.  Median age was 60 years, median no. of prior therapies was four, and all patients had received prior purine analog therapy.  If patients tolerated treatment during week 1, dose escalation occurred during week 2.  Dose escalation did not occur in four patients, as a result of severe tumor lysis syndrome; three of these patients required hemodialysis.  Thirty-four patients (53%) achieved response, including 30 partial responses (PRs; 47%), three nodular PRs (5%), and one complete response (1.6%).  A majority of high-risk patients responded; 12 (57%) of 21 patients with del(17p13.1) and 14 (50%) of 28 patients with del(11q22.3) responded irresp. of lymph node size.  Median progression-free survival among responders was 10 to 12 mo across all cytogenetic risk groups.  Reducing the no. of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P ≤ .01), resulted in improved tolerability and treatment delivery.  Conclusion: Flavopiridol achieves significant clin. activity in patients with relapsed CLL, including those with high-risk genomic features and bulky lymphadenopathy.  Subsequent clin. trials should use the amended treatment schedule developed herein and prophylactic corticosteroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8rg3AnSwf4rVg90H21EOLACvtfcHk0ljG1GGXDNmktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWisLs%253D&md5=5068ee1b36a882f0609ae5f89f6efe4f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.6944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.6944%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DAndritsos%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFlynn%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DSmith%26aufirst%3DL.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DRaymond%26aufirst%3DC.%2BA.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DVillalona-Calero%26aufirst%3DM.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DPhase%2520II%2520study%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%2520demonstrating%2520high%2520response%2520rates%2520in%2520genetically%2520high-risk%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6012%26epage%3D6018%26doi%3D10.1200%2FJCO.2009.22.6944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozewski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarjoura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span><span class="refDoi"> DOI: 10.1182/blood-2008-07-168583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1182%2Fblood-2008-07-168583" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=2637-2645&author=M.+A.+Phelpsauthor=T.+S.+Linauthor=A.+J.+Johnsonauthor=E.+Hurhauthor=D.+M.+Rozewskiauthor=K.+L.+Farleyauthor=D.+Wuauthor=K.+A.+Blumauthor=B.+Fischerauthor=S.+M.+Mitchellauthor=M.+E.+Moranauthor=M.+Brooker-McEldowneyauthor=N.+A.+Heeremaauthor=D.+Jarjouraauthor=L.+J.+Schaafauthor=J.+C.+Byrdauthor=M.+R.+Greverauthor=J.+T.+Dalton&title=Clinical+response+and+pharmacokinetics+from+a+phase+1+study+of+an+active+dosing+schedule+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1182%2Fblood-2008-07-168583"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-168583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-168583%26sid%3Dliteratum%253Aachs%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHurh%26aufirst%3DE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DFarley%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520response%2520and%2520pharmacokinetics%2520from%2520a%2520phase%25201%2520study%2520of%2520an%2520active%2520dosing%2520schedule%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D2637%26epage%3D2645%26doi%3D10.1182%2Fblood-2008-07-168583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Zeidner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litzow, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gocke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosner, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Little, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7 + 3) in newly diagnosed acute myeloid leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">–</span> <span class="NLM_lpage">1179</span><span class="refDoi"> DOI: 10.3324/haematol.2015.125849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3324%2Fhaematol.2015.125849" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1172-1179&author=J.+Zeidnerauthor=M.+Fosterauthor=A.+Blackfordauthor=M.+R.+Litzowauthor=L.+E.+Morrisauthor=S.+A.+Stricklandauthor=J.+E.+Lancetauthor=P.+Boseauthor=M.+Y.+Levyauthor=R.+Tibesauthor=I.+Gojoauthor=C.+D.+Gockeauthor=G.+L.+Rosnerauthor=R.+F.+Littleauthor=J.+J.+Wrightauthor=L.+A.+Doyleauthor=B.+D.+Smithauthor=J.+E.+Karp&title=Randomized+multicenter+phase+II+study+of+flavopiridol+%28alvocidib%29%2C+cytarabine%2C+and+mitoxantrone+%28FLAM%29+versus+cytarabine%2Fdaunorubicin+%287+%2B+3%29+in+newly+diagnosed+acute+myeloid+leukemia&doi=10.3324%2Fhaematol.2015.125849"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2015.125849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2015.125849%26sid%3Dliteratum%253Aachs%26aulast%3DZeidner%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DM.%26aulast%3DBlackford%26aufirst%3DA.%26aulast%3DLitzow%26aufirst%3DM.%2BR.%26aulast%3DMorris%26aufirst%3DL.%2BE.%26aulast%3DStrickland%26aufirst%3DS.%2BA.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DBose%26aufirst%3DP.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DGocke%26aufirst%3DC.%2BD.%26aulast%3DRosner%26aufirst%3DG.%2BL.%26aulast%3DLittle%26aufirst%3DR.%2BF.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DRandomized%2520multicenter%2520phase%2520II%2520study%2520of%2520flavopiridol%2520%2528alvocidib%2529%252C%2520cytarabine%252C%2520and%2520mitoxantrone%2520%2528FLAM%2529%2520versus%2520cytarabine%252Fdaunorubicin%2520%25287%2520%252B%25203%2529%2520in%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1172%26epage%3D1179%26doi%3D10.3324%2Fhaematol.2015.125849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drye, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorcy, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carraway, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladstone, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Othus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagel, J. M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1742</span><span class="refDoi"> DOI: 10.3324/haematol.2012.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.3324%2Fhaematol.2012.062539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=1736-1742&author=J.+E.+Karpauthor=E.+Garrett-Mayerauthor=E.+H.+Esteyauthor=M.+A.+Rudekauthor=B.+D.+Smithauthor=J.+M.+Greerauthor=D.+M.+Dryeauthor=K.+Mackeyauthor=K.+S.+Dorcyauthor=S.+D.+Goreauthor=M.+J.+Levisauthor=M.+A.+McDevittauthor=H.+E.+Carrawayauthor=K.+W.+Pratzauthor=D.+E.+Gladstoneauthor=M.+M.+Showelauthor=M.+Othusauthor=L.+A.+Doyleauthor=J.+J.+Wrightauthor=J.+M.+Pagel&title=Randomized+phase+II+study+of+two+schedules+of+flavopiridol+given+as+timed+sequential+therapy+with+cytosine+arabinoside+and+mitoxantrone+for+adults+with+newly+diagnosed%2C+poor-risk+acute+myelogenous+leukemia&doi=10.3324%2Fhaematol.2012.062539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2012.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2012.062539%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DDrye%26aufirst%3DD.%2BM.%26aulast%3DMackey%26aufirst%3DK.%26aulast%3DDorcy%26aufirst%3DK.%2BS.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DMcDevitt%26aufirst%3DM.%2BA.%26aulast%3DCarraway%26aufirst%3DH.%2BE.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DGladstone%26aufirst%3DD.%2BE.%26aulast%3DShowel%26aufirst%3DM.%2BM.%26aulast%3DOthus%26aufirst%3DM.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520two%2520schedules%2520of%2520flavopiridol%2520given%2520as%2520timed%2520sequential%2520therapy%2520with%2520cytosine%2520arabinoside%2520and%2520mitoxantrone%2520for%2520adults%2520with%2520newly%2520diagnosed%252C%2520poor-risk%2520acute%2520myelogenous%2520leukemia%26jtitle%3DHaematologica%26date%3D2012%26volume%3D97%26spage%3D1736%26epage%3D1742%26doi%3D10.3324%2Fhaematol.2012.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zeidner, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1312</span><span class="NLM_x">–</span> <span class="NLM_lpage">1318</span><span class="refDoi"> DOI: 10.1016/j.leukres.2015.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.leukres.2015.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=26521988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKgs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=1312-1318&author=J.+F.+Zeidnerauthor=J.+E.+Karp&title=Clinical+activity+of+alvocidib+%28flavopiridol%29+in+acute+myeloid+leukemia&doi=10.1016%2Fj.leukres.2015.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia</span></div><div class="casAuthors">Zeidner, Joshua F.; Karp, Judith E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1312-1318</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory.  Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clin. activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone).  FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, resp., with encouraging findings in both patient populations warranting further investigation.  This review highlights the mechanism of action of alvocidib, pre-clin. studies of alvocidib in AML, and the clin. trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsjt81Z_94g7Vg90H21EOLACvtfcHk0liXUcIi0FwcTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKgs77N&md5=fc79799812a30d42a31f647f98445b95</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DZeidner%26aufirst%3DJ.%2BF.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DClinical%2520activity%2520of%2520alvocidib%2520%2528flavopiridol%2529%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D1312%26epage%3D1318%26doi%3D10.1016%2Fj.leukres.2015.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Wiernik, P. H.</span><span> </span><span class="NLM_article-title">Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span><span class="refDoi"> DOI: 10.1517/13543784.2016.1169273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1517%2F13543784.2016.1169273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=729-734&author=P.+H.+Wiernik&title=Alvocidib+%28flavopiridol%29+for+the+treatment+of+chronic+lymphocytic+leukemia&doi=10.1517%2F13543784.2016.1169273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F13543784.2016.1169273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2016.1169273%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DAlvocidib%2520%2528flavopiridol%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D729%26epage%3D734%26doi%3D10.1517%2F13543784.2016.1169273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Shirsath, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">P276–00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="refDoi"> DOI: 10.1186/1476-4598-11-77</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1186%2F1476-4598-11-77" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=23075291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVeitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=77&author=N.+P.+Shirsathauthor=S.+M.+Manoharauthor=K.+S.+Joshi&title=P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+modulates+cell+cycle+and+induces+apoptosis+in+vitro+and+in+vivo+in+mantle+cell+lymphoma+cell+lines&doi=10.1186%2F1476-4598-11-77"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines</span></div><div class="casAuthors">Shirsath, Nitesh P.; Manohar, Sonal M.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mantle cell lymphoma (MCL) is a well-defined aggressive lymphoid neoplasm characterized by proliferation of mature B-lymphocytes that have a remarkable tendency to disseminate.  This tumor is considered as one of the most aggressive lymphoid neoplasms with poor responses to conventional chemotherapy and relatively short survival.  Since cyclin D1 and cell cycle control appears as a natural target, small-mol. inhibitors of cyclin-dependent kinases (Cdks) and cyclins may play important role in the therapy of this disorder.  We explored P276-00, a novel selective potent Cdk4-D1, Cdk1-B and Cdk9-T1 inhibitor discovered by us against MCL and elucidated its potential mechanism of action.  Methods: The cytotoxic effect of P276-00 in three human MCL cell lines was evaluated in vitro.  The effect of P276-00 on the regulation of cell cycle, apoptosis and transcription was assessed, which are implied in the pathogenesis of MCL.  Flow cytometry, western blot, immunoflourescence and siRNA studies were performed.  The in vivo efficacy and effect on survival of P276-00 was evaluated in a Jeko-1 xenograft model developed in SCID mice.  PK/PD anal. of tumors were performed using LC-MS and western blot anal.  Results: P276-00 showed a potent cytotoxic effect against MCL cell lines.  Mechanistic studies confirmed down regulation of cell cycle regulatory proteins with apoptosis.  P276-00 causes time and dose dependent increase in the sub G1 population as early as from 24 h.  Reverse transcription PCR studies provide evidence that P276-00 treatment down regulated transcription of antiapoptotic protein Mcl-1 which is a potential pathogenic protein for MCL.  Most importantly, in vivo studies have revealed significant efficacy as a single agent with increased survival period compared to vehicle treated.  Further, preliminary combination studies of P276-00 with doxorubicin and bortezomib showed in vitro synergism.  Conclusion: Our studies thus provide evidence and rational that P276-00 alone or in combination is a potential therapeutic mol. to improve patients' outcome in mantle cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6o4aP0rgOLVg90H21EOLACvtfcHk0lhcupR-Pdy6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVeitL8%253D&md5=d9fb611081f55e30556484dec7d0994b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-11-77&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-11-77%26sid%3Dliteratum%253Aachs%26aulast%3DShirsath%26aufirst%3DN.%2BP.%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520modulates%2520cell%2520cycle%2520and%2520induces%2520apoptosis%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520mantle%2520cell%2520lymphoma%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%26date%3D2012%26volume%3D11%26spage%3D77%26doi%3D10.1186%2F1476-4598-11-77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.+H.+Fiebigauthor=S.+Sharma&title=P276%E2%80%9300%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models&doi=10.1158%2F1535-7163.MCT-06-0614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0lhcupR-Pdy6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934%26doi%3D10.1158%2F1535-7163.MCT-06-0614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300&doi=10.1158%2F1535-7163.MCT-06-0613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0lhcupR-Pdy6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D918%26epage%3D925%26doi%3D10.1158%2F1535-7163.MCT-06-0613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanwalkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276–00 in pancreatic cancers</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="refDoi"> DOI: 10.1186/1479-5876-10-161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1186%2F1479-5876-10-161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22873289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVShsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=161&author=M.+J.+Rathosauthor=K.+Joshiauthor=H.+Khanwalkarauthor=S.+M.+Manoharauthor=K.+S.+Joshi&title=Molecular+evidence+for+increased+antitumor+activity+of+gemcitabine+in+combination+with+a+cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300+in+pancreatic+cancers&doi=10.1186%2F1479-5876-10-161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers</span></div><div class="casAuthors">Rathos, Maggie J.; Joshi, Kavita; Khanwalkar, Harshal; Manohar, Sonal M.; Joshi, Kalpana S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clin. trials.  Gemcitabine is a std. of care for the treatment of pancreatic cancer.  The present study investigated the effect of the combination of P276-00 and gemcitabine in five pancreatic cancer cell lines.  Methods: Cytotoxic activity was evaluated by Propidium Iodide assay.  Cell cycle and apoptosis was analyzed by flow cytometry.  Genes and proteins known to inhibit apoptosis and contribute to chemoresistance were analyzed using western blot anal. and RT-PCR.  In vivo efficacy was studied in PANC-1 xenograft model.  Results: The combination of gemcitabine followed by P276-00 was found to be highly to weakly synergistic in various pancreatic cancer cell lines as assessed by the combination index.  Enhancement of apoptosis in PANC-1 cells and decrease in the antiapoptotic protein Bcl-2 and survivin was seen.  P276-00 potentiated the gemcitabine-induced cytotoxicity by modulation of proteins involved in chemoresistance to gemcitabine and cell cycle viz. antiapoptotic proteins p8 and cox-2, proapoptotic protein BNIP3 and cell cycle related proteins Cdk4 and cyclin D1.  The above results could explain the novel mechanisms of action of the combination therapy.  We also show here that gemcitabine in combination with P276-00 is much more effective as an antitumor agent compared with either agent alone in the PANC-1 xenograft tumor model in SCID mice.  Conclusions: The chemosensitzation of pancreatic tumors to gemcitabine would likely be an important and novel strategy for treatment of pancreatic cancer and enable the use of lower and safer concns., to pave the way for a more effective treatment in this devastating disease.  Phase IIb clin. trials of P276-00 in combination with gemcitabine in pancreatic cancer patients are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgjY9v9dHnkLVg90H21EOLACvtfcHk0lgWo7UAUti8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVShsr%252FN&md5=d15dd412f77d6af51cf3022d54b89cf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-10-161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-10-161%26sid%3Dliteratum%253Aachs%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DKhanwalkar%26aufirst%3DH.%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DMolecular%2520evidence%2520for%2520increased%2520antitumor%2520activity%2520of%2520gemcitabine%2520in%2520combination%2520with%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%2520in%2520pancreatic%2520cancers%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2012%26volume%3D10%26spage%3D161%26doi%3D10.1186%2F1479-5876-10-161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Manohar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padgaonkar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalota-Badhwar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, K. S.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitor, P276–00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells</span> <span class="citation_source-journal">Prostate Cancer Prostatic Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1038/pcan.2011.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fpcan.2011.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22083267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlKhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=15-27&author=S.+M.+Manoharauthor=A.+A.+Padgaonkarauthor=A.+Jalota-Badhwarauthor=S.+V.+Raoauthor=K.+S.+Joshi&title=Cyclin-dependent+kinase+inhibitor%2C+P276%E2%80%9300%2C+inhibits+HIF-1%CE%B1+and+induces+G2%2FM+arrest+under+hypoxia+in+prostate+cancer+cells&doi=10.1038%2Fpcan.2011.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells</span></div><div class="casAuthors">Manohar, S. M.; Padgaonkar, A. A.; Jalota-Badhwar, A.; Rao, S. V.; Joshi, K. S.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate Cancer and Prostatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">PCPDFW</span>;
        ISSN:<span class="NLM_cas:issn">1365-7852</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Hypoxia-inducible factor-1 (HIF-1) is a master regulator of the transcriptional response to oxygen deprivation and controls genes involved in glycolysis, angiogenesis, migration and invasion.  Overexpression of HIF-1α has been demonstrated in many common human cancers.  Methods: Luciferase reporter gene assay under hypoxia and normoxia was used to demonstrate transcriptional inhibition of HIF-1 by P276-00.  Detailed studies such as western blotting, reverse-transcriptase-PCR and immunofluorescence were carried out to elucidate its mechanism of action.  Cytotoxic potential of P276-00 under normoxia and hypoxia was detd. on prostate cancer cells using CCK-8 assay, and cell-cycle anal. was carried out using flow cytometry.  Antiangiogenic activity of P276-00 was demonstrated by migration assay and tube-formation assay.  Efficacy study of P276-00 was performed in a PC-3 xenograft model.  Results: P276-00 inhibits transcriptional activation of HIF-1 under hypoxia.  It suppressed hypoxia-mediated nuclear HIF-1α expression, as well as phosphorylation of Akt and 4E-BP1 and abrogated expression of HIF-1-inducible gene viz. vascular endothelial growth factor.  Under hypoxia, P276-00 did not exhibit enhanced cytotoxic activity in prostate cancer cells but arrested them in the G2/M phase of the cell cycle.  The tubular formation of human umbilical vein endothelial cells and migration of prostate cancer cells were also inhibited by P276-00 in vitro.  In addn., it demonstrated significant in vivo efficacy in the PC-3 xenograft model.  Conclusions: Given its low toxicity profile, its demonstrated antitumor activity and its potential to inhibit the HIF-1 pathway, P276-00 should be considered as antiangiogenic chemotherapy for prostate cancer.  Prostate Cancer and Prostatic Diseases (2012) 15, 15-27; doi:10.1038/pcan.2011.51; published online 15 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbySLd0vaYPbVg90H21EOLACvtfcHk0lgWo7UAUti8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlKhsbg%253D&md5=cd2498cc0a8c39b336deebe12beab925</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fpcan.2011.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fpcan.2011.51%26sid%3Dliteratum%253Aachs%26aulast%3DManohar%26aufirst%3DS.%2BM.%26aulast%3DPadgaonkar%26aufirst%3DA.%2BA.%26aulast%3DJalota-Badhwar%26aufirst%3DA.%26aulast%3DRao%26aufirst%3DS.%2BV.%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitor%252C%2520P276%25E2%2580%259300%252C%2520inhibits%2520HIF-1%25CE%25B1%2520and%2520induces%2520G2%252FM%2520arrest%2520under%2520hypoxia%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DProstate%2520Cancer%2520Prostatic%2520Dis.%26date%3D2012%26volume%3D15%26spage%3D15%26epage%3D27%26doi%3D10.1038%2Fpcan.2011.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Raje, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chhetri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirstea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pozzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrasco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scadden, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span> </span><span class="NLM_article-title">Preclinical activity of P276–00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1038/leu.2008.378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fleu.2008.378" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=961-970&author=N.+Rajeauthor=T.+Hideshimaauthor=S.+Mukherjeeauthor=M.+Raabauthor=S.+Valletauthor=S.+Chhetriauthor=D.+Cirsteaauthor=S.+Pozziauthor=C.+Mitsiadesauthor=M.+Rooneyauthor=T.+Kiziltepeauthor=K.+Podarauthor=Y.+Okawaauthor=H.+Ikedaauthor=R.+Carrascoauthor=P.+G.+Richardsonauthor=D.+Chauhanauthor=N.+C.+Munshiauthor=S.+Sharmaauthor=H.+Parikhauthor=B.+Chabnerauthor=D.+Scaddenauthor=K.+C.+Anderson&title=Preclinical+activity+of+P276%E2%80%9300%2C+a+novel+small-molecule+cyclin-dependent+kinase+inhibitor+in+the+therapy+of+multiple+myeloma&doi=10.1038%2Fleu.2008.378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.378%26sid%3Dliteratum%253Aachs%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DM.%26aulast%3DVallet%26aufirst%3DS.%26aulast%3DChhetri%26aufirst%3DS.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DPozzi%26aufirst%3DS.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DRooney%26aufirst%3DM.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DPodar%26aufirst%3DK.%26aulast%3DOkawa%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DMunshi%26aufirst%3DN.%2BC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DParikh%26aufirst%3DH.%26aulast%3DChabner%26aufirst%3DB.%26aulast%3DScadden%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPreclinical%2520activity%2520of%2520P276%25E2%2580%259300%252C%2520a%2520novel%2520small-molecule%2520cyclin-dependent%2520kinase%2520inhibitor%2520in%2520the%2520therapy%2520of%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D961%26epage%3D970%26doi%3D10.1038%2Fleu.2008.378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Cassaday, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chawla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nachankar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopal, A. K.</span><span> </span><span class="NLM_article-title">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276–00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span> <span class="citation_source-journal">Clin. Lymphoma Myeloma Leuk.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span><span class="refDoi"> DOI: 10.1016/j.clml.2015.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.clml.2015.02.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25816934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=392-397&author=R.+D.+Cassadayauthor=A.+Goyauthor=S.+Advaniauthor=P.+Chawlaauthor=R.+Nachankarauthor=M.+Gandhiauthor=A.+K.+Gopal&title=A+phase+II%2C+single-arm%2C+open-label%2C+multicenter+study+to+evaluate+the+efficacy+and+safety+of+P276%E2%80%9300%2C+a+cyclin-dependent+kinase+inhibitor%2C+in+patients+with+relapsed+or+refractory+mantle+cell+lymphoma&doi=10.1016%2Fj.clml.2015.02.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma</span></div><div class="casAuthors">Cassaday Ryan D; Goy Andre; Advani Suresh; Chawla Purvi; Nachankar Rajesh; Gandhi Mansi; Gopal Ajay K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">392-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Overexpression of cyclin D1 is a hallmark feature of mantle cell lymphoma (MCL).  Many of the oncogenic effects of cyclin D1 are mediated through cyclin-dependent kinases (CDKs).  P276-00 is a potent small molecule inhibitor of CDK4-D1, CDK1-B, and CDK9-T, with promising activity in preclinical models.  In phase I studies of P276-00 in patients with refractory solid neoplasms, it was well-tolerated with a mild trend toward single-agent efficacy.  PATIENTS AND METHODS:  A phase II study of P276-00 was conducted in patients with relapsed or refractory MCL at the recommended dose of 185 mg/m(2)/day from days 1 to 5 of a 21-day cycle.  Thirteen patients were enrolled in the present study.  RESULTS:  Of the 13 patients, 11 experienced disease progression, 1 patient was withdrawn because of an adverse event (AE), and 1 patient died.  Also, 11 patients (84.6%) experienced a treatment-emergent AE deemed related to P276-00.  Of the 13 patients, 9 (69.2%) received ≥ 2 cycles of treatment, which was the predefined threshold to be evaluable for efficacy.  Treatment was discontinued early in 2 patients because of AEs (1 of which was attributed to P276-00 administration) and in 2 patients because of disease progression.  Finally, 2 patients experienced stable disease for an estimated median duration of 60.5 days (range, 58-63 days).  The estimated median time to progression for the predefined efficacy population was 43 days (range, 38-58 days).  CONCLUSION:  Given the results observed in the present study, if evaluation of CDK inhibition in MCL continues, it should be considered earlier in the disease course or as a part of combination strategies for relapsed or refractory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9BvQqGeRc9p6KlWarZTAzfW6udTcc2eb6EWOSR9u2vLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnos1Wlsw%253D%253D&md5=b1062faa6262674828e4338d26e66e00</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2015.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2015.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DCassaday%26aufirst%3DR.%2BD.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DS.%26aulast%3DChawla%26aufirst%3DP.%26aulast%3DNachankar%26aufirst%3DR.%26aulast%3DGandhi%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DA.%2BK.%26atitle%3DA%2520phase%2520II%252C%2520single-arm%252C%2520open-label%252C%2520multicenter%2520study%2520to%2520evaluate%2520the%2520efficacy%2520and%2520safety%2520of%2520P276%25E2%2580%259300%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%2520Leuk.%26date%3D2015%26volume%3D15%26spage%3D392%26epage%3D397%26doi%3D10.1016%2Fj.clml.2015.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Vishwakarma, R. A.; Bharate, S. B.; Bhushan, S.; Mondhe, D. M.; Jain, S. K.; Meena, S.; Guru, S. K.; Pathania, A. S.; Kumar, S.; Behl, A.; Mintoo, M. J.; Bharate, S. S.; Joshi, P.</span><span> </span><span class="NLM_article-title">Rohitukine Analogs as Cyclin-dependent Kinase Inhibitors and a Process for the Preparation Thereof</span>. WO2014170914A1, US20160052915, EP2986605, CA2908084, IN2013DE01142, October 23,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+A.+Vishwakarma&author=S.+B.+Bharate&author=S.+Bhushan&author=D.+M.+Mondhe&author=S.+K.+Jain&author=S.+Meena&author=S.+K.+Guru&author=A.+S.+Pathania&author=S.+Kumar&author=A.+Behl&author=M.+J.+Mintoo&author=S.+S.+Bharate&author=P.+Joshi&title=Rohitukine+Analogs+as+Cyclin-dependent+Kinase+Inhibitors+and+a+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DRohitukine%2520Analogs%2520as%2520Cyclin-dependent%2520Kinase%2520Inhibitors%2520and%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Huwe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannis, A.</span><span> </span><span class="NLM_article-title">Small molecules as inhibitors of cyclin-dependent kinases</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2122</span><span class="NLM_x">–</span> <span class="NLM_lpage">2138</span><span class="refDoi"> DOI: 10.1002/anie.200200540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1002%2Fanie.200200540" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2122-2138&author=A.+Huweauthor=R.+Mazitschekauthor=A.+Giannis&title=Small+molecules+as+inhibitors+of+cyclin-dependent+kinases&doi=10.1002%2Fanie.200200540"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200540%26sid%3Dliteratum%253Aachs%26aulast%3DHuwe%26aufirst%3DA.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DGiannis%26aufirst%3DA.%26atitle%3DSmall%2520molecules%2520as%2520inhibitors%2520of%2520cyclin-dependent%2520kinases%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2122%26epage%3D2138%26doi%3D10.1002%2Fanie.200200540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lolli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span><span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+%C3%89.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0lhPWr15MA0WBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibition by flavoalkaloids</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">632</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.2174/138955712800626683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2174%2F138955712800626683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=22512551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCkurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=632-649&author=S.+K.+Jainauthor=S.+B.+Bharateauthor=R.+A.+Vishwakarma&title=Cyclin-dependent+kinase+inhibition+by+flavoalkaloids&doi=10.2174%2F138955712800626683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibition by flavoalkaloids</span></div><div class="casAuthors">Jain, S. K.; Bharate, S. B.; Vishwakarma, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">632-649</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chromone alkaloids and flavoalkaloids are an important group of natural products possessing promising medicinal properties.  A chromone alkaloid rohitukine is a major bioactive chem. constituent of plant Dysoxylum binectariferum (Meliaceae) which is phylogenetically related to the Ayurvedic plant, D. malabaricum used for treatment of rheumatoid arthritis.  This chromone alkaloid led to discovery of 2 synthetic flavoalkaloids: flavopiridol (Sanofi) and P-276-00 (Piramal) which have reached to advanced stages of clin. development for cancer treatment.  Flavopiridol (Alvocidib; L868275; HMR-1275; NSC 649890 of Sanofi-Aventis + NCI) is approved as an orphan drug for treatment of chronic lymphocytic leukemia and is currently undergoing phase II studies as monotherapy and also as in combination regimes with traditional chemotherapy agents.  P-276-00 (12) is currently in phase II clin. studies for advanced refractory neoplasms and multiple myeloma.  Extensive amt. of medicinal chem. efforts were reported on these flavoalkaloids.  Flavopiridol demonstrated potent and specific in vitro inhibition of variety of cyclin-dependent kinases with clear block in cell cycle progression at the G1/S and G2/M phases.  Preclin. studies demonstrated the capacity of flavopiridol to induce programmed cell death, promote differentiation, inhibit angiogenic processes and modulate transcriptional events.  The co-crystd. structure of deschloro-flavopiridol with CDK-2 is available and key interactions in the ATP binding site were reported.  Flavopiridol was also studied for the treatment of arthritis and atherosclerotic plaque formation.  The present review comprises discovery, medicinal chem., pharmacol. and preclin./clin. development of flavoalkaloids as CDK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDQdAK15QBLLVg90H21EOLACvtfcHk0lhR5WxZWxdgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCkurs%253D&md5=98702838814112f01f0f7585d9e6e994</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F138955712800626683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712800626683%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DCyclin-dependent%2520kinase%2520inhibition%2520by%2520flavoalkaloids%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D632%26epage%3D649%26doi%3D10.2174%2F138955712800626683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">De Azevedo, W. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller-Dieckmann, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span> </span><span class="NLM_article-title">Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1073/pnas.93.7.2735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1073%2Fpnas.93.7.2735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=8610110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADyaK28XitVCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=2735-2740&author=W.+F.+De+Azevedoauthor=H.+J.+Mueller-Dieckmannauthor=U.+Schulze-Gahmenauthor=P.+J.+Worlandauthor=E.+Sausvilleauthor=S.+H.+Kim&title=Structural+basis+for+specificity+and+potency+of+a+flavonoid+inhibitor+of+human+CDK2%2C+a+cell+cycle+kinase&doi=10.1073%2Fpnas.93.7.2735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase</span></div><div class="casAuthors">de Azevedo, Walter Filgueira, Jr.; Mueller-Dieckmann, Hans-Joachim; Schulze-Gahmen, Ursula; Worland, Peter J.; Sausville, Edward; Kim, Sung-Hou</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2735-40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The central role of cyclin-dependent kinases (CDKs) in cell cycle regulation makes them a promising target for study inhibitory mols. that can modify the degree of cell proliferation.  The discovery of specific inhibitors of CDKs such as polyhydroxylated flavones has opened the way to investigation and design of antimitotic compds.  A novel flavone, (-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride hemihydrate (L868276), is a potent inhibitor of CDKs.  A chlorinated form, flavopiridol, is currently in phase I clin. trials as a drug against breast tumors.  The authors detd. the crystal structure of a complex between CDK2 and L868276 at 2.33-Å resoln. and refined to an Rfactor of 20.3%.  The arom. portion of the inhibitor binds to the adenine-binding pocket of CDK2, and the position of the Ph group of the inhibitor enables the inhibitor to make contacts with the enzyme not obsd. in the ATP complex structure.  The anal. of the position of this Ph ring not only explains the great differences of kinase inhibition among the flavonoid inhibitors but also explains the specificity of L868276 to inhibit CDK2 and CDC2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgo__S6absqbVg90H21EOLACvtfcHk0lhR5WxZWxdgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVCisLs%253D&md5=8f499ae6716cdf8f70f15d5907a69b1b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.7.2735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.7.2735%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BAzevedo%26aufirst%3DW.%2BF.%26aulast%3DMueller-Dieckmann%26aufirst%3DH.%2BJ.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26aulast%3DSausville%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26atitle%3DStructural%2520basis%2520for%2520specificity%2520and%2520potency%2520of%2520a%2520flavonoid%2520inhibitor%2520of%2520human%2520CDK2%252C%2520a%2520cell%2520cycle%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D2735%26epage%3D2740%26doi%3D10.1073%2Fpnas.93.7.2735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4126</span><span class="NLM_x">–</span> <span class="NLM_lpage">4134</span><span class="refDoi"> DOI: 10.1021/jm000231g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000231g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4126-4134&author=K.+S.+Kimauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=L.+Qianauthor=S.+T.+Chaoauthor=L.+Leithauthor=Y.+F.+Kellyauthor=R.+N.+Misraauthor=J.+T.+Huntauthor=S.+D.+Kimballauthor=W.+G.+Humphreysauthor=B.+S.+Wautletauthor=J.+G.+Mulheronauthor=K.+R.+Webster&title=Thio-+and+oxoflavopiridols%2C+cyclin-dependent+kinase+1-selective+inhibitors%3A+synthesis+and+biological+effects&doi=10.1021%2Fjm000231g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm000231g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000231g%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%2BT.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DY.%2BF.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DThio-%2520and%2520oxoflavopiridols%252C%2520cyclin-dependent%2520kinase%25201-selective%2520inhibitors%253A%2520synthesis%2520and%2520biological%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4126%26epage%3D4134%26doi%3D10.1021%2Fjm000231g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Murthi, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brizuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisclair, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansuri, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, K.</span><span> </span><span class="NLM_article-title">Structure-activity relationship studies of flavopiridol analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1037</span><span class="NLM_x">–</span> <span class="NLM_lpage">1041</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00156-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2FS0960-894X%2800%2900156-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=1037-1041&author=K.+K.+Murthiauthor=M.+Dubayauthor=C.+McClureauthor=L.+Brizuelaauthor=M.+D.+Boisclairauthor=P.+J.+Worlandauthor=M.+M.+Mansuriauthor=K.+Pal&title=Structure-activity+relationship+studies+of+flavopiridol+analogues&doi=10.1016%2FS0960-894X%2800%2900156-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900156-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900156-6%26sid%3Dliteratum%253Aachs%26aulast%3DMurthi%26aufirst%3DK.%2BK.%26aulast%3DDubay%26aufirst%3DM.%26aulast%3DMcClure%26aufirst%3DC.%26aulast%3DBrizuela%26aufirst%3DL.%26aulast%3DBoisclair%26aufirst%3DM.%2BD.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26aulast%3DMansuri%26aufirst%3DM.%2BM.%26aulast%3DPal%26aufirst%3DK.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520flavopiridol%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D1037%26epage%3D1041%26doi%3D10.1016%2FS0960-894X%2800%2900156-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Schoepfer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhuri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1741</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1021/jm0108348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0108348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1Ojt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1741-1747&author=J.+Schoepferauthor=H.+Fretzauthor=B.+Chaudhuriauthor=L.+Mullerauthor=E.+Seeberauthor=L.+Meijerauthor=O.+Lozachauthor=E.+Vangrevelingheauthor=P.+Furet&title=Structure-based+design+and+synthesis+of+2-benzylidene-benzofuran-3-ones+as+flavopiridol+mimics&doi=10.1021%2Fjm0108348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of 2-Benzylidene-benzofuran-3-ones as Flavopiridol Mimics</span></div><div class="casAuthors">Schoepfer, Joseph; Fretz, Heinz; Chaudhuri, Bhabatosh; Muller, Lionel; Seeber, Egge; Meijer, Laurent; Lozach, Olivier; Vangrevelinghe, Eric; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1741-1747</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 2-benzylidene-benzofuran-3-ones, e.g., I, were designed and synthesized to mimic flavopiridol, a well-established inhibitor of cyclin-dependent kinases (CDKs) which is currently undergoing clin. evaluation.  The underlying design concepts as well as the synthesis and structure-activity relationships (CDKs 1, 2, and 4 enzyme assays) of these mimics are described.  Inhibitors of CDKs 1 and 2 that are more potent and selective than flavopiridol were obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMUkviflNUZ7Vg90H21EOLACvtfcHk0lilt_Q5mBQu7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1Ojt7g%253D&md5=2c9dfd7bb0a07444e518b6706a936ed5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm0108348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0108348%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DFretz%26aufirst%3DH.%26aulast%3DChaudhuri%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DSeeber%26aufirst%3DE.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%25202-benzylidene-benzofuran-3-ones%2520as%2520flavopiridol%2520mimics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1741%26epage%3D1747%26doi%3D10.1021%2Fjm0108348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Ahn, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhapuram, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasandani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitscher, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lushington, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himes, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roby, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span> </span><span class="NLM_article-title">Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.10.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmc.2006.10.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=702-713&author=Y.+M.+Ahnauthor=L.+Vogetiauthor=C.+J.+Liuauthor=H.+K.+Santhapuramauthor=J.+M.+Whiteauthor=V.+Vasandaniauthor=L.+A.+Mitscherauthor=G.+H.+Lushingtonauthor=P.+R.+Hansonauthor=D.+R.+Powellauthor=R.+H.+Himesauthor=K.+F.+Robyauthor=Q.+Yeauthor=G.+I.+Georg&title=Design%2C+synthesis%2C+and+antiproliferative+and+CDK2-cyclin+a+inhibitory+activity+of+novel+flavopiridol+analogues&doi=10.1016%2Fj.bmc.2006.10.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.063%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%2BJ.%26aulast%3DSanthapuram%26aufirst%3DH.%2BK.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DVasandani%26aufirst%3DV.%26aulast%3DMitscher%26aufirst%3DL.%2BA.%26aulast%3DLushington%26aufirst%3DG.%2BH.%26aulast%3DHanson%26aufirst%3DP.%2BR.%26aulast%3DPowell%26aufirst%3DD.%2BR.%26aulast%3DHimes%26aufirst%3DR.%2BH.%26aulast%3DRoby%26aufirst%3DK.%2BF.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antiproliferative%2520and%2520CDK2-cyclin%2520a%2520inhibitory%2520activity%2520of%2520novel%2520flavopiridol%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D702%26epage%3D713%26doi%3D10.1016%2Fj.bmc.2006.10.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Jain, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. B.</span><span> </span><span class="NLM_article-title">KF/alumina catalyzed regioselective benzylation and benzoylation using solvent-free grind-stone chemistry</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">8929</span><span class="NLM_x">–</span> <span class="NLM_lpage">8933</span><span class="refDoi"> DOI: 10.1039/c2ra21154h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1039%2Fc2ra21154h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlKjtbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=8929-8933&author=S.+K.+Jainauthor=S.+Meenaauthor=B.+Singhauthor=J.+B.+Bharateauthor=P.+Joshiauthor=V.+P.+Singhauthor=R.+A.+Vishwakarmaauthor=S.+B.+Bharate&title=KF%2Falumina+catalyzed+regioselective+benzylation+and+benzoylation+using+solvent-free+grind-stone+chemistry&doi=10.1039%2Fc2ra21154h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">KF/alumina catalyzed regioselective benzylation and benzoylation using solvent-free grind-stone chemistry</span></div><div class="casAuthors">Jain, Shreyans K.; Meena, Samdarshi; Singh, Baljinder; Bharate, Jaideep B.; Joshi, Prashant; Singh, Varun P.; Vishwakarma, Ram A.; Bharate, Sandip B.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8929-8933</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Potassium fluoride-impregnated on alumina catalyzes a solvent-free regioselective O-benzylation, benzoylation and cinnamylation of phenols.  Reaction proceeds simply by triturating together equiv. amts. of phenol and corresponding halide in the presence of 5 mol% of KF/alumina for 5-20 min with a mortar and pestle, without need for any additive, such as a phase-transfer catalyst or solvent.  Key features of the protocol include its efficiency also for solid-solid precursors and regioselectivity for phenolic hydroxyl groups vs. alc. hydroxy groups.  Utility of the protocol for N- and S-benzylation has also been explored.  Products were obtained in excellent yields and the catalyst can be easily recycled several times without significant loss of activity.  The synthesis of the target compds. was achieved using 5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-2-methyl-4H-1-benzopyran-4-one (chromene alkaloid rohitukine) was a starting material.  The title compds. thus formed included benzyl ethers, such as a rohitukine methoxybenzyl ether (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgV_-p46avmrVg90H21EOLACvtfcHk0lilt_Q5mBQu7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlKjtbjP&md5=9ad74c68d324cfaece9586a92788ef59</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fc2ra21154h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ra21154h%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%2BK.%26aulast%3DMeena%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DBharate%26aufirst%3DJ.%2BB.%26aulast%3DJoshi%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DV.%2BP.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26aulast%3DBharate%26aufirst%3DS.%2BB.%26atitle%3DKF%252Falumina%2520catalyzed%2520regioselective%2520benzylation%2520and%2520benzoylation%2520using%2520solvent-free%2520grind-stone%2520chemistry%26jtitle%3DRSC%2520Adv.%26date%3D2012%26volume%3D2%26spage%3D8929%26epage%3D8933%26doi%3D10.1039%2Fc2ra21154h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span> </span><span class="NLM_article-title">Regulation of protein kinase C-epsilon and its age-dependence</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">482</span><span class="NLM_x">, </span> <span class="NLM_fpage">1201</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2016.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bbrc.2016.12.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=482&publication_year=2017&pages=1201-1206&author=C.+Kangauthor=J.+Qinauthor=W.+Oseiauthor=K.+Hu&title=Regulation+of+protein+kinase+C-epsilon+and+its+age-dependence&doi=10.1016%2Fj.bbrc.2016.12.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2016.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2016.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DOsei%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DK.%26atitle%3DRegulation%2520of%2520protein%2520kinase%2520C-epsilon%2520and%2520its%2520age-dependence%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D482%26spage%3D1201%26epage%3D1206%26doi%3D10.1016%2Fj.bbrc.2016.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Fabiani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosignoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Bartolomeo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuccelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morozzi, G.</span><span> </span><span class="NLM_article-title">Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21(WAF1/Cip1) and p27(Kip1) and with induction of differentiation in HL60 cells</span> <span class="citation_source-journal">J. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1093/jn/138.1.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1093%2Fjn%2F138.1.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18156402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2008&pages=42-48&author=R.+Fabianiauthor=P.+Rosignoliauthor=A.+De+Bartolomeoauthor=R.+Fuccelliauthor=G.+Morozzi&title=Inhibition+of+cell+cycle+progression+by+hydroxytyrosol+is+associated+with+upregulation+of+cyclin-dependent+protein+kinase+inhibitors+p21%28WAF1%2FCip1%29+and+p27%28Kip1%29+and+with+induction+of+differentiation+in+HL60+cells&doi=10.1093%2Fjn%2F138.1.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cell cycle progression by hydroxytyrosol is associated with upregulation of cyclin-dependent protein kinase inhibitors p21WAF1/Cip1 and p27Kip1 and with induction of differentiation in HL60 cells</span></div><div class="casAuthors">Fabiani, Roberto; Rosignoli, Patrizia; De Bartolomeo, Angelo; Fuccelli, Raffaela; Morozzi, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nutrition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-48</span>CODEN:
                <span class="NLM_cas:coden">JONUAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-3166</span>.
    
            (<span class="NLM_cas:orgname">American Society for Nutrition</span>)
        </div><div class="casAbstract">Recent evidence indicates that the cancer preventive activity of olive oil can be mediated by the presence of minor components, such as antioxidant phenolic compds.  However, their mechanisms of action remain largely unknown.  In this study, we investigated the in vitro effects of one of the main olive oil phenols, hydroxytyrosol [3,4-dihydroxyphenylethanol (3,4-DHPEA)], on proliferation, cell cycle progression, apoptosis, and differentiation of HL60 human promyelocytic leukemia cells.  3,4-DHPEA showed a potent inhibitory activity on DNA synthesis, as evidenced by a 92% redn. of [3H]-thymidine incorporation at 100 μmol/L, and an induced apoptosis, as evidenced by the release of cytosolic nucleosomes and flow cytometry.  This phenol, 3,4-DHPEA, was also able to inhibit the progression of the cell cycle in synchronized HL60 cells, which accumulated in the G0/G1 phase of the cell cycle after 25 h of treatment.  Furthermore, 3,4-DHPEA induced differentiation on HL60 cells with a max. effect (22% of cells) at 100 μmol/L after 72 h of treatment.  Among the different proteins involved in the regulation of the cell cycle, 3,4-DHPEA reduced the level of cyclin-dependent kinase (CDK) 6 and increased that of cyclin D3.  With regard to the CDK inhibitors, p15 was not altered by 3,4-DHPEA treatment, whereas the expression of p21WAF1/Cip1 and p27Kip1 was increased at both protein and mRNA levels.  To our knowledge, these results provide the 1st evidence that 3,4-DHPEA may effect the expression of genes involved in the regulation of tumor cell proliferation and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ5ipBfVO407Vg90H21EOLACvtfcHk0liyV3irLvaQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVSksA%253D%253D&md5=63513a48e2cc23c6fdc49255e65a556a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1093%2Fjn%2F138.1.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjn%252F138.1.42%26sid%3Dliteratum%253Aachs%26aulast%3DFabiani%26aufirst%3DR.%26aulast%3DRosignoli%26aufirst%3DP.%26aulast%3DDe%2BBartolomeo%26aufirst%3DA.%26aulast%3DFuccelli%26aufirst%3DR.%26aulast%3DMorozzi%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520cell%2520cycle%2520progression%2520by%2520hydroxytyrosol%2520is%2520associated%2520with%2520upregulation%2520of%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%2520p21%2528WAF1%252FCip1%2529%2520and%2520p27%2528Kip1%2529%2520and%2520with%2520induction%2520of%2520differentiation%2520in%2520HL60%2520cells%26jtitle%3DJ.%2520Nutr.%26date%3D2008%26volume%3D138%26spage%3D42%26epage%3D48%26doi%3D10.1093%2Fjn%2F138.1.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Xie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span> </span><span class="NLM_article-title">Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1481</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span><span class="refDoi"> DOI: 10.1038/aps.2016.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Faps.2016.49" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1481-1489&author=S.+Xieauthor=H.+Jiangauthor=X.+W.+Zhaiauthor=F.+Weiauthor=S.+D.+Wangauthor=J.+Dingauthor=Y.+Chen&title=Antitumor+action+of+CDK+inhibitor+LS-007+as+a+single+agent+and+in+combination+with+ABT-199+against+human+acute+leukemia+cells&doi=10.1038%2Faps.2016.49"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.49%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhai%26aufirst%3DX.%2BW.%26aulast%3DWei%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%2BD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DAntitumor%2520action%2520of%2520CDK%2520inhibitor%2520LS-007%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520ABT-199%2520against%2520human%2520acute%2520leukemia%2520cells%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D1481%26epage%3D1489%26doi%3D10.1038%2Faps.2016.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Evers, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. A.</span><span> </span><span class="NLM_article-title">Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">G722</span><span class="NLM_x">–</span> <span class="NLM_lpage">G727</span><span class="refDoi"> DOI: 10.1152/ajpgi.1996.271.4.G722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1152%2Fajpgi.1996.271.4.G722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=G722-G727&author=B.+M.+Eversauthor=T.+C.+Koauthor=J.+Liauthor=E.+A.+Thompson&title=Cell+cycle+protein+suppression+and+p21+induction+in+differentiating+Caco-2+cells&doi=10.1152%2Fajpgi.1996.271.4.G722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.1996.271.4.G722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.1996.271.4.G722%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DB.%2BM.%26aulast%3DKo%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26atitle%3DCell%2520cycle%2520protein%2520suppression%2520and%2520p21%2520induction%2520in%2520differentiating%2520Caco-2%2520cells%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1996%26volume%3D271%26spage%3DG722%26epage%3DG727%26doi%3D10.1152%2Fajpgi.1996.271.4.G722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Determining partition coefficient (Log P), distribution coefficient (Log D) and ionization constant (pKa) in early drug discovery</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.2174/1386207319666160502123917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.2174%2F1386207319666160502123917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27137915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=461-469&author=S.+S.+Bharateauthor=V.+Kumarauthor=R.+A.+Vishwakarma&title=Determining+partition+coefficient+%28Log+P%29%2C+distribution+coefficient+%28Log+D%29+and+ionization+constant+%28pKa%29+in+early+drug+discovery&doi=10.2174%2F1386207319666160502123917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery</span></div><div class="casAuthors">Bharate, Sonali S.; Kumar, Vikas; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">461-469</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">An early prediction of physicochem. properties is highly desirable during drug discovery to find out a viable lead candidate.  Although there are several methods available to det. partition coeff. (log P), distribution coeff. (log D) and ionization const. (pKa), none of them involves simple and fixed, miniaturized protocols for diverse set of compds.  Therefore, it is necessary to establish simple, uniform and medium-throughput protocols requiring small sample quantities for the detn. of these physicochem. properties.  Log P and log D were detd. by shake flask method, wherein, the compd. was partitioned between presatd. noctanol and water phase (water/PBS pH 7.4) and the concn. of compd. in each phase was detd. by HPLC.  The pKa detn. made use of UV spectrophotometric anal. in a 96-well microtiter plate contg. a series of aq. buffers ranging from pH 1.0 to 13.0.  The medium-throughput miniaturized protocols described herein, for detn. of log P, log D and pKa, are straightforward to set up and require very small quantities of sample (< 5 mg for all three properties).  All established protocols were validated using diverse set of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH4U64-_rEprVg90H21EOLACvtfcHk0liyV3irLvaQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVags7w%253D&md5=6340eb95ac545ff52afedefe4d63d074</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2174%2F1386207319666160502123917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207319666160502123917%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DDetermining%2520partition%2520coefficient%2520%2528Log%2520P%2529%252C%2520distribution%2520coefficient%2520%2528Log%2520D%2529%2520and%2520ionization%2520constant%2520%2528pKa%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2016%26volume%3D19%26spage%3D461%26epage%3D469%26doi%3D10.2174%2F1386207319666160502123917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1561</span><span class="NLM_x">–</span> <span class="NLM_lpage">1567</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.bmcl.2015.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=25740159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1561-1567&author=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=Thermodynamic+equilibrium+solubility+measurements+in+simulated+fluids+by+96-well+plate+method+in+early+drug+discovery&doi=10.1016%2Fj.bmcl.2015.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery</span></div><div class="casAuthors">Bharate, Sonali S.; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1561-1567</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An early prediction of soly. in physiol. media (PBS, SGF and SIF) is useful to predict qual. bioavailability and absorption of lead candidates.  Despite of the availability of multiple soly. estn. methods, none of the reported method involves simplified fixed protocol for diverse set of compds.  Therefore, a simple and medium-throughput soly. estn. protocol is highly desirable during lead optimization stage.  The present work introduces a rapid method for assessment of thermodn. equil. soly. of compds. in aq. media using 96-well microplate.  The developed protocol is straightforward to set up and takes advantage of the sensitivity of UV spectroscopy.  The compd., in stock soln. in methanol, is introduced in microgram quantities into microplate wells followed by drying at an ambient temp.  Microplates were shaken upon addn. of test media and the supernatant was analyzed by UV method.  A plot of absorbance vs. concn. of a sample provides satn. point, which is thermodn. equil. soly. of a sample.  The established protocol was validated using a large panel of com. available drugs and with conventional miniaturized shake flask method (r2 >0.84).  Addnl., the statistically significant QSPR models were established using exptl. soly. values of 52 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEhIADhdQd3LVg90H21EOLACvtfcHk0lhIyu_ybbnTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSrsbc%253D&md5=e118b10c67ca311ea5da994793546c11</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DThermodynamic%2520equilibrium%2520solubility%2520measurements%2520in%2520simulated%2520fluids%2520by%252096-well%2520plate%2520method%2520in%2520early%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1561%26epage%3D1567%26doi%3D10.1016%2Fj.bmcl.2015.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhIyu_ybbnTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lolli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troiani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span><span class="refDoi"> DOI: 10.1038/emboj.2008.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1038%2Femboj.2008.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=18566585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1907-1918&author=S.+Baumliauthor=G.+Lolliauthor=E.+D.+Loweauthor=S.+Troianiauthor=L.+Rusconiauthor=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=S.+Knappauthor=L.+N.+Johnson&title=The+structure+of+P-TEFb+%28CDK9%2Fcyclin+T1%29%2C+its+complex+with+flavopiridol+and+regulation+by+phosphorylation&doi=10.1038%2Femboj.2008.121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation</span></div><div class="casAuthors">Baumli, Sonja; Lolli, Graziano; Lowe, Edward D.; Troiani, Sonia; Rusconi, Luisa; Bullock, Alex N.; Debreczeni, Judit E.; Knapp, Stefan; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1907-1918</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pos. transcription elongation factor b (P-TEFb) (CDK9/cyclin T (CycT)) promotes mRNA transcriptional elongation through phosphorylation of elongation repressors and RNA polymerase II.  To understand the regulation of a transcriptional CDK by its cognate cyclin, we have detd. the structures of the CDK9/CycT1 and free cyclin T2.  There are distinct differences between CDK9/CycT1 and the cell cycle CDK CDK2/CycA manifested by a relative rotation of 26° of CycT1 with respect to the CDK, showing for the first time plasticity in CDK cyclin interactions.  The CDK9/CycT1 interface is relatively sparse but retains some core CDK-cyclin interactions.  The CycT1 C-terminal helix shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.  Flavopiridol, an anticancer drug in phase II clin. trials, binds to the ATP site of CDK9, inducing unanticipated structural changes that bury the inhibitor.  CDK9 activity and recognition of regulatory proteins are governed by autophosphorylation.  We show that CDK9/CycT1 autophosphorylates on Thr186 in the activation segment and three C-terminal phosphorylation sites.  Autophosphorylation on all sites occurs in cis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2808s0tnBrVg90H21EOLACvtfcHk0li7e5yckhalgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1emsb4%253D&md5=c28cc6d1c178c79a12cfab03da9c45dc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Femboj.2008.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2008.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DTroiani%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structure%2520of%2520P-TEFb%2520%2528CDK9%252Fcyclin%2520T1%2529%252C%2520its%2520complex%2520with%2520flavopiridol%2520and%2520regulation%2520by%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1907%26epage%3D1918%26doi%3D10.1038%2Femboj.2008.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Crespi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penman, B. W.</span><span> </span><span class="NLM_article-title">Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">248</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1006/abio.1997.2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1006%2Fabio.1997.2145" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=1997&pages=188-190&author=C.+L.+Crespiauthor=V.+P.+Millerauthor=B.+W.+Penman&title=Microtiter+plate+assays+for+inhibition+of+human%2C+drug-metabolizing+cytochromes+P450&doi=10.1006%2Fabio.1997.2145"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2145%26sid%3Dliteratum%253Aachs%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26aulast%3DMiller%26aufirst%3DV.%2BP.%26aulast%3DPenman%26aufirst%3DB.%2BW.%26atitle%3DMicrotiter%2520plate%2520assays%2520for%2520inhibition%2520of%2520human%252C%2520drug-metabolizing%2520cytochromes%2520P450%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D248%26spage%3D188%26epage%3D190%26doi%3D10.1006%2Fabio.1997.2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bharate, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vishwakarma, R. A.</span><span> </span><span class="NLM_article-title">Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1016/j.ejps.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=10.1016%2Fj.ejps.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=27422078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eis7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=203-211&author=V.+Kumarauthor=S.+S.+Bharateauthor=R.+A.+Vishwakarma&title=Modulating+lipophilicity+of+rohitukine+via+prodrug+approach%3A+Preparation%2C+characterization%2C+and+in+vitro+enzymatic+hydrolysis+in+biorelevant+media&doi=10.1016%2Fj.ejps.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media</span></div><div class="casAuthors">Kumar, Vikas; Bharate, Sonali S.; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203-211</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rohitukine is a medicinally important natural product which has inspired the discovery of two anticancer clin. candidates.  Rohitukine is highly hydrophilic in nature which hampers its oral bioavailability.  Thus, herein our objective was to improve the drug-like properties of rohitukine via prodrug-strategy.  Various ester prodrugs were synthesized and studied for soly., lipophilicity, chem. stability and enzymic hydrolysis in plasma/esterase.  All prodrugs displayed lower aq. soly. and improved lipophilicity compared with rohitukine, which was in accordance with the criteria of compds. in drug-discovery.  The stability of synthesized prodrugs was evaluated in buffers at different pH, SGF, SIF, rat plasma and in esterase enzyme.  The rate of hydrolysis in all incubation media was dependent primarily on the acyl promoieties.  Hexanoyl ester prodrug of rohitukine, 3d, was stable under chem. conditions; however it was completely hydrolyzed to rohitukine, in plasma and in esterase in 4 h.  Hexanoate ester 3d appeared to be the most promising prodrug as it remained intact at gastric/intestinal pH and was completely transformed to the parent compd. in plasma as desired for an ideal prodrug.  The data presented herein, will help in designing prodrugs with desired physicochem. properties in future in structurally similar chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhioU_tMke-LVg90H21EOLACvtfcHk0li7e5yckhalgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eis7vL&md5=32781e4682481225bf0219d8094fd634</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBharate%26aufirst%3DS.%2BS.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DModulating%2520lipophilicity%2520of%2520rohitukine%2520via%2520prodrug%2520approach%253A%2520Preparation%252C%2520characterization%252C%2520and%2520in%2520vitro%2520enzymatic%2520hydrolysis%2520in%2520biorelevant%2520media%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D92%26spage%3D203%26epage%3D211%26doi%3D10.1016%2Fj.ejps.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR','PDB','3BLR'); return false;">PDB: 3BLR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-7"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i94"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01765">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_01608"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01765">10.1021/acs.jmedchem.7b01765</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H, <sup>13</sup>C, DEPT NMR, HRMS, and HPLC scans of all compounds; results of in vivo efficacy in murine models; additional molecular modeling details; kinase profiling data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_001.pdf">jm7b01765_si_001.pdf (30.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01765/suppl_file/jm7b01765_si_002.csv">jm7b01765_si_002.csv (8.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01765&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01765%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01765" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799762ace2a3d7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
